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aa amino acid 
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ALL acute lymphoblastic leukemia
alloHSCT allogeneic haemopoietic stem cell transplantation
ALT / ALAT alanine amino transferase
AML acute myeloid leukemia
AST / ASAT aspartaat amino transferase 
AUC area under the curve
BSA bovine albumin fraction V
CI confidence interval
CLL chronic lymphocytic leukemia
CMV cytomegalovirus
CPE cytopathogenic effect
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DAPI 4,6-diamidino-2-phenylindole
DILI drug induced liver injury
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EASL European association for study of the liver 
EBV Epstein-Barr virus
EGFR epidermal growth factor receptor 
EDTA-plasma Ethylenediaminetetraacetic acid - plasma
EIA immunosorbent assay
ELISA enzyme linked immunosorbent assay
FBS fetal bovine serum
FDA Food and drug administration
GBS Guillain-Barré syndrome
Gt genotype
GVHD graft versus host disease
HAI histology activity index
HAV hepatitis A virus
HBsAg+ hepatitis B surface antigen positive
HBV hepatitis B virus
HCV hepatitis C virus
HEV hepatitis E virus
HSPG heparin sulfate proteoglycans 
HIV human immunodeficiency virus
HTX heart transplantation
i.v. intravenous
IgG immunoglobulin G
IgM immunoglobulin M
IU international units
JAK/STAT Janus kinase / signal transducer and activator of transcription 
Kb kilobases
LIMS laboratory information management system
LLOD Lower limit of detection
LTX liver transplantation
LuTX lung transplantation
MAPK / ERK mitogen activating phosphokinase / extracellular signal-
regulated kinases
MDS myelodysplastic syndrome
MM multiple myeloma
METC medisch ethische commissie
MUD matched unrelated donor
NAT nucleic acid testing
NHL non-Hodgkin’s lymphoma
Nm nanometer
KTX kidney transplantation
OD optical density
ORF  open reading frame
Peg-INF pegylated interferon
PCP papain-like cysteine protease
p.i. post infection
PBS phosphate buffered saline
pORF protein of open reading frame
PSAP motif  proline-serine-alanine-proline motif
R-CHOP rituximab - cyclophosphamide, hydroxydaunorubicin, oncovin, 
prednisolone
PRP polyprotein domain
RdRp RNA dependent RNA polymerase
RNA ribo nucleic acid
ROC receiver operator curve
RT-PCR reverse transcription - polymerase chain reaction
S/N signal to noise
SD standard deviation
SIB sibling
SOT solid organ transplant
SF1 superfamily 1
TCID50 50% tissue culture infectious dose
UBC umbilical cord blood
ULN upper limit of normal
UK United Kingdom
uPA/NOG urokinase-type plasminogen activator / NOD/Shi-scid/IL-2Rγnull
USA United States of America
UTR untranslated regions
WHO world health organization
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Chapter 1
General introduction
Taken in part from
Hepatitis E virus: current concepts and 
future perspectives
Harry R. Dalton, Suzan D. Pas, Richie G. Madden 
and Annemiek A. van der Eijk 
Current Infectious Disease Reports (2014) 16:399. 
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Chapter 1
HISTORY OF HEPATITIS E VIRUS DISCOVERY
Hepatitis E virus (HEV) has probably been around for quite some time. Already 
in the 18th century outbreaks of jaundice, with coinciding fatalities in pregnant 
women (a hallmark of genotype (gt) 1-2 hepatitis E virus infections) were 
reported in Europe1. Following an epidemic of non-A non-B hepatitis in the late 
70s2, hepatitis E virus (HEV) was discovered as a virus transmitted via the feco-
oral route, through experimental infection of a volunteer in 19833 with a pool of 
stools from patients suffering from hepatitis. The virus was visualized by electron 
microscopy and subsequently cynomolgus macaques (Macaca fascicularis) were 
infected. The HEV genome was sequenced in 19904, 5, after which its protein 
functions were characterized6. In 2009, the structure of HEV was further 
elucidated through X-ray crystallography.7
It has been estimated that HEV gt 1 and gt 2 infection alone causes >3 million 
symptomatic cases of acute hepatitis E each year that result in approximately 
70,000 deaths8. For many years, hepatitis E was considered a disease of certain 
developing countries, that was associated with mortality in pregnant women. 
Our understanding of HEV infection has changed radically in the past decade, 
with HEV being currently considered a global threat to human health. 
TAXONOMY
Only 12 years after its discovery in 1983 HEV was assigned as a family member 
of the family Caliciviridae, genus Calicivirus on the basis of clinical symptoms and 
structural features. It soon became clear, however, that the virus did not have 
all intrinsic features of a calicivirus and as a result its taxonomical position was 
changed in 1998, grouping this species into an unassigned family and within 
the genus hepatitis E-like viruses. In 2004, the genus hepatitis E-like viruses 
was renamed to Hepevirus, which was assigned to the family Hepeviridae in 
20089. Recently, taxonomic division of the family Hepeviridae was completely 
changed as a result of the discovery of multiple HEVs in different hosts and 
the contradictory taxonomical positioning proposed by researchers. The family 
Hepeviridae now comprises the genera, Orthohepevirus and Piscihepevirus and 
an additional, unconfirmed genus Hepelivirus, of which the genus taxonomic 
positioning is based on partial RdRp sequences only10 (Figure 1).
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Figure 1 Taxonomy of HEV. Blue boxes indicate accepted taxonomic positioning, grey box is 
currently unconfirmed. The species Piscihepevirus A was previously called cut throat trout virus. 
Although ICTV does not specify classification on the level of genotype, it is illustrated in this figure 
for historical reference.
The recent reclassification of HEV genotypes was defined on basis of ORF1 motifs 
(methyltransferase, helicase and RdRP) and concatenated ORF1/ORF2 sequences. 
Within the species Orthohepevirus A, there are four genotypes, HEV gt 1-4, 
known to infect humans, which can be divided into two groups (genotype 1-2 
and 3-4) on basis of host, epidemiology and geographical distribution (Figure 
1 and Figure 2). Among these four genotypes the nucleic acid identity ranges 
between 73-77%, with >83% within a genotype11. The utility of HEV subtypes 
within HEV gt 3 is a subject of debate. Inconsistencies of the previously suggested 
24 subtypes12 have been observed 13, 14, probably due to the small part of ORF2 
not being representative for the complete genome sequence variation. Therefore 
the ICTV recommends not to use sub-genotyping, but rather assignments as 
‘clades’. HEV gt 1-4 belong to one serotype15.
genotype
species
family
genus
Hepeviridae
Piscihepevirus HepelivirusOrthohepevirus
Orthohepevirus
B
Orthohepevirus
C
Orthohepevirus
A
Orthohepevirus
D
HEV-1 (human) 
HEV-2 (human) 
HEV-3 (human, pig,
wild boar, deer, rabbit, 
mongoose)
HEV-4 (human, pig)
HEV-5 (wild boar)
HEV-6 (wild boar)
HEV-7 (camel)
Avian (chicken) C1 (rat, greater 
bandicoot rat,
Asian musk
shrew)
C2 (ferret, mink)
Bat-HEV
Piscihepevirus
A
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Figure 2 Predominant geographical distribution of HEV16
HEV REPLICATION STRATEGY
The hepatitis E virion is non-enveloped and 27-34 nm in size. The viral genome 
is single stranded positive sense RNA of ~7.2Kb, grouped into group IV positive 
single stranded RNA viruses. The genome consists of a 5’ m7G-cap, short 5’ 
untranslated regions (UTR), 3 partially overlapping open reading frames (ORF) 
of positive polarity, a short 3’UTR and a 3’ polyA tail 5. The life cycle of HEV is 
not completely understood, but studies performed in recent years have provided 
important insights into its replication strategy. 
The virus replication cycle (Figure 3) starts with virus capture on the host cell 
by non-specific sticky molecules called heparin sulfate proteoglycans (HSPG)17 
acting as attachment factors (Figure 3, step 1). The virus is thought to enter the 
host cell by a so far unknown receptor18 (Figure 3, step 2,3), after which the 
positive stranded genomic RNA is released (Figure 3, step 4) into the cytosol by 
an unknown process after which ORF1 is immediately transcribed.
General introduction
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Figure 3 HEV replication cycle18  © Georg Thieme Verlag KG
ORF1 encodes a nonstructural polyprotein of 1693 aminoacids, with 
methyltransferase, papain-like cysteine protease (PCP), RNA helicase and RNA-
dependent RNA polymerase (RdRP) activity4, 6 (Figure 3, step 5 and Figure 4). 
PCPs are found in a wide range of positive stranded RNA viruses and mediate the 
processing of non-functional proteins, whereby the X-or macro domain (Figure 4) 
flanks the PCP coding sequence19. HEV RNA helicase belongs to the superfamily 
class 1 (SF1) of helicases, which mediate the unwinding of 5’-overhangs (5’-
3’), have RNA triphosphatase (RTPase) activity and thereby play an important 
role in forming viral cap20. The HEV RdRP belongs to the supergroup III of viral 
RNA polymerases and is involved in the first steps of HEV genome replication, 
transcribing the positive sense genome into negative sense RNA (Figure 3, step 
6), which is subsequently used as template for generation of positive sense 
genomic and 2.2 Kb subgenomic RNA (Figure 3, step 8 and Figure 4). 
Besides the known and functionally established protein, ORF1 also encodes a Y 
domain, polyproline (PRP or V (variable)) domain and X (or macro) domain (with 
a highly conserved glycine triade, pink triangle Figure 4). The function of the Y 
domain is unknown, however the polyproline region (V, Figure 4) seems to play a 
role in viral adaptation21 and is also designated as a protein hinge region6.
 
Once +ssRNA is transcribed into –ssRNA (Figure 3, step 7), a precursor ORF2 
protein is translocated to the endoplasmic reticulum and undergoes glycosylation 
at N137, N310 and N547 aminoacid residues (Figure 3, step 9 and Figure 4, 
blue stars)22. This glycosylation has been shown to be crucial in the formation 
of infectious HEV particles23. ORF2 encodes the viral capsid protein of 660 
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aminoacids / 88kDa, containing three distinct domains, namely shell (S, aa129-
319), middle (M, aa230-455) and protruding (P, aa456-606) domains24. pORF2 
is a multifunctional protein, as it is involved in virion assembly25 (encapsidating 
the viral genome (Figure 3, step 10)), host-virus interaction by heparin sulfate 
proteoglycans (syndecans)17 during the viral capture, and harbors virus 
neutralizing epitopes within the aa458-607 region of the P domain24, 26-28. The 
pE2 domain (aa394-606) forms tight homodimers, of which aa597-602 of the 
dimeric domain (aa459-606) is involved in dimerization and both aa394-459 and 
aa607-660 have a stabilizing function25. This homodimerization is essential for 
virus-host interaction. A truncated ORF2 peptide p239 (aa368-606) forms 23 
nm virus like particles and is used as antigen in the currently available hepatitis 
E virus vaccine. 
Figure 4 HEV genomic organization6, 18, 29. 
ORF3 was previously thought to be transcribed into a 123aa protein30. However, 
Graff et al31 described a bicistronic 2.2Kb subgenomic RNA fragment to encode 
both pORF3 and pORF2 in separate reading frames. It was shown that not the 
first, but the third in-frame AUG initiated translation of ORF3. Therefore, pORF3 
was found to be 9 aminoacids smaller (114aa) than previously described. The 
first four amino acids of ORF3 (MNNM) are thought to be the promoter31, as they 
are highly conserved within the species and shown to be a cis-reactive element32. 
pORF3, a 13 kDa phosphoprotein, contains two hydrophobic domains D1 (aa7-
General introduction
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123), D2 (aa28-53) and two proline rich domains, P1 (aa66-77) and P2 (aa95-
111)30, 31. These proline rich motifs (PXXP) interact with Scr homology (SH3) 
domains of host intracellular signaling proteins and bind and inhibit mitogen 
activating phosphokinase (MAPK). These observations, and the association 
of pORF3 to epidermal growth factor receptor (EGFR)33, suggest that pORF3 
regulates transcription by interacting in MAPK/ERK and JAK/STAT intracellular 
signaling pathway thereby hampering immune activation34. In addition, studies 
have shown that the pORF3 aa1-32 interact with the cytoskeleton (tubulin)35, 
a part of pORF3 is able to interact with non-glycosylated pORF2 (by aa58-81)36 
and that a PSAP motif (aa95-98) within the P2 domain associates with lipids of 
the vacuolar protein sorting pathway37. These findings suggest pORF3 plays an 
import role in the replication cycle through virion release by budding (Figure 3, 
step 11,12). However, it is still unclear how the lipid-ORF3 complex is removed 
from the virion before infecting new host cells (Figure 3, step 13).
DIAGNOSING HEV INFECTION
Confirmation of HEV infection relies on the detection of HEV specific serum 
IgM and IgG antibodies and/or HEV RNA testing in serum or feces38. Until 
very recently HEV has proven difficult to culture and this method is not used 
for diagnostic purposes; moreover real-time PCR techniques are more sensitive 
than virus culture. In immune-compromised patients antibody production may 
be delayed or absent39, however this has not been studied in detail for HEV 
infections. In immune-competent individuals, there is a narrow window (mean 
28, range 17-48 days)40 in which HEV RNA can be detected in serum and/or 
feces. Therefore, a combination of serology and RNA detection is required to 
diagnose HEV infection in such individuals. The diagnosis of reinfection can be 
more problematic, and may be more common than currently appreciated. Such 
patients are typically anti-HEV IgM negative, and so the diagnosis depends on 
the demonstration of HEV RNA by PCR16. When patients with reinfection present 
after the viremic period they will be PCR and anti-HEV IgM negative, but anti-HEV 
IgG positive. These results are indistinguishable from those found in more distant 
previous infection, and so the only way of making a diagnosis of reinfection in 
this situation is by demonstrating IgG antibodies of high avidity and/or a rising 
titer of IgG in a convalescent sample. However these additional serological assays 
are rarely performed in routine clinical practice.
22
Chapter 1
HEV serology
Performance of commercial and in house anti-HEV IgM and IgG assays have 
been compared and there appears to be discordance between the results of 
some assays. Some anti-HEV IgG commercial assays have low sensitivities, 
particularly to detect antibodies raised to HEV infection that has occurred more 
than 1 year before41. This almost certainly has resulted in an underestimation 
of HEV prevalence in many of the early studies. Differences in assay design are 
considerable and include: (1) the format used, like direct, indirect, or a μ chain 
based capture assay, (2) the genotype of the antigens used. In most ELISA’s only 
gt 1 and 2 recombinant antigens are used, while only one assay currently uses 
gt 1 and 3 antigens in their assays and, (3) the corresponding structural regions 
of the recombinant antigens which currently are all ORF2 + ORF3 and, (4) the 
presently preferred use of antigen dimers.
There is limited validation data on currently used serological assays. One IgG 
assay has been partially validated against convalescent sera taken up to 7 years 
following PCR-proven acute infection, and was shown to have a sensitivity of 
98%, although it’s specificity has not been completely confirmed41. Further 
validation of existing serological assays for detecting HEV infection is urgently 
needed.
HEV molecular testing
Until recently, molecular testing for HEV has been problematic, as only a range of 
in-house assays have been used. A comparison among 20 European laboratories 
showed a wide variability in the results of quantitative assays42, highlighting that 
international standardization is urgently needed. In addition HEV genotyping 
is important for research purposes and epidemiologic studies43, Conventional 
RT-PCR products are used for genotyping HEV on different genome segments. 
Partial ORF2 sequences have historically been widely used44, while Zhai et al45 
showed that a 306bp region of RdRp (ORF1) was statically most representative 
for the complete HEV genome flanked by conserved primer sites. 
General introduction
23
C
h
ap
te
r 
1EPIDEMIOLOGY
The epidemiology of HEV gt 1-2 infections is distinct from HEV gt 3-4 infections. 
In resource-low countries, with poor hygiene, hepatitis E virus gt 1 causes a self-
limiting hepatitis in young adults, with a case fatality rate of 0.2-4%. However 
mortality of gt 1 infections in pregnant females ranges from 25 to 31%16, 46, 47. 
HEV gt 3 is found in pigs worldwide, and gt 4 is found in pigs in China and Japan. 
Although HEV infections in swine herds are asymptomatic, infected pigs excrete 
large quantities of HEV in their feces. The pig is considered to be a primary 
host and there is a close similarity between HEV strains obtained from pigs and 
humans48. HEV is highly infectious in pig herds with a basic reproductive ratio (R0) 
ranging up to 8. Once HEV has been introduced into a pig herd, infection will 
soon be wide-spread49, 50. HEV RNA was detected in 33-55% of fecal samples of 
Dutch pig farms, and in 6.5% of the commercially available porcine livers51, 52. 
HEV has also been found in many other animals including deer and rabbits53, 
which can also be a source of human infection. In comparison to pigs, they are a 
less important reservoir for human infection. HEV has also been documented in 
a range of other mammals, including rats, bats, and ferrets54-56. It is uncertain if 
these animal reservoirs pose a risk to human health. For example rat HEV is not 
transmissible to rhesus monkeys, suggesting that it is unlikely to be pathogenic 
to primates, including humans 57.
There are a number of possible routes of infection (Figure 5), but in most human 
hepatitis E cases, it is impossible to determine the source or route of infection. 
This is largely due to the incubation period of approximately 6 weeks, which 
period is often too long to remember what was consumed and to identify HEV 
RNA in consumed products. However, consumption of infected pork products 
has been well documented. HEV has been found in retail pork in grocery stores 
in several European countries, Japan and the United States of America (USA). In 
2012, HEV gt 3 was identified throughout the human food chain in the United 
Kingdom (UK) and shown to be present in 10% of tested retail sausages58. HEV 
requires cooking temperatures of 71oC for 20 minutes to be inactivated, which 
is much longer than sausages usually are cooked59. HEV has also been found in 
several food products like traditional French air-dried pig liver sausages, which 
are not cooked at all60. A recent case control study from the UK suggested that 
processed pork products such as ham and pork pies can also be a source of 
infection61. 
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Another source of infection is infected water (Figure 5) as HEV has been found 
in surface fresh and sea water62. In southwest England, 50% of cases of hepatitis 
E were found to live within 2 km from the coast63, which led to the speculation 
that recreational use of HEV contaminated water is a source of HEV infection. In 
addition, a recent study found HEV in shellfish64. 
Figure 5 HEV transmission routes16
It has previously been documented that the sero-prevalence of anti-HEV IgG 
in many developed countries was low, ranging from 1 to 2%. However these 
studies may be flawed, as assays of poor sensitivity were used (see above). Also, 
the incidence of hepatitis E among humans has been poorly documented, but 
undoubtedly varies between and within countries and over time. The incidence 
in the UK has been estimated to be about 0.2%65, and in the USA about 0.7%66. 
With a population of about 316 million, this implies that over 2.2 million 
infections occur in the USA annually. Virtually all of these are asymptomatic or 
unrecognized, as no FDA approved HEV diagnostics are currently available in the 
USA.
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1CLINICAL ASPECTS OF HEPATITIS E
Acute HEV gt 3 and HEV gt 4 infections in immune-competent persons are 
usually self-limiting lasting 4–6 weeks, requiring no treatment. Asymptomatic 
infection is very common, in an outbreak of hepatitis E gt 3 on a cruise ship, 
67% of the infected individuals had no symptoms67. However in sporadic cases 
acute HEV infection may develop into fulminant hepatitis, that may even require 
liver transplantation95. Symptoms of hepatitis E are largely non-specific and 
indistinguishable from other causes of viral hepatitis, like jaundice, anorexia, 
lethargy, abdominal pain, vomiting, fever, fatigue. Less common symptoms are 
myalgia, pruritis, weight loss, headaches, arthralgia and neurological symptoms68. 
Notably, in immune-compromised patients like solid organ transplant patients 
HEV gt 3 infection may become chronic. Up to this date no cases of chronic 
hepatitis E have been reported for genotypes 1, 2 and 4 infections16. A chronic 
HEV infection is defined by HEV viremia in plasma or stool detected by RT-PCR 
for 6 months or more. Persistent chronic infection has been reported in immune-
compromised patients, with one study reporting 57% of liver transplant patients 
developing chronic hepatitis69. Treatment with tacrolimus, an immunosuppressive 
drugs inhibiting the T-cell signal transduction and interleukin-2 production70, has 
been found to be the risk factor for development of chronic hepatitis E virus 
infections71. Still little is known about the incidence and clinical consequences 
of chronic HEV infection and its clinical consequences in immune-compromised 
patients in The Netherlands. 
TREATMENT OF HEPATITIS E
Currently there are no WHO nor EASL / AASLD guidelines for treatment of 
hepatitis E. Most cases of acute hepatitis E infection are self-limiting, requiring 
only symptomatic or no treatment. However a minority of the patients develop 
fulminant hepatitis, some of which may eventually require liver transplantation72, 73. 
Especially patients with severe hepatitis and underlying chronic liver disease have 
a poor prognosis, although currently several have been treated successfully with 
ribavirin74.
Treatment of acute HEV infections in immune-competent individuals mainly 
consists of symptomatic treatment in combination with the use of antiviral 
26
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moieties like ribavirin75. This thesis focuses predominantly on the immune-
compromised individuals infected with HEV. Treatment of HEV infection after 
transplantation includes reduction of immunosuppressive therapy and treatment 
with anti-viral agents, of which both safety and efficacy have been studied for 
other infections than hepatitis E virus. No randomised controlled studies have 
been conducted to evaluate the efficacy of these antivirals for hepatitis E virus 
infection, due to the relatively small number of chronically infected patients in 
need of treatment. 
The first choice of intervention, reducing the dose of immunosuppressive drugs 
targeting T cells can lead to HEV clearance in up to one third of patients71, 76. 
Non-specific antiviral drugs targeting the immune system, like Peg-IFN-α-2a/b 
and oral ribavirin have been successfully used to treat HEV infection in liver- and 
kidney transplant recipients as well as in a HIV infected patient 27,39 59-61. 
Tapering immunosuppressive drugs or treatment with Peg-IFN-α-2a/b is not always 
possible or desirable due to the high risk of transplant rejection, which may lead 
to chronic allograft dysfunction and death. For these patients treatment with 
ribavirin can be considered. Rapid clearance of HEV RNA in plasma (within three 
months) with normalizing ALT levels are observed after start of ribavirin therapy 
and a sustained viral load reduction can be induced in patients with chronic HEV 
infection77-79. The optimal daily dose and duration of ribavirin treatment is still 
largely unknown. In case reports and small case series, sustained response has 
been described with daily dosages between 200 mg and 800 mg80 leading to 
undetectable HEV RNA in the faeces. 
Currently there are no more specific antiviral drugs available targeting well 
defined hepatitis E virus replication steps, like nucleoside analogues in hepatitis B 
virus treatment or protease inhibitors in hepatitis C infected patients.
HEPATITIS E PREVENTION STRATEGIES 
Currently, no specific preventive strategies other than immunization - currently 
only available in China – are practiced. In general, no surveillance efforts, nor 
efforts to raise knowledge or awareness among the public are currently in 
place. Immune-compromised individuals do get dietary advice – not to eat raw 
meat products – but the advice is not focused specifically on prevention of HEV 
infection.
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1Since hepatitis E virus cannot efficiently be cultured, future vaccine development 
strategies will most likely have to rely on recombinant technologies. In the past 
decade, many candidate hepatitis E vaccines have been developed, but only 
two of these were tested throughout phase II-IV clinical trials. Both vaccines are 
based on genotype 1 (recombinant) ORF2 antigens, are alum adjuvant and are 
currently used in a regimen of three intra muscular doses at 0, 1 and 6 months. 
Although human HEV’s belong to four genotypes, they are considered to be one 
serotype, and therefore these vaccines may be expected to be effective to all four 
genotypes81-83.
One HEV vaccine candidate is based on a 56kDa recombinant ORF2 protein, 
produced in a baculovirus vector based expression system in SF2 insect cells. 
This vaccine has been developed and tested, in a phase I and later a double 
blinded placebo controlled phase II clinical trial sponsored by GlaxoSmithKline 
and the United States army84. This vaccine showed to be effective in 95% of 
the –mainly- healthy young men in Nepal. Though, the manufacturer considered 
the production of this vaccine not cost-effective and clinical trials were stopped.
The second HEV vaccine is based on a short ORF2 peptide, HEV239 (Figure 4) 
aa368-606, produced in a bacterial (Escherichia coli) expression system85. The 
peptide forms dimers and aggregates into virus like particles, which is imperative 
to induce neutralizing antibodies. It has been shown to induce protective 
immunity in primates against gt 1 and gt 4 infections85. The safety of the vaccine 
was evaluated in a phase I clinical trial, and showed the vaccine was well tolerated 
with no serious side-effects. In a double-blind randomized controlled phase II 
clinical trial a higher (~100%) antibody response and a 89% protective efficacy 
was achieved after a three dose immunization schedule rather than a two-dose 
schedule86. Later, a large-scale phase III clinical trials confirmed the efficacy data, 
and showed the vaccine can be used for rapid control measurements in case of 
an emerging epidemic, since 100% of the participants had antibody responses 
lasting for at least 5 months after the first dose87. After the completion of this 
phase III clinical trial, the HEV239 vaccine was licensed for the Chinese market 
in 2011 and launched in 2012 under the name ‘Hecolin’ by Xiamen Innovax, 
Xiamen, China. The vaccine is currently not registered in other countries. The 
phase IV was recently published and is discussed in chapter 5, the summarizing 
discussion.
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OUTLINE OF THIS THESIS
This thesis focuses on the diagnosis and clinical features of HEV infections in 
immune-compromised patients in the Netherlands and the establishment of an 
animal model for this disease. 
As described in chapter 2, we first assessed commercially available ELISAs, the 
most basic diagnostic assay for detection of HEV specific antibodies, to reliably 
study difference of the antibody kinetics in immune-compromised compared to 
immune competent individuals.
Chapter 3 describes the identification of specific immune-compromised patient 
groups suffering from hepatitis E and the related clinical sequelae: chapter 3.1 
focuses on solid organ transplant recipients, chapter 3.2 on heart transplant 
patients and chapter 3.3. describes the identification allogeneic haemopoietic 
stem cell transplantation patients (allo HSCT), as a newly identified immune-
compromised patient group with HEV infections. 
Chapter 4 describes an in vitro method and an in vivo model for virus propagation. 
The in vivo model, based on the use of chimeric mice, can also be used as a 
model to study the pathogenesis of a chronic HEV infection in an immune-
compromised host.
Finally, in chapter 5 the findings of these studies are summarized and discussed, 
also in the light of data generated by other recently conducted studies.
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ABSTRACT 
Background 
Hepatitis E virus (HEV) genotype 3 is recognized as an emerging pathogen in 
industrialized countries. The currently commercially available HEV specific enzyme 
linked immunosorbent assays (ELISAs) are primarily designed for the detection of 
antibodies against genotypes 1 (Birma) and 2 (Mexico) and may not sensitively 
detect HEV genotype 3 or 4.
Objectives 
To evaluated the analytical and clinical performances of eight commercially 
available HEV serum antibody IgM and IgG specific ELISAs for genotype 1 and 3 
HEV infections in a clinical setting. To study the antibody responses against HEV 
of immunocompromised versus immunocompetent patient groups.
Study design 
Analytical performance, diagnostic sensitivity and specificity was assessed using 
well-defined reference samples and samples from patients with PCR-confirmed 
HEV infection (n=88) and a specificity panel (n=98). 
Results 
Limiting dilutions indicated that highest analytical sensitivity in head-to-head 
comparison was measured for the Mikrogen_new IgG assay. Taking the serum 
working dilutions of each assay into account, the Wantai IgG assay was the 
most sensitive assay . ROC analysis showed AUC-values of 0.943, 0.964, 0.969, 
0.971, 0.974 and 0.994 for the DSI, Mikrogen_old, MP-diagnostics, Mikrogen_
new, Wantai and DiaPro anti-HEV IgM assays, respectively. Highest specificity of 
currently available assays was found for the IgM Wantai assay (>99%). If anti-
HEV IgM and IgG results from each supplier were combined, DSI and Wantai 
assays were able to detect the highest number of (passed) HEV infections. 
Conclusions 
Our study shows that current commercial HEV ELISAs can be used to diagnose 
HEV genotype 3 infection adequately in a clinical setting.
Diagnostic performance of selected commercial HEV IgM and IgG ELISAs
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BACKGROUND
Hepatitis E virus (HEV) is a positive sense, single-stranded RNA virus that causes 
subclinical, acute and chronic infections, characterized by hepatitis, though extra-
hepatic manifestations have been described. Four genotypes are known to infect 
humans (genotype 1-4), of which epidemiology and geographical distribution 
differs between genotype 1-2 and 3-4. HEV genotype 3 and to lesser extend 
genotype 4, is recognized as an emerging pathogen in industrialized countries40, 
88 and can cause chronic hepatitis in immunocompromised individuals leading to 
rapid fibrosis of the liver89. 
HEV infection is diagnosed by laboratory testing, since it’s clinical presentation 
does not differ from other pathogens causing hepatitis. Till this date the virus 
cannot efficiently be cultured for diagnostic purposes, thus detection of IgM and 
IgG antibodies and virus RNA are the modes to confirm HEV infection38.
In immunocompromised patients (e.g. solid organ transplant recipients, 
hematological patients) antibody production is often delayed39 and detection 
of HEV RNA is suggested to diagnose HEV infection in this patient group90. In 
immunocompetent individuals, the narrow window in which HEV RNA can be 
detected in serum or feces, is confined to the acute phase of the disease (mean 
28, range 17-48 days)40. Therefore serology is needed to diagnose HEV infection 
in patients who present themselves after vireamic period.
Though HEV has one serotype, the role of currently commercially available 
serological assays is questioned in genotype 3 and 4 endemic countries. The 
current commercial HEV specific enzyme linked immunosorbent assays (ELISAs) 
have recombinant ORF2/3 antigens coated which are primarily designed for the 
detection of antibodies against genotypes 1 (Birma) and 2 (Mexico) and may 
not sensitively detect HEV genotype 3 or 441, 90-92. The sole ELISA assay using 
genotype 1 and 3 antigens (Mikrogen) was recently introduced in the market.
A few in-house assays have been described93, 94, but since continuity and robustness 
of routinely used assays is essential in clinical settings, most laboratories prefer 
(CE-marked / FDA-approved) commercial assays. The HEV specific immunoblot 
(Recomblot, Mikrogen) 91, 95 uses the same antigens as the Mikrogen IgM/IgG 
ELISA and is labor intensive. The knowledge on the performance of current 
commercially available IgM and IgG ELISAs is limited, specifically if IgM and IgG 
of the same commercial company is preferably combined in routine work-up.
Available assays differ in the accuracy for detection of an acute or past HEV 
infection. In addition, previous publications have assessed the performance of 
either HEV specific IgG 41, 96-99 or IgM 93, 95 solely. 
34
Chapter 2
OBJECTIVES 
We have evaluated the analytical and diagnostic performance of selected 
commercially available IgM and IgG ELISAs for the detection of both genotype 
1 and 3 HEV infections, using a well-defined serum-panel of PCR confirmed 
HEV infected patients. Secondly, we studied the HEV antibody responses in 
immunocompetent and immunocompromised patients.
STUDY DESIGN
Sample collection 
The samples used in our retrospective study had been collected in the time period 
of 2003-2011 during hospitalization and routine visits to our out-patient clinic 
for clinical assessments. Serum/EDTA-plasma samples have been stored at -20˚C 
and -80˚C respectively. 
Sensitivity panel
To assess the analytical sensitivity we performed a two-fold endpoint titration of a 
genotype 1 and 3 HEV IgM and IgG antibody positive serum, starting from 1/125 
and 1/25 respectively. Presence of HEV antibodies of these secondary standards 
was confirmed by the -previous- routinely used MP-Diagnostics ELISA and HEV 
RNA was detected by HEV RT-PCR. Additionally, for IgG a two-fold endpoint 
titration (starting from 1/25) was performed using the WHO reference reagent 
for HEV antibody, (human serum NIBSC code: 95/584) of which the antigenic 
trait is unknown100. Lower limit of detection (LLOD) was calculated for each anti-
HEV IgG ELISA using the WHO IS, taking the working dilution of each assay into 
account, as described before41.
To select samples for the diagnostic sensitivity panel, a LIMS database search 
was performed for HEV RNA positivity, HEV genotype, immune status, sequential 
sample availability and clinical information. Eighty-eight samples were selected 
from 17 immunocompromised, 15 immunocompetent and 4 patients with an 
unknown immune status (total 36), whose HEV infections were confirmed by 
real-time RT-PCR. Time frame of infection was determined with reference to 
clinical symptoms and retrospective HEV PCR testing (Table 1). 
Diagnostic performance of selected commercial HEV IgM and IgG ELISAs
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Table 1 Sample distribution of diagnostic sensitivity panel
Time of drawl (t=) Samples 
(n=)
Patients 
(n=)
Samples per immune 
statusa (n=)
Samples per genotype 
(n=)
IC ICT Unkn geno1 geno3 Unkn
Prior to infection 12 12 12  0 0 0  9 3
< 6 wks 34b 31 16 14 4b 7 18b 9
>  6 wks < 6 mos 22 19 15  4 3 0 16 6
>6 mos 20 16 16  3 1 1 17 2
a ICT Immunocompetent, IC=immunocompromised, Unkn = unknown 
b one sample was excluded in the Mikrogen_new assay due to sample volume.
Specificity panel
To assess the assay’s specificity, a serum/EDTA-plasma sample panel was constituted 
of acute Epstein-Barr virus (EBV) infection (n=10), human cytomegalovirus (CMV) 
infection (n=10), B19 virus infection (n=10), hepatitis A virus (HAV) (n=10), 
hepatitis B virus (HBV) (n=10), hepatitis C virus (HCV) infections (n=10) and 
healthy blood donors (n=28). Additionally 10 samples were selected from 10 
HEV infected transplant recipients prior to their HEV infection. 
Selection of immunoassays for HEV antibody detection
For detection of both anti-HEV IgM and IgG in serum or EDTA-plasma samples, eight 
commercially available HEV ELISAs were selected on basis of prior publications41, 
93, common use in Dutch laboratories and availability. IgM and IgG ELISAs were 
selected from MP-diagnostics, (IgM v3.0, MP Biomedicals, Singapore, former 
Genelabs (GL)), Dia.Pro (Milano, Italy), DRG (Marburg, Germany), DSI93 (RPC 
Diagnostic systems, Novgorod, Russia), Diacheck (MP-products, the Netherlands), 
Wantai Biological Pharmacy (PE2-assay, Beijing, China) and Mikrogen (recomWell 
Neuried, Germany). From Mikrogen, two versions recomWell anti-HEV IgM 
assays were selected, one available in The Netherlands up until Feb. 2011, and 
the ‘new’ version available from Nov 2012 in the Netherlands. 
All HEV IgM and IgG ELISAs indirectly detected HEV antibodies using synthetic 
ORF2 and 3 peptides coated on a polystyrene plate, except for the HEV-IgM PE2 
ELISA from Wantai being an μ-chain capture ELISA101. In all ELISAs, genotype 1 
and 2 antigens were used, except for the new version RecomWell HEV-IgM assay 
(Mikrogen), which is coated with genotype 1, 2 and 3 ORF3 antigens.
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ELISA procedures were used according to the manufacturer’s instructions, positive 
and blank controls were taken for quality assurance. Signal to cut-off (s/co)-ratios 
were interpreted according to manufacturer’s instructions. Subsequent statistical 
analysis was performed using IBM SPSS statistics software v.20.
HEV-RNA detection and sequence analysis
The internally controlled quantitative real-time RT-PCR amplified a conserved 
ORF3 region of 77bp as described before 89, 90. For phylogenetic analyses, ORF1 
RdRp (nt 4254–4560) sequences of 321 bp were generated on a ABI3130XL 
using previously described methods90. 
RESULTS
Analytical sensitivity
IgM limiting dilutions indicated that the highest analytical sensitivity among the 
IgM ELISAs for genotype 1 was achieved by MP-Diagnostics and Wantai assay. 
For genotype 3 IgM antibody titration, the Wantai assay was the most sensitive 
assay (Table 2). Remarkably, a wide variety of s/co -ratio’s was observed of which 
the IgM and IgG Wantai assay stood out (s/co-ratios of 18 as upper limit of 
detection). 
IgG limiting dilutions indicated that the highest analytical sensitivity in head-to-
head comparison (titration curves) was measured for the Mikrogen_new assay. 
Though, the Wantai assay had an equal sensitivity for genotype 1 (Table 2). 
Remarkably, if the LLOD was calculated taken the serum working dilutions of 
each assay into account, the Wantai anti-HEV IgG assay was the most sensitive 
assay with 0.69 IU/ml (Table 2). For all samples, the IgM and IgG Diacheck assays 
had the lowest sensitivity and were therefore excluded for further validation. 
Additionally, both Dia.Pro and DRG proved to be the exact same assay, though 
from two different manufacturers and we therefore excluded the most expensive 
assay (DRG) from further validation.
Diagnostic performance of selected commercial HEV IgM and IgG ELISAs
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Table 2 Performance of IgM and IgG specific ELISAs
* WHO reference sample, lower limit of detection (LLOD) taking the serum work dilution of each 
assay into account, receiver operator curve (ROC), area under the curve value (AUC), confidence 
interval (CI), sensitivity (sens.), specificity (spec.)
Specificity anti-HEV IgM ELISAs
The specificity panel was assessed only for IgM, since no gold standard for IgG 
is available. From the specificity panel (n=98), 16 samples were reactive in the 
IgM MP-Diagnostics assay, 10 samples in the IgM DSI assay, 2 samples in the 
IgM Dia.Pro assay, 1 sample in the IgM Mikrogen_new assay and none in the 
IgM Mikrogen_old and Wantai assay. HEV-RNA could not be detected in these 
reactive sera by sensitive real-time RT-PCR assay. The boxplot (Figure 1), shows 
a high variety of aspecifc reactions among the different IgM assays in specific 
subpanels of acute infections. Two IgM assays (DSI and MP-Diagnostics) showed 
aspecific reactions with sera from both acute CMV (n=6 and 5, respectively) and 
HAV infections (n=2 and 3, respectively). Remarkably, the DSI IgM ELISA, had a 
median s/co-ratio above the cutoff of the assay in case of acute CMV infections. 
Noteworthy are the low s/co-ratio’s in all groups of the specificity panel of the 
Wantai assay, since this assay had the highest s/co-ratio’s in HEV-IgM/IgG positive 
sera. The overall specificity was calculated (Table 2), resulting in the highest score 
for IgM Mikrogen_old (>99%) and IgM Wantai assay (>99%).
analytical sensitivity (titers) clinical performance IgM
IgM (titers) IgG (titers) LLOD*
IgG (IU/ml)
ROC* analysis Sens. Spec.
geno1 geno3 geno1 geno3 WHO* WHO* AUC (95%CI)
Mikrogen_old 4000 250 6400  800 1600 6.31 0.964 (0.940-0.989) 52% >99%
Mikrogen_new  32000 16000 >12800 3200 3200 3.16 0.971 (0.938-1.000) 74%  99%
MP-Diagnostics >64000 4000 3200 100 800 2.63 0.969 (0.948-0.991) 74%  84%
DSI 8000 4000 3200 800 800 1.25 0.943 (0.900-0.986) 71%  90%
Dia.Pro 32000 32000 6400 100 800 2.63 0.994 (0.982-1.000) 81%  98%
Wantai >64000 >64000 >12800 1600 1600 0.69 0.974 (0.941-1.000) 75% >99%
DRG 32000 32000 6400 100 800 2.63 excluded
Diacheck 1000 125 3200 100 400 5.25
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Figure 1 Specificity of selected anti-HEV IgM ELISAs. Boxplot showing the mean, interquartile 
ranges, outliers (o) and extremes (*) of the signal to cut-off (s/co) ratios of six HEV-IgM detecting 
ELISAs in patients with diagnosed acute infections of CMV (n=10), EBV (n=10), HAV (n=10, n=9 
for Mikrogen_new assay), HBV (n=10), HCV (n=10), B19 (n=10), healthy blood donors (n=28) and 
samples of transplant recipients (TR) before HEV infection (n=10). Colors are indicated in the legend 
(o Mikrogen_old, o Mikrogen_new, o MP-diagnostics, o DSI, o DiaPro, o Wantai) 
Diagnostic sensitivity of the anti-HEV IgM ELISAs
To assess the clinical accuracy of de IgM ELISAs, the diagnostic sensitivity panel was 
processed using six IgM ELISAs. Cohen’s kappa (ĸ) concordance was calculated, 
with ‘intermediate results (s/co-ratio’s interpreted according to manufacturer’s 
instructions) both considered as reactive or non-reactive, which yielded higher 
or equal concordance levels for the assays using ‘intermediate’ results assigned 
as non-reactive (Table 3). The ĸ-levels ranged between 0.562 and 0.948 and 
the highest ĸ-levels among the IgM ELISAs were the Dia.PRO/Wantai IgM assays 
(ĸ=0.900) and the Mikrogen_new/Wantai IgM assays (ĸ=0.948). 
Furthermore, receiver operator curve (ROC) analysis resulted in highest area 
under the curve of 0.971, 0.974 and 0.994 for the Mikrogen_new, Wantai and 
DiaPro HEV IgM assays, respectively (Table 2).
The overall diagnostic sensitivity ranged from 52% for the Mikrogen_old IgM 
assay to 81% for the IgM Dia.PRO assay (Table 2). If only acute samples (<6wks 
after infection, n=34) were taken into account, the diagnostic sensitivity was 
65% for Mikrogen_old, 73% for Mikrogen new, 74% for MP diagnostics, DSI 
and Wantai and 79% for Dia.Pro assays.
Diagnostic performance of selected commercial HEV IgM and IgG ELISAs
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Table 3 Cohen’s Kappa concordance of anti-HEV IgM and IgG specific ELISAs
anti-HEV IgM
Mikrogen_old Mikrogen_new
MP-
Diagnostics DSI Dia.Pro Wantai
anti-
HEV 
IgG
Mikrogen_old - 0.744 0.562 0.642 0.653 0.721
Mikrogen_new 0.739 - 0.743 0.810 0.873 0.948
MP-Diagnostics 0.643 0.559 - 0.738 0.726 0.723
DSI 0.783 0.854 0.621 - 0.792 0.763
Dia.Pro 0.678 0.667 0.813 0.653 - 0.900
Wantai 0.730 0.893 0.530 0.892 0.610 -
Performance of combined anti-HEV IgM and IgG ELISAs
Since in most clinical laboratories IgM and IgG ELISAs of one commercial provider 
are combined in routine work-up, we assessed the combined results of both anti-
HEV IgM and IgG ELISAs of one provider to diagnose a HEV infection at different 
time points in the infection. None of the assays were able to detect anti-HEV IgM 
nor IgG in 9 of 78 samples, though HEV RNA could be detected (median viral 
load 2.35 log10 IU/ml, range 1.41-7.09). These nine samples belonged to seven 
immunocompromised transplantation recipients, of which six samples were 
drawn <6 weeks after infection and two between 6 weeks and 6 months after 
infection. Anti-HEV IgM and/or IgG antibodies (IgM/IgG ratio) were detected in 
51 (40/40), 61 (57/33), 63 (62/39) and 66 (56/56) samples for Mikrogen_old, 
MP-Diagnostics, Dia.PRO assay and Mikrogen_new assay respectively, whereas 
both DSI and Wantai IgM and IgG assays combined could detect HEV specific 
antibodies in 67 of 78 samples. For these two assays IgM/IgG nominator of 
positive samples was 55/50 and 58/57 samples respectively.
Antibody kinetics of genotype 1 and 3 in the immunocompetent and 
immunocompromised
To gain insight in the antibody kinetics in groups with different immune status 
and detected responses to the two assessed genotypes, the s/co-ratios of these 
different panels were plotted (Figure 2 and Figure 3). Figure 2 shows a difference 
in magnitude of the immune responses in the compared groups. However anti-
HEV IgM could be detected in only in 7/16 immunocompromised patients and 
18/18 immunocompetent patients in the acute phase (<6wks) of the infection, 
indicating a delayed immune response in the immunocompromised group. 
The immunocompetent group shows a classic pattern of quickly rising IgM 
levels immediately after infection, which declines after 6 weeks and becomes 
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undetectable after 6 months (Figure 2, lower left panel). In contrast to the 
immunocompromised group (of which 50% were chronically infected), having 
low IgM levels immediately after HEV infection, which rise during the course 
of infection. Furthermore, Figure 3 shows that genotype 3 IgM antibodies can 
efficiently be detected in assays which have genotype 1 and 2 antigens coated.
The difference between immunocompromised and immunocompetent groups 
in IgG antibody kinetics is less apparent than for IgM, both showing seemingly 
steady IgG antibody levels after 6 weeks of infection (Figure 2, right panels). 
However, only two assays (Mikrogen_new and Wantai) were able to detect IgG 
in all samples of the immunocompetent group (n=4) six months after infection. 
Also for IgG, genotype 3 antibodies were detected using genotype 1 and 2 
coated ELISAs.
DISCUSSION
Autochthonous HEV infection, caused by genotype 3, is recognized as an 
emerging infectious disease in industrialized countries. Only limited data are 
available on the diagnostic performance of commercial IgM and IgG ELISAs or 
combination of these two and the sensitivity of ELISAs coated with genotype 1 
and 2 antigens is questioned for the detection of genotype 3 and 4. Our study 
gives more insight in diagnostic performance and antibody kinetics of commercial 
anti-HEV IgM and IgG assays of immunocompromised and immunocompetent 
patients with genotype 1 and 3 HEV infections.
The results of this study show a variety in analytical sensitivity among the tested 
assays for both IgM and IgG antibodies and if used on clinical specimens also 
varying clinical specificity ranging from 84 – more than 99% and sensitivity 
ranging from 52-79%. If the IgM and IgG results from each commercial supplier 
were combined to assess the diagnostic value, only DSI and Wantai assays were 
able to identify HEV specific antibodies in 86% of samples. These data should 
be interpreted for each setting separately, depending on the objective for which 
the ELISAs is used. In clinical practice, IgM is the most valuable serological tool 
to diagnose an acute HEV infection. Comparing the currently available assays, 
the Wantai assay had the best specificity (>99%), most discriminative s/co-ratios 
and comparable diagnostic sensitivity. For public health studies in genotype 3 
endemic areas, it should be taken into account that the Mikrogen_new assay 
had a better analytical sensitivity for IgG if head-to-head compared to other 
assays. However, taking the working dilution of this assay (1:101) and the Wantai 
Diagnostic performance of selected commercial HEV IgM and IgG ELISAs
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assay (1:11) into account, Wantai had the lowest LLOD (0.69IU/ml). Furthermore, 
specificity could not be assessed for IgG and we did not include samples with a 
long (>5 years) follow up period and can therefore not draw any conclusions on 
performance of the selected assays over longer periods of times. 
It is known that antigenicity of the pE2 peptide (aa394-606) used in the Wantai 
assay, is superior to other shorter E2 peptides, because of the stabilizing effect 
an 60 amino acid extension has on the dimer formation of the antigen27. The 
Wantai assay is the only assay which uses an μ-chain capture strategy in the 
anti-HEV IgM assay. Generally, μ-chain capture ELISAs have higher specificity and 
sensitivity than indirect ELISAs102, 103. Taken together, this may explain the high s/
co-ratios seen in the Wantai anti-HEV IgM and IgG assays.
The seemingly moderate diagnostic sensitivity in this study may be explained 
by the 67.1% of the samples in this sensitivity panel, which were selected from 
17 immunocompromised individuals, having HEV-RNA in their peripheral blood, 
though inferior antibody levels than immunocompetent individuals. In 11.5% of 
the patients none of the assays could detect any antibody responses. 
Furthermore, antibody kinetics directed against genotype 1 and 3 infections in 
groups with different immune status confirmed findings of previous studies95, 99, 
concluding there are no sensitivity problems in the detection of genotype 3 using 
ELISA assays coated with only genotype 1 and 2 antigens. Though the diagnostic 
sensitivity panels used in our study indicate the different antibody kinetics among 
immunocompromised compared to immunocompetent group, the numbers 
used were relatively small and need to be assessed eventually in larger panels 
to gain statistical significance. A second limitation of our study is the absence of 
HEV genotype 2 and 4 samples, which were not available for this study.
Collectively, though there is a wide variety among the selected assays, our data 
show that the HEV ELISAs can be used to diagnose both HEV genotype 1 and 3 
infections in a clinical setting. Considering the high concordance and specificity 
of the best performing assays and the availability of HEV RNA assays, there’s no 
longer a need to perform serologically confirmatory testing in diagnostic settings.
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ABSTRACT
The recent increase in reports of hepatitis E virus (HEV) infections in solid organ 
transplant (SOT) recipients prompted us to screen all living heart- (HTX), lung- 
(LungTX), liver- (LTX) and kidney- (KTX) transplant recipients (n=1197) attending 
the out-patient clinic of the largest transplantation centre in The Netherlands. 
In each SOT-category, HEV infections were found. In twelve patients (1%) HEV 
infection was identified by RT-PCR, ten of them had developed symptomatic 
chronic HEV infection. Phylogenetic analyses of the ORF1 sequences of the HEVs 
involved, classified all within genotype 3, without indications for a common 
source. Retrospective analysis of samples from the confirmed cases revealed that 
HEV RNA was detected on average 64 days prior to HEV specific IgM. This is 
the first systematic survey among all SOT recipients, confirming that they are at 
risk to develop chronic HEV infection, and stressing the importance of HEV RNA 
screening in SOT recipients.
Clinical implications of hepatitis E
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INTRODUCTION
Hepatitis E virus (HEV) may cause acute or chronic infection in humans, characterized 
by hepatitis and gastro-enteritis. HEV is shed through stool of infected individuals, 
and most commonly transmitted by fecally contaminated water. In addition to 
this, food-borne and blood-borne transmission have been documented, and direct 
zoonotic transmission has been suggested. Direct person-to-person transmission is 
thought to be rare. Hepatitis E viruses are small (24-34 nm) non-enveloped viruses, 
with a single stranded, positive sense RNA genome of around 7,500 base pairs and 
three partially overlapping open reading frames (ORF 1-3)104. Four genotypes (1-4) 
have been described in humans. Genotype 1 is responsible for large water-borne 
HEV outbreaks in endemic non-industrialized countries. In industrialized countries 
HEV genotype 3 predominantly infects pigs, wild boars and deer but also humans 
and is recognized as a zoönotic agent. However the main modes of transmission 
of genotype 3 viruses remain to be determined 40, 105. Prevalence of genotype 3 
HEV RNA in pooled grab samples collected at Dutch pig farms was estimated 
to be about 55%106 while 6.5% of commercially available porcine livers tested 
positive for HEV RNA, while the viruses could also be detected in surface waters 
52. This indicates that insufficiently heated pig meat products or environmental 
exposures may be a source of human infection. As awareness for HEV infection is 
rising, the numbers of human case reports of HEV infection also increase. Especially 
the numbers of reports concerning immune-compromised individuals including 
solid organ transplant (SOT) recipients71, 107, 108, hematological patients109 and HIV 
infected individuals110 have increased. 
Systematic analysis of exposure histories of newly diagnosed genotype 3 HEV 
cases has demonstrated that HEV is under diagnosed, but failed to provide a 
clear source for most infections 44, 111. Recently, HEV was recognized as a cause 
of chronic hepatitis in immunocompromised patients 112-114. On the basis of sero-
epidemiological studies it has been estimated that 2% of the Dutch population 
has been infected with HEV115, whereas symptomatic acute and chronic infections 
are diagnosed only sporadically. Given the level of exposure of the population, HEV 
infections in the Netherlands are probably largely under-diagnosed. Since HEV has 
been reported to cause acute and severe liver disease in SOT recipients116, we set 
out to screen all living SOT recipients visiting the out-patient clinic of ErasmusMC 
for HEV RNA. ErasmusMC is the largest SOT centre in the Netherlands, where 24% 
of Dutch SOT recipients are transplanted. At the time of testing this SOT study 
population consisted of 256 heart- (HTX), 53 lung- (LungTx), 300 liver- (LTX), 574 
kidney (KTX) and 14 multiple adult SOT recipients. The cross- sectional analysis 
50
Chapter 3.1
conducted in this study was designed to enable us to identify SOT recipients with 
acute or chronic HEV infection, eligible for treatment of their hepatitis. 
MATERIALS AND METHODS
Sample collection 
We conducted a cross-sectional analysis of all living adult SOT recipients of whom 
serum or EDTA-plasma samples were available in the biobank of ErasmusMC. 
These samples had been collected during routine visits to our out-patient clinic 
for clinical assessments and have been stored at -20˚C and -80˚C respectively. 
To select samples, a LIMS database search was performed for last post-
transplantation sample availability (preferably EDTA-plasma) within the following 
arbitrarily chosen timeframes: HTX from 2000 to March 2011, LTX from 2009 to 
March 2011, KTX from 2009 to March 2011 and LungTx from 2007 to March 
2011. Each enrolled subject had signed an informed consent that allowed future 
testing of archived bio-samples. Additionally, all HEV RNA positive non-SOT 
recipients represented in our biobank were genotyped and used as reference for 
phylogenetic analysis. This study was approved by the medical ethical committee 
of the hospital (MEC approval: MEC-2011-277).
HEV specific antibody detection
For detection of both HEV specific IgM and specific IgG in serum or plasma 
samples the commercially available HEV ELISA v3.0 (MPdiagnostics, former 
Genelabs, Singapore) was used according to the manufacturer’s instructions. 
Samples of HEV-RNA positive patients were retrospectively tested during the 
entire course of infection to study the kinetics of antibody responses (IgM and 
IgG) and viremia in the confirmed cases.
HEV-RNA detection 
All samples were screened for the presence of HEV RNA by a real-time RT-PCR 
based on Ahn et al.117 and Zhao et al.118 amplifying a conserved ORF3 region 
of 77bp. Primers were adapted to detect all four genotypes. Briefly, RNA was 
extracted using MagnaPureLC (Roche Diagnostics, Almere, The Netherlands) and 
total nucleic acid isolation kit with an input and output volume of 200μl and 
100μl, respectively. The extraction was internally controlled by the addition of 
a known concentration of Phocine Distemper Virus. 20 μl extracted RNA was 
amplified in a 50μl final volume one-step RT-PCR, containing 12.5 μl 4x TaqMan® 
Clinical implications of hepatitis E
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Fast Virus 1-Step Master Mix (Lifetechnologies, Nieuwerkerk a/d Ijssel, The 
Netherlands), 0.5 ul (1U/ul) Uracil-N-Glycosylase (Lifetechnologies, Nieuwerkerk 
a/d IJssel, The Netherlands), 30 pmol HEV fwd (‘5- CGGTGGTTTCTGGGGTGA-‘3) 
45 pmol HEV rev (‘5-GCRAAGGGRTTGGTTGG-‘3), 5 pmol HEV probe (‘5-FAM-
ATTCTCAGCCCTTCGC-MGB-‘3). The internal control was amplified in a 
separate reaction using TaqMan® Fast Virus 1-Step Master Mix, 0.5 ul (1U/ul) 
Uracil-N-Glycosylase and primers/probe as described before 119. Amplification 
was performed in a LC480 (Roche Applied Science, Almere, The Netherlands) 
using Fit point analysis module. Quality assurance was performed using the free 
MedlabQC software. Criterion for a successful RT-PCR run was Ct values of both 
internal control and positive PCR control should be within 3xSD of mean. 
Case definition 
A case of HEV infection was defined as a patient with a HEV RNA positive serum 
or plasma sample and was confirmed either by showing HEV specific serum IgM 
or IgG antibody or by showing the presence of HEV RNA in sequential serum 
or plasma samples. Chronic infection was diagnosed by retrospective testing of 
stored samples of identified cases and was defined as having HEV RNA in serum 
or plasma for more than 6 months. 
Sequence analysis
For phylogenetic analyses ORF1 RdRp (nt 4254–4560) sequences of 307 bp 
were generated using previously described primer set MJ-C 45. Briefly, cDNA 
was prepared in 50μl volume reaction containing 23μl HEV RNA, 20 pmol EAP 
4576–4595 5’-AGGGTGCCGGGCTCGCCGGA-3’, 1x first strand buffer, 0.1M 
DTT, 10mM dNTP, 80U RNAsin (Promega, Leiden, The Netherlands), 200 units 
Superscript III RT (LifeTech, Bleiswijk, The Netherlands) and 5 min 65°C and 1 hour 
50°C as thermal profile. Subsequently, an outer PCR reaction was performed in a 
9700 PCR machine (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands) 
amplifying 10μl cDNA in a 50μl final PCR mix volume, containing 1x PCR buffer, 5 
mM MgCl2, 10 mM dNTP, 2.5 units HotStarTaq DNA Polymerase (Qiagen, Venlo, 
The Netherlands), 20 pmol ISP 4232–4253 5’-GTATTTCGGCCTGGAGTAAGAC-3’ 
and 20 pmol EAP 4576–4595 5’-AGGGTGCCGGGCTCGCCGGA-3’. Thermal 
profile of PCR was 15 min 95˚C, 40 cycles of 20’’94˚C, 30’’60˚C, 45’’72˚C 
and 10’ 72˚C. If necessary, a nested PCR was performed using 2 μl outer PCR 
product, the same reaction conditions and PCR profile as for outer PCR, but 
ISP 4232–4253 5’-GTATTTCGGCCTGGAGTAAGAC-3’ and IAP 4561–4583 
5’-TCACCGGAGTGYTTCTTCCAGAA-3’ as primers. The amplicon was sequenced 
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with 5 pmol of the above-mentioned primers. One microliter of the amplicon was 
sequenced with the BigDye Terminator version 3.1 cycle sequencing kit (Applied 
Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). The PCR products were 
purified using Performa DTR V3 purification plate (Edgebio, Sopachem, Ochten, 
The Netherlands) and separated on an ABI 3130XL sequencer (Applied Biosystems). 
The sequence data were analyzed using a Sequence Navigator software sequencer 
(Applied Biosystems) and SeqMan v9.0 (DNASTAR, Madison,WI). Obtained HEV 
sequences and GenBank reference sequences 45 were aligned and phylogenetic 
relationships were calculated using maximum likelihood method, Kimura-2 
parameter (Mega5.05) and bootstrap resampling (n =1,000). The sequences of all 
isolates were deposited into GenBank under accession no. JQ015399- JQ015448.
RESULTS
A total of 1197 SOT recipients were screened: 256 HTX-, 53 LungTX- , 300 LTX-, 
574 KTX- and 14 multiple SOT recipients. The latter group consisted of four 
patients with a kidney-heart transplant, one patient with a kidney-lung transplant 
and nine patients with a kidney-liver transplant. Twelve patients with HEV infection 
were identified: five (1.95%) HTX-, one (1.89%) LungTX-, three (1%) LTX-,and 
one (0.17%) KTX- recipients and two multiple SOTs (14.2%)(1 HTX-KTX and 1 
LTX-KTX). In ten cases (83%) the viral hepatitis had progressed into a chronic HEV 
infection (Table 1). The median age of all the HEV infected cases was 56.9 years 
(range 19.9-63.5) and 75% (n=9) were male. Immunosuppression at time of first 
HEV RNA detection was in ten HEV cases prednisolone and tacrolimus based, 
combined with either mycophenolate mofetil (n=3) or everolimus (n=2). In two 
cases immunosuppression was a both cyclosporine and prednisolone (n=1) or 
both mycophenolate mofetil and prednisolone (n=1) based regimen.
Table 1 Overview of HEV in Dutch Solid Organ Transplant recipients
SOT Group* Recipients 
included (No.)
confirmed HEV infection Chronic HEV
No. (%) No.
HTX 256  5  1.95  5
LungTX  53  1  1.89  1
LTX 300  3  1.00  2
KTX  574  3  0.17  1
Multiple SOT†   14  2 14.29  1
Total 1197 12 1.00 10
* SOT solid organ transplant, HTX heart transplant, LTX liver transplant, KTX kidney transplant, 
† 9 KTX-LTX, 4 KTX-HTX and 1 KTX-LungTx 
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Pathology
All chronic HEV cases had elevated liver enzyme values, with a median peak 
ALAT level of 329 U/l (upper limit of normal (ULN) 30 U/L, range 70-909), ASAT 
level of 189 U/l (ULN 36 U/L, range 56-1016), γ-GT level of 303 U/l (ULN 49 
U/L, range 72-1740). Peak bilirubin levels were elevated in 50% of the cases 
(ULN 16 U/L, median 15 U/l, range 5-100). From nine patients with chronic HEV 
infection, liver biopsies were available. Inflammatory activity compatible with 
viral hepatitis was shown in eight of these cases. Other pathological findings 
were F0-F2 fibrosis, steatosis 1-2 (Brunt classification), cholestasis and presence 
of Councilmanbodies. 
Virological parameters
All twelve confirmed HEV cases were retrospectively tested for HEV RNA, anti-
HEV IgM and IgG to characterize the course of their infection in relation to the 
transplantation date. One HEV infection was traced back to 2003 (LuTX), one to 
2008 (KTX), one to 2009 (multiple SOT recipient, KTX-HTX), seven to 2010 (5 HTX, 
1 LTX and 1 multiple SOT recipient, KTX-LTX) and two to 2011 (both LTX). Among 
the twelve confirmed cases, one LTX patient was identified with an acute HEV 
infection, who apparently had cleared the virus (HEV RNA undetectable) within 
6 days. Anti-HEV IgM was detected at the same date of detecting HEV RNA, 
however anti-HEV IgG was not detected. In a second acute HEV case (multiple 
SOT, LTX-KTX) neither anti-HEV IgM nor IgG serum antibodies were detected, 
but HEV RNA was positive (median Ct 38.6 in consecutive monthly EDTA-plasma 
specimen) for 3.9 months at time of writing this manuscript, and could therefore 
not yet be assigned as a chronic infection. In all ten chronic HEV cases HEV RNA 
was detected for at least 6 months, with a median period of 10.8 months (range 
6.3 -55.1) and a median peak Ct value in EDTA-plasma of 20.2 (range 16.7-23.6). 
The course of infection of two arbitrarily chosen representative cases of chronic 
HEV infection, one liver (A) and one heart (B) transplant recipient is shown in 
Figure 1, respectively. Both patients show a rise in ALAT values at the time of HEV 
RNA positivity in peripheral blood. In patient A, anti-HEV IgM and IgG serum 
antibodies were detected at the time of HEV RNA positivity, however in patient 
B HEV RNA was detected prior to anti-HEV IgM serum antibodies. Both fecal 
samples collected from these patients (indicated with * in Figure 1) were HEV 
RNA positive, showing that HEV may indeed be found in the feces of infected 
patients. In fecal samples collected from patients with confirmed chronic HEV 
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infection (n=7), HEV RNA was detected during viremic stage (median Ct 18,2 
range 15.5-28.0). No fecal samples were available from the two acute cases.
To assess the choice of diagnostic techniques for detection of HEV infection in 
SOT recipients, we studied the kinetics of antibody responses (IgM and IgG) 
and viremia in the confirmed cases (n=12). The median lag time from HEV RNA 
positivity to anti-HEV IgM detection was 64 days (range -35 – 842 days). Four 
patients did have detectable anti-HEV IgM titer at the same day of HEV RNA 
positivity, in one case anti-HEV IgM was detected 35 days before HEV RNA and in 
one case no anti-HEV IgM was detected. HEV specific IgG titers, however, were 
not detected in five of twelve cases. One case showed borderline reactivity in only 
one sample and in the other six cases HEV specific IgG titers were detectable on 
average 129 days later than HEV RNA (range 0- 842 days). In two cases anti HEV 
IgG was detectable at the same time as HEV RNA detection.
The median time between transplantation and first HEV-RNA positive sample of 
all confirmed HEV cases proved to be from -0.3 to 20.0 years (median 1.99 years). 
Figure 1 Course of HEV infection in solid organ transplant patients. Plotted are the liver 
enzyme values, ALAT en HEV RNA Ct-values of a (A) liver transplant patient and a (B) Heart transplant 
patient prior to and during a chronic HEV infection. Both patient A and B received a tacrolimus based 
immunosuppressive regimen, patient B also received prednisolone. -■ - HEV RNA (semi-quantative 
Ct-value), ---▲--- ALAT (U/L),  ̶  Upper Limit of Normal ALAT (=30 U/L); ̶  Limit of detection HEV RNA 
(Ct-value = 40). * Feces specimen tested HEV RNA positive.
Phylogenetic analysis 
The ORF1b sequences generated from ten cases showed that all these viruses 
grouped within genotype 3. Since there are no Dutch ORF1b sequences available 
in GenBank, we generated ORF1b sequences from 40 other acute and chronic 
Dutch HEV cases as a reference. These samples were found HEV-RNA positive 
among anti-HEV IgM and/or IgG positive samples from our biobank. Hereafter, 
the EDTA-plasma or serum-samples of these individuals were retrospectively 
tested to disclose the time of infection, indicated in the taxon names (Figure 2, 
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NLyyyy-specimen number). Phylogenetic analyses did reveal indications for neither 
a common origin nor nosocomial HEV transmission in these SOT recipients.
Figure 2 Phylogenetic tree of HEV ORF1 sequences 
including Dutch cases of acute and chronic HEV 
infections. Phylogenetic relation of 306 bp ORF1 
region was calculated using Maximum likelihood, K2P 
analysis with bootstrapping (n=1000). Branch lengths 
are proportional to the evolutionary relationship 
between the sequences and internodal confidence of 
>70% is depicted in the tree. HEV sequences of Dutch 
origin and year of infection are indicated as NLyyyy-
isolate number, Genbank accession numbers are no. 
JQ015399- JQ015448.
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DISCUSSION
Recent publications71, 107, 108, 116 describing HEV infection in SOT recipients, 
prompted us to perform a retrospective cross sectional survey in all SOT recipients 
of the largest transplantation centre in the Netherlands. We showed that SOT 
recipients are indeed at risk of HEV infection. Furthermore, we found that nine 
(83%) out of twelve chronic cases identified had been treated with a tacrolimus 
based immunosuppressive regimen. The use of this drug has previously been 
described as a risk factor for developing chronic HEV infection 71.
The cross-sectional screening by RT-PCR, resulted in the detection of both acute 
and chronic HEV infections, but could not provide information about previously 
acquired and cleared HEV infections among the SOT recipients. We screened our 
SOT population by real-time RT-PCR, for two reasons. First, the immune response 
of transplant recipients is reduced due to the use of immunosuppressive drugs, 
and therefore specific antibodies against HEV might not be detectable. Secondly, 
the currently commercially available HEV specific ELISA’s are primarily developed 
for the detection of antibodies to genotypes 1 (Birma) and 2 (Mexico) and may not 
sensitively detect HEV genotype 3 or 4 91.There is only limited information about 
the validation of HEV genotype 3 serological assays and it has been documented 
that seroprevalence measured may vary considerably with on the assays used 41, 93, 
115. It should also be noted that detection levels and specificity of HEV RNA among 
Dutch (unpublished observations) and other European laboratories differ greatly 42. 
Therefore standardization with WHO international standards should be encouraged. 
Although, at first glance, the observed 1% of actively HEV infected individuals 
among the SOT recipients may seem low, it should be emphasized that HEV 
infection can be life threatening in immunocompromised patients. Misdiagnosis 
of HEV as drug-induced liver injury120,121 or auto-immune hepatitis infections have 
been reported and subsequent treatment by raising immune suppression would 
be counterproductive: in about 30% of the cases temporary reduction of immune 
suppression resulted in immune mediated control and clearance of HEV 71. 
The present study also shows that HEV RNA may be detected on an average 65 
and 129 days prior to the appearance of anti-HEV IgM and IgG serum antibodies, 
respectively. Therefore, in SOT recipients with elevated liver enzyme values (ALAT 
or ASAT), the diagnosis of HEV infection should be considered and confirmed by 
HEV RNA detection in addition to other infections causing hepatitis. 
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In conclusion, this is the first systematic survey of HEV infections among all SOT 
recipients in a major transplant center, which shows that they indeed are at risk 
for acquiring chronic HEV infection. Given the serious consequences of chronic 
HEV infection in immunocompromised individuals, systematic HEV RNA screening 
of SOT recipients should be implemented, as this life threatening condition may 
be treated successfully.
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ABSTRACT
Background & Aims: Recent reports have shown that hepatitis E virus (HEV) 
infection can become chronic in solid organ transplant recipients, but few studies 
have systematically investigated the clinical consequences of this chronic HEV 
infection in solid organ transplant (SOT) recipients. 
Methods: We describe an in depth study of six chronic HEV infected heart 
transplant recipients to gain more insight in clinical, biochemical and virological 
presentation . 
Results: In six patients (2,3%) chronic HEV infection, genotype 3, was identified. 
Immunosuppression in these patients was tacrolimus based, combined with 
either everolimus or prednisolone and/or mycophenolate mofetil. Median follow-
up after case detection was 26 months (range 21-40 months). All chronic HEV 
cases had elevated liver enzyme values. IgM antibodies at presentation were 
positive in two out of six (33%) patients. Liver histology showed in four out of 
six (67%) patients developed advanced fibrosis within two years after infection. 
One patient spontaneously cleared the HEV infection, one after dose reduction 
of immunosuppressive therapy and three during ribavirin therapy. One patient 
has not managed to clear the virus yet and is still on ribavirin therapy.
Conclusion: chronic HEV infection in HTX recipients may lead to rapid fibrosis 
of the liver. We advise additional HEV RNA screening in solid organ transplant 
recipients with elevated liver enzymes, since antibody production is often 
delayed as shown in these patients. Dose reduction of immunosuppressive 
therapy should be the first intervention strategy to achieve viral clearance in 
chronic HEV infected immunocompromised patients. Ribavirin treatment should 
be considered in cases of chronic HEV.
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INTRODUCTION
Hepatitis E virus is a non-enveloped virus with a single-stranded, positive sense 
RNA genome of approximately 7,500 base pairs and three partially overlapping 
open reading frames (ORF 1-3) 15. There are four mammalian genotypes prevalent: 
genotypes 1 and 2, endemic in developing countries causing waterborne 
outbreaks and genotypes 3 and 4, seen in sporadic cases in industrialized 
countries and thought to be zoonotic of origin15, 105.
In the Netherlands, the prevalence of genotype 3 hepatitis E virus in fecal tanks 
on pig farms is estimated to be about 55% 51, while HEV RNA was found in 6.5% 
of commercial porcine livers 52, suggesting a role for undercooked pig meat in 
pig-to-human infection. Contributing to this theory is the homology between 
strains detected in pigs that were also found in Dutch patients of up to 100% 44, 
106. Close nucleotide identity to strains isolated in Dutch pigs was also found in 
HEV infected patients in Germany and Scandinavia112, 122, which implies a shared 
distribution of genotype 3 hepatitis E virus in these countries and possibly the 
rest of Western Europe. 
While hepatitis E virus has always been considered to cause solely acute infection, 
the last few years reports on persistent chronic infection with genotype 3 in 
immunocompromised patients, mostly with solid organ transplantation, have 
been published 69, 90, 107, 112, 122-124. Moreover, chronic HEV infection in these 
patients can lead to rapid fibrosis and even cirrhosis 112, 113, 122. Therefore diagnosis 
of chronic HEV infection in solid organ transplant recipients is vital, to start early 
intervention and prevent irreversible liver damage. Though some case studies 
have addressed intervention with ribavirin or peginterferon-alpha treatment, 
there is no current guideline or standardized treatment protocol available 80, 124-
130. Few studies have systematically investigated the clinical consequences of this 
chronic HEV infection in solid organ transplant (SOT) recipients. In a previous 
study, we found a HEV point prevalence of 1% in 1200 SOT recipients 90. Half 
of HEV infected patients were heart transplant (HTX) recipients. The aim of 
the current study was therefore to investigate the clinical presentation of HEV 
infection in heart transplant (HTX) recipients and management options including 
antiviral treatment.
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MATERIALS AND METHODS
Case definition and sample collection 
In previous study we identified one patient with a transient viremia and six 
chronically HEV infected HTX recipients in a timeframe of 2000-2011 90. A case 
of HEV infection was defined as a patient with an HEV RNA positive serum or 
EDTA-plasma sample and was confirmed either by showing HEV specific serum 
IgM or IgG antibody or by showing the presence of HEV RNA in sequential serum 
or plasma samples. Chronic infection was defined as having HEV RNA in serum 
or EDTA-plasma for more than 6 months and diagnosed by retrospective testing 
of stored samples. These samples were collected during routine visits to our 
outpatient clinic for clinical assessments had been stored at -20°C (serum) and 
-80°C (EDTA-plasma or feces). To verify excretion of HEV RNA via stool, available 
fecal samples were screened by RT-PCR. Additionally, spouses of identified cases 
were asked to donate a serum sample for serological screening of HEV specific 
antibodies. Each enrolled subject had consented in future testing of archived 
bio-samples. The study protocol conforms to the ethical guidelines of the 1975 
Declaration of Helsinki as reflected in a priori approval by the local medical ethical 
committee (MEC approval: MEC-2011-277).
HEV specific antibody detection
For both HEV specific IgM and HEV specific IgG detection in serum or EDTA 
plasma samples the commercially available enzyme-linked immunosorbent 
assay (ELISA) (Wantai, Beijing, China) was used according to the manufacturer’s 
instructions.
HEV-RNA detection 
All samples were screened for the presence of HEV RNA by an internally 
controlled quantitative real-time RT-PCR, described previously 90. The RT-PCR had 
a lower limit of detection (95% hit rate) of 143 IU/ml as determined by the 1st 
WHO stardard for HEV RNA NAT-Based assays (6329/10, Paul Ehrlich Institute, 
Germany).
Sequence analysis
For phylogenetic analyses ORF1 RdRp (nt 4254–4560) sequences of 306 bp were 
generated using previously described primer set MJ-C 45. Detailed methods have 
been described previously 90. The sequences of all isolates were deposited into 
GenBank under accession no. JQ15418, JQ15423-JQ15425 and JQ15427-JQ15428.
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Liver biopsy
Liver biopsies were performed using either a 14-gauge needle or an 18-gauge 
needle in combination with a plugged biopsy. All samples were fixed with 
formalin, embedded in paraffin and subsequently stained. Staining included: 
Hematoxylin and Eosin (HE), Periodic acid-Schiff (PAS), PAS-diastase (PAS-D), sirus 
red, copper, iron, reticulin and CK7. All biopsies were evaluated by the same 
pathologist (FJtK). Necroinflammatory activity was scored using the Histology 
Activity Index 131, while the grade of steatosis and iron deposition were classified 
according to respectively Brunt et al. 132 and Brunt et al. 133.
RESULTS 
Patients
A total of 1200 SOT recipients were screened previously, of which 263 were HTX 
recipients 90 (Figure 1). Out of all HTX recipients, four were multiple SOT recipients 
with a kidney-heart transplant. All HEV PCR positive cases were retrospectively 
tested for HEV RNA, anti-HEV IgM and IgG to characterize the course of the 
infection in relation to the date of transplantation. 
Figure 1 Flow chart of patient selection
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In seven (2.7%) patients HEV RNA was detectable in at least one sample. HEV 
infection could be confirmed in six patients: five heart transplant (HTX) recipients 
and one kidney-heart transplant (HTX KTX) recipient. In one patient, HEV RNA 
was only detected in a single sample and could not be confirmed by either 
detectable HEV RNA or HEV specific IgG or IgM antibodies in any previous or 
subsequent samples available; therefore this patient did not fulfill the case 
definition. Moreover, no elevation of liver enzymes was documented in this 
patient.
All six confirmed cases developed a chronic HEV infection (HEV RNA detectable 
for at least six months). The median age of all HEV infected patients at the time 
of infection was 50.0 years (range 38.3-62.4) and 83% (n=5) were male. Median 
time from transplantation to HEV infection was 7.5 years (range 1-20 years). In 
the samples studied, all chronic patients were infected after 2008. All six chronic 
HEV infected patients received tacrolimus based immunosuppression (Table 1). 
Table 1 Baseline* characteristics of six HTX recipients with chronic HEV infection
Age 
(years)
Gender Year of 
trans-
plantation
Year of 
first HEV 
RNA + 
sample
Time 
HTX to 
infection 
(years)
Immuno-
suppressive 
therapy
IgM IgG
1 51.3 M 2008 2010 2 P/T/MMF + +
2 55.7 M 1997 2010 13 P/T - -
3 47.2 F 2009 2010 1 P/T + -
4 62.4 M 2008 2010 2 P/T - -
5 49.3 M HTX: 1996
KTX: 2008
2009 13 E/T - -
6 38.3 M 1990 2010 20 P/T - -
*Characteristics at the time of first HEV RNA positive sample, M=male, F=female, HTX=heart 
transplant, KTX=kidney transplant, P=prednisolone, T=tacrolimus, MMF=mycophenolate mofetil, 
E=everolimus, C=cyclosporin
Virological parameters
All chronic infected patients produced HEV specific IgM antibodies at some time 
point after HEV RNA became detectable in serum, though in only two patients 
(33%) IgM antibodies were positive at time of first HEV RNA positive sample. 
The median time from the first HEV RNA positive sample to IgM seroconversion 
was 122 days (range 0-301 days). The median time to IgG seroconversion 
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varied widely from 127 days before seroconversion of IgM to 475 days after 
seroconversion of IgM. 
Fecal HEV shedding was found in all chronic HEV infected patients during viremia. 
Spouses of patients were tested for HEV infection. None of them had detectable 
HEV RNA or experienced anti-HEV IgM or IgG seroconversion in their serum. 
Phylogenetic analysis 
The ORF1b sequences generated from the six chronic cases showed that all virus 
isolates grouped within genotype 3. Both HEV genotype 3 genbank sequences 
(accession numbers are taxon names, Figure 2) and HEV ORF1b sequences 
published previously 90 (accession no. JQ15401, JQ15406-JQ15417, JQ15419-
JQ15422, JQ15426 and JQ15429-JQ15448) as reference. The latter samples 
were retrospectively tested to disclose the year of infection, indicated in the taxon 
names (Figure 2, NLyyyy-specimen number). Phylogenetic analyses did neither 
reveal indications for a common origin, nor for nosocomial HEV transmission.
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Figure 2 Phylogenetic tree of ORF1 HEV 
sequences in six chronic HEV infected heart 
transplant recipients. Phylogenetic relation of 306 
bp ORF1 region was calculated using Maximum 
likelihood, K2P analysis with bootstrapping 
(n=1000). Branch lengths are proportional to the 
evolutionary relationship between the sequences 
and internodal confidence of >70% is depicted 
in the tree. Heart transplant recipients and heart-
kidney transplant recipients are indicated in the 
taxa with respectively HTX and HTX KTX. HEV 
sequences of Dutch origin90 and year of infection 
are indicated as NLyyyy-isolate number, Genbank 
accession numbers are no JQ15401, JQ15406-
JQ15417, JQ15419-JQ15422, JQ15426 and 
JQ15429-JQ15448. No indication for a common 
origin, nor for nosocomial HEV transmission was 
found.
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Liver histology
All chronic HEV infected patients underwent a liver biopsy. Typical signs of acute 
viral hepatitis were seen with inflammatory activity, councilman bodies and 
acidophilic degeneration (Figure 3). Inflammatory activity was predominantly 
located in the periportal area (Figure 3A). Histology Activity Index scores 131 were 
calculated for all biopsies (Table 2). Advanced fibrosis was seen in four patients 
(67%) of whom three had been infected with HEV for less than one year. The 
lowest HAI score (sum=1) belonged to the patient in whom a liver biopsy was 
taken only 5 months after the first HEV RNA positive sample in this patient. 
All biopsies displayed some steatosis, but in four of the six biopsies a marked 
steatosis ranging from 5 to 25% was seen.
Table 2 Liver biopsy results in six chronic HEV infected HTX recipients
Infection 
time in 
months*
HAI**-Knodell score Total 
HAI 
score
Steato-
sis† 
Cholestasis Iron‡
Peri-
portal 
necrosis
Intra-
lobulair 
inflam-
mation
Portal 
inflam-
mation
Fibrosis
1 9 1 3 2 3 9 0 none 1+
2 5 1 2 1 3 7 1 focal none
3 7 3 3 3 3 12 0 none none
4 5 0 1 0 0 1 1 none none
5 22 3 3 3 3 12 1 none none
6 8 1 1 1 1 4 1 none none
*Calculated from time point at which first sample was positive for HEV RNA up to biopsy date 
**HAI=Histology Activity Index 131, †According to Brunt et al.132, ‡According to Brunt et al.133
Figure 3 Histological presentation of chronic hepatitis E infection in heart transplant 
recipients. (A) Liver biopsy showing a typical pronounced portal lymphocytic infiltration with several 
plasma cells. Some minor lobular infiltration is present. Degeneration of hepatocytes can be seen 
with the typical presence of councilman bodies. (B) Detail of 3A: The arrows indicate an acidophilic 
hepatocyte degeneration with typical presence of Councilman bodies. (C): Pronounced portal fibrosis 
with septa.
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Clinical course and management
An overview of the clinical course and management of the chronic HEV infected 
patients including serum through levels of tacrolimus, dose reduction of 
concomitant immunosuppressant therapy and treatment with orally administrated 
ribavirin is given in Figure 4. Liver enzyme values were elevated in all cases, with 
a median peak ALT level of 356 U/l (range 81-817), AST level of 230 U/l (range 
66-672), Alkaline phosphatase level of 170 U/l (range 80-278) and γ-GT level of 
308 U/l (range 196-1740). bilirubin levels were elevated in three patients [17, 
18 and 95 µmol/l). All patients that had peak ALT levels of more than four times 
the upper limit of normal (ULN male=40 U/l; female 30 U/l) had advanced liver 
fibrosis on presentation. One patient (see Figure 4D) experienced only moderate 
elevation of liver enzymes throughout the whole course of HEV infection with 
peak ALT (81 U/l) of two times the upper limit of normal. Interestingly, patient 
2 had a peak ALT level of more than 20 times the ULN (817 U/l), but was the 
only patient to clear the chronic HEV infection spontaneously (Figure 4B). No 
dose reduction of immunosuppressive therapy was possible or necessary in this 
patient. Moreover, patient 2 was the only patient that had IgG seroconversion 
before IgM seroconversion. IgG seroconversion occurred 127 days before IgM 
seroconversion and was accompanied with subsequent rapid increase of HEV 
viral load. At the time of IgM seroconversion HEV RNA had almost become 
undetectable.
Immunosuppressive therapy was reduced in the other patients. Patient 3 
managed to clear the HEV infection after dose reduction of tacrolimus (Figure 
4C). A decrease in HEV viral load was seen after mycophenolate mofetil (MMF) 
was stopped in patient 1 (Figure 4A) and after a subsequent three-month course 
of low-dose ribavirin therapy, patient 1 was able to rapidly clear the HEV infection. 
An almost similar course could be observed in patient 4 and 6 (Figure 4D and 
F respectively). In these two patients tacrolimus dose was slightly reduced, but 
both cleared the virus only after a stepwise dose increase of ribavirin and were 
therefore treated for 9 and 8 months respectively. Interestingly, patient 6 became 
IgM antibody negative immediately after clearing the HEV infection, but remained 
IgG antibody positive during follow up. Patient 5 (Figure 4E) did have a drop in 
ALT after dose reduction of tacrolimus, but no effect was seen with respect to the 
HEV viral load. After introduction of ribavirin, the viral load initially dropped, but 
increased for unknown reasons after 3 months. There were no indications that 
this patient was non-compliant to the ribavirin therapy. At the time of writing, 
patient 6 was treated for 9 months with ribavirin including several increases in 
dosage, though HEV RNA was still detectable in last follow-up sample. 
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Figure 4 Clinical course of chronic HEV infection in six heart transplant recipients. (A) Patient 
1. (B) Patient 2: received three times R-CHOP for a lymphoma, explaining the peaks in prednisolone. 
(C) Patient 3. (D) Patient 4 . (E) Patient 5: received a kidney transplant in 2008, explaining the increase 
in immunosuppressant therapy. (F) Patient 6. The ALT upper limit of normal is 30U/L and 40U/L for 
females and males respectively. The HEV RNA lower limit of detection is 143 (=2.16 log) IU/ml.
spouses of the HEV-infected patients in this study did not
have an active infection or had seroconversion, in accordance
with the theory that person-to-person infection is unlikely.
In our cohort, all patients received tacrolimus-based
immunosuppressive therapy. Previously, tacrolimus has
been described as a risk factor for developing chronic HEV
Figure 4 Clinical course of chronic HEV infection in 6 heart transplant recipients. (A) Patient 1. (B) Patient 2, who received 3 times
rituximab-cyclophosphamide, hydroxydaunorubicin, oncovin, prednisolone (R-CHOP) treatment for lymphoma, which explains the
prednisolone peaks. (C) Patient 3. (D) Patient 4. (E) Patient 5, who received a kidney transplant in 2008, which explains the increase in
immunosuppressant therapy. (F) Patient 6. The ALT upper limit of normal is 30 U/liter and 40 U/liter for females and males, respectively.
The HEV RNA lower limit of detection is 143 (2.16 log) IU/ml.
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DISCUSSION
We studied six chronic HEV infected heart transplant recipients in depth to gain 
more insight in clinical, biochemical and virological presentation. The six patients 
represented 2.3% of 263 HTX recipients of whom HEV infection was identified 
and confirmed by real-time RT-PCR and serology. All patients developed chronic 
HEV infection and phylogenetic analysis classified all isolates within genotype 3. 
No direct relations between the isolated viruses were shown, thereby excluding 
a common source in our patients. 
Production of HEV specific IgM and IgG antibodies was delayed up to 301 and 
539 days respectively after HEV RNA was detectable for the first time. This finding 
supports previous reports that testing for HEV infection in transplant recipients 
with elevated liver enzymes should be performed by HEV RNA (real time RT-PCR) 
rather than screening for antibodies 112, 123. 
Sixty-seven percent of the chronic infected patients had already progressed 
to advanced fibrosis within two years after initial infection. Rapid progression 
of fibrosis in HEV infected transplant recipients has been described before 112, 
113, 122. We cannot exclude the presence of some pre-existing liver disease e.g. 
due to right sided heart failure before transplantation or as a consequence of 
drug induced liver disease post-transplantation. However, 4 out of 6 patients 
had normal liver enzyme values before the first positive HEV PCR. The current 
study again emphasizes that early detection, and where possible intervention, is 
needed to prevent severe liver damage.
All (chronic) HEV infected patients had elevated liver enzyme values shortly 
after HEV RNA was first detectable in serum. Therefore, in patients on 
immunosuppressive drugs, hepatitis E virus infection should always be part of 
the differential diagnosis of all raised liver enzymes. Interestingly, a high peak 
ALT level (>20 times the ULN) was seen in the only patient that spontaneously 
cleared the chronic HEV infection. Previously, in a group of 85 HEV infected 
transplant recipients, clearance of HEV infection within 6 months was associated 
with higher peak ALT levels compared to transplant recipients that did not clear 
the HEV infection within 6 months 71. Our study showed that even after an 
infection duration of more than 6 months, HEV can be cleared spontaneously in 
immunocompromised patients. 
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Previous studies have indicated that non-travel-associated HEV infection route 
is thought to be zoonotic of origin15, 105. Indeed, we found that the non-
immunocompromised spouses of the HEV infected patients in this study did not 
have an active infection or experienced seroconversion, in accordance with the 
theory that person-to-person infection is unlikely to occur. 
In our cohort, all patients received tacrolimus based immunosuppressive 
therapy. Previously, tacrolimus has been described as a risk factor for developing 
chronic HEV infection in solid organ transplant recipients 71. The first step in 
the approach of chronic HEV infected patients is, where possible, a reduction 
of immunosuppressive therapy. In this study, dose reduction led to clearance 
of the HEV infection in one patient and in a decline in the viral load of HEV 
in other patients. However, in the majority of patients, complete clearance of 
HEV infection only followed treatment with ribavirin. An approach with stepwise 
dosing of ribavirin seems therefore reasonable to minimize side effects and 
optimize effectively. Low-dose ribavirin was able to normalize liver enzymes 
within weeks, but in all patients viral clearance took longer. The time correlation 
between ribavirin therapy and reduction in viral load and liver parameters adds 
further weight to the effectiveness of ribavirin in HEV infection in this patient 
group.
A clear limitation, due to design, of our study is, that earlier cleared infections 
may have been missed. 
In conclusion chronic HEV infection in heart transplant recipients may lead to 
rapid fibrosis of the liver. The current study highlights the need for early detection 
of HEV infection in immunocompromised patients and the importance of early 
medical intervention if possible by reducing immunosuppressive therapy and if 
insufficient, by introduction of ribavirin. We advise additional HEV RNA screening 
in immunocompromised patients with elevated liver enzymes, since antibody 
production is often delayed.
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ABSTRACT
Hepatitis E virus (HEV) is increasingly acknowledged as a cause of hepatitis in 
healthy individuals as well as immunocompromised patients. Little is known of 
HEV infection in recipients of allogeneic hematopoietic stem cell transplantation 
(alloHSCT). Therefore, we set out to study the incidence and sequelae of HEV 
as a cause of hepatitis in a recent cohort of 328 alloHSCT recipients. HEV-RNA 
was tested in episodes of liver enzyme abnormalities. In addition, HEV-RNA and 
HEV serology were assessed pre- and post-alloHSCT. We found 8 (2.4%) cases of 
HEV infection, of which 5 had developed chronic HEV infection. Seroprevalence 
pre-alloHSCT was 13%. 4 patients died with HEV viremia, with signs of ongoing 
hepatitis, having a median time of infection of 4.1 months. The 4 surviving patients 
cleared HEV after a median period of 6.3 months. One patient was diagnosed 
with HEV reactivation after a preceding infection prior to alloHSCT. While the 
incidence of developing acute HEV post-alloHSCT is relatively low, the probability 
of developing chronic hepatitis in severely immunocompromised patients is high. 
Therefore, alloHSCT recipients should be screened pre-transplantation by HEV 
serology and RNA. Furthermore, a differential diagnosis including hepatitis E is 
mandatory in all alloHSCT patients with severe liver enzyme abnormalities.
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INTRODUCTION
In 1983, a new waterborne hepatitis agent was found after an outbreak of 
unexplained hepatitis at a military camp, later identified as Hepatitis E Virus (HEV). 
HEV is endemic in resource-limited countries and an emerging health issue in 
industrialized countries.16, 105 It is a causative agent of acute and chronic hepatitis, 
transmitted via fecal-oral route, with a mostly self-limiting course in healthy 
individuals. In human HEV infection, there are four known genotypes prevalent, 
with genotypes 1 and 2 responsible for large waterborne HEV outbreaks in 
developing countries (Africa and Asia), and genotypes 3 and 4 generally seen 
in sporadic cases as a zoönotic infection in industrialized countries.16, 134 Since 
the first evidence of chronic hepatitis due to HEV in recipients of solid organ 
transplants, an increasing awareness for HEV has become apparent.69, 112
Persistent chronic infection and cirrhosis have been reported in 
immunocompromised patients, with most cases in solid organ transplant 
recipients.69 However, HEV was recently also reported in recipients of allogeneic 
stem cell transplantation (alloHSCT).135-138 A prevalence of 1-3% of hepatitis E 
viremia in recipients of solid organ transplants has been reported, with 47-83% 
of the patients developing chronic hepatitis.71, 89, 90, 139 So far, the incidence and 
sequelae of hepatitis due to HEV in recipients of alloHSCT is largely unknown.
Following two recent cases of HEV infection in our clinic, we set out to 
retrospectively evaluate the point prevalence and clinical sequelae of HEV 
infection in a cohort of alloHSCT recipients in our clinic, and we studied the role 
of HEV in transplant recipients presenting with liver enzyme abnormalities.
MATERIALS AND METHODS
Sample collection
We conducted a retrospective cross-sectional analysis of all adult alloHSCT 
recipients transplanted in the period January 2006 to July 2011, whose serum 
or EDTA-plasma samples were available in the biobank of Erasmus MC, 
Rotterdam, The Netherlands. These samples, stored at -20°C or -80°C, had been 
collected during routine visits to our outpatient clinic for clinical assessment 
of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivation. To select 
samples, a Laboratory Information Management System database search was 
performed for last pre-transplantation and most recent post-transplantation 
sample availability. In addition to the cross-sectional analysis, samples were 
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selected from patients experiencing episodes with alanine transaminase (ALT) 
abnormalities grade 2 to 4, according to Common Terminology Criteria for 
Adverse Events v3.0 (CTCAE). CTCAE grade 2 to 4 ALT abnormalities are defined 
as at least 2.5 times the upper limit of normal. This study was approved by the 
medical ethical committee of Erasmus MC, Rotterdam, The Netherlands (MEC 
approval: 2012-522).
Virological parameters 
For detection of both HEV specific IgM and IgG in serum or plasma samples 
the commercially available HEV ELISAs (Wantai, Beijing, PR China) were used. 
Available peripheral blood, feces and cerebrospinal fluid (CSF) samples of HEV-
RNA positive patients were retrospectively analyzed during the course of infection 
to study the kinetics of serum antibody responses (IgM and IgG) and viremia in 
different body compartments.
All samples were screened for HEV-RNA by an internally controlled quantitative 
real-time RT-PCR, described previously.13 The RT-PCR had a lower limit of detection 
(95% hit rate) of 143 (2.16 log) IU/ml as determined by the 1st WHO standard 
for HEV RNA NAT-Based assays (6329/10, Paul Ehrlich Institute, Germany). 
Phylogenetic analysis was performed to determine genotype, to exclude a 
common source of infection, and to examine potential HEV reactivation. 
Statistical analysis and data collection were performed using Microsoft Office 
Excel 2007 and SPSS v20.
Case definition
A case of HEV infection was defined as a patient with a HEV RNA positive serum 
or plasma sample, and was confirmed either by showing HEV specific serum IgM 
or IgG antibody response, or by showing the presence of HEV RNA in sequential 
samples. Chronic infection was diagnosed by retrospective testing of stored 
samples of identified cases and was defined as having HEV viremia of more than 
six months.
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RESULTS
Patient characteristics 
A total of 207 episodes of acute ALT abnormalities, occurring in 138 out of 
328 alloHSCT recipients, were evaluated, in addition to a cross-sectional RT-
PCR analysis of all 328 patients (Figure 1). As delineated in Table 1, the cohort 
included 178 (54%) male and 150 (46%) female patients with a median age 
at transplantation of 50 (range: 17-66) years. Stem cell sources included sibling 
donors (n=145, 44%), adult matched unrelated donors (MUD) (n=137, 42%) 
and Umbilical Cord Blood (UCB) grafts (n=46, 14%). Acute myeloid leukemia 
was the most frequent diagnosis for transplantation (n=142, 43%), followed 
by acute lymphoblastic leukemia (n=49, 15%), and non-Hodgkin’s lymphoma 
(n=31, 9%). All patients received graft versus host disease (GVHD) prophylaxis 
with a combination of a calcineurin inhibitor (cyclosporine A) and mycophenolate 
according to local policy. Acute GVHD grade II-IV occurred in 130 (40%) patients, 
and chronic extensive GVHD was present in 122 (37%) patients. At the time of 
analysis (2012, December), 180 (55%) patients were still alive, with a median 
follow-up of 40.9 (range: 10-77) months from alloHSCT. 
Figure 1 Overview of sample selection and study results
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Table 1 Patient characteristics of the cohort (n=328)
Characteristic Number
 Age of Transplantation (years)
  Median (range) 50.4 (17-66)
 Sex, number (%)
  Male 178 (54%)
  Female 150 (46%)
 Diagnosis, number (%)
  AML 142 (43%)
  ALL 49 (15%)
  NHL 31 (9%)
  CLL 24 (7%)
  MM 18 (5%)
  MDS 16 (5%)
  Other  48 (15%)
 Type of allogenic transplantation, number (%)
  UCB  46 (14%)
  MUD 137 (42%)
  SIB 145 (44%)
 GVHD, number (%)
  Acute grade I 42 (13%)
  Acute grade II - IV 130 (40%)
  Chronic limited 32 (10%)
  Chronic extensive 122 (37%)
 Patients alive
   Number (%) 180 (55%)
 Time to follow-up (months)
Median (range)  40.9 (10-77)
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; 
GVHD, graft versus host disease; MDS, myelodysplastic syndrome; MM, multiple myeloma; MUD, 
matched unrelated donor; NHL, non-Hodgkin’s lymphoma; SIB, sibling; UCB, umbilical cord blood.
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Virological parameters
In total, eight (2.4%) cases of confirmed HEV infection were found in 328 
patients, of which seven (88%) were identified by cross-sectional analysis, and 
one (13%) by screening the episodes of acute ALT abnormalities. 
HEV specific IgG prior to alloHSCT was detected in 41 (13%) patients. Two 
(0.6%) patients were IgM positive, though HEV viremia could not be confirmed 
by RT-PCR. Presence or absence of HEV specific antibodies (both IgM and IgG) 
prior to alloHSCT was not predictive for HEV infection after alloHSCT, tested by 
Pearson’s chi square- test of independency (p=0.313). 
The courses of HEV infection of all eight cases are presented in Figure 2. Clinical 
and virological features are delineated in Table 2. Patients will be annotated 
according to their assigned letter: ‘patients A–H’. Within the eight cases, 
complete HEV IgM and IgG seroconversion occurred in five patients, of whom 
four eventually cleared the virus and one deceased with a HEV viremia (patient 
A–C,F,H). Median time from first HEV RNA detection to HEV-IgM and HEV-
IgG conversion of these patients was 65 (range: 0-245) days, and 126 (range: 
-594-351) days, respectively. Three patients, who all died with HEV viremia, had 
aberrant serodynamics: one patient did not have detectable HEV-IgG, with only 
one serum sample testing HEV-IgM positive (patient G). Two patients did not 
have detectable HEV-IgM levels (patients D,E). One of them had detectable HEV-
IgG in only one sample (patient D) and one had detectable HEV-IgG levels at time 
of alloHSCT, though declining to undetectable at the time of death seven months 
later (patient E).
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Figure 2 Courses of hepatitis E infection in all eight individual patients. (A) HEV RNA 
persisted, although HEV-IgM and HEV-IgG seroconversion occurred under immunosuppressive 
therapy. This patient deceased of therapy refractory  progressive gastro-intestinal GVHD with 
concurrent chronic HEV infection. (B) Acute ALT abnormalities arose during HEV infection. This 
patient was mistakenly diagnosed as hepatic GVHD, and immunosuppression was intensified 
multiple times because of persisting liver enzyme abnormalities. Patient cleared HEV with stopping 
all immunosuppression, after the diagnosis of HEV infection in this study. (C) This patient developed 
primary graft failure of a 8/8 HLA-matched unrelated donor graft after reduced intensity condition 
with rabbit antithymocyte globulin, fludarabine, and a single donor fraction of 2 gray total body 
irradiation. HEV RNA was present after second alloHSCT. This patient cleared the infection after HEV-
IgM and HEV-IgG seroconversion, supported by reduction of immunosuppressive therapy.(D) This 
patient developed graft failure of a 7/8 HLA-matched unrelated donor graft after reduced intensity 
conditioning with rabbit antithymocyte globulin, fludarabine, and a single fraction of 2 gray total 
body irradiation. Patient’s disease relapsed three months after graft failure. Reinduction therapy was 
started with alemtuzumab (ALEM) and a second alloHSCT was prepared. However, due to recurrent 
infections, patient was not able to complete treatment. Patient died shortly after his second cycle of 
alemtuzumab because of complications of a meningitis and secondary sepsis with Escherichia coli. Of 
note, patient’s CSF samples tested positive for HEV.
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HEV-Open Reading Frame 1b (ORF1b) sequences were generated of all eight cases 
and deposited in Genbank under the accession numbers JQ015439, JQ015407, 
KC171439-KC1714444, KC171447, KC171450 and KC171451. Phylogenetic 
analysis did not identify a common or nosocomial source of HEV transmission. 
All HEV isolates were classified within genotype 3, as shown in the phylogenetic 
tree (Figure 3). Interestingly, confirmed HEV reactivation occurred in one patient, 
as described below (patient H).
Characteristics of HEV RNA positive patients
The median age of eight HEV infected patients was 56 (range 39-66) years at 
transplantation, including five (63%) males and three (37%) females (Table 2). 
All patients were screened for hepatitis B virus, hepatitis C virus, EBV, adenovirus, 
varicella zoster virus, herpes simplex virus type 1 and 2, and CMV by PCR to 
exclude the role of other potential hepatrophic viruses. All tested samples were 
undetectable by PCR, except for one patient experiencing CMV reactivation at 
the time of HEV infection (patient E). In this patient, HEV viremia persisted after 
successful treatment with ganciclovir, excluding the role of CMV in hepatitis in 
this patient. All eight patients received a graft from an alternative donor, including 
peripheral blood grafts from an adult MUD in five patients (63%) and UCB 
grafts in three (37%) patients. Plasma’s of the adult MUD grafts were HEV RNA 
negative. No samples of the UCB grafts were available for HEV RNA screening, 
yet two of three UCB recipients were HEV viremic at the time of alloHSCT (patient 
G,H). Six patients received multiple blood transfusions within three months prior 
to HEV infection, including platelet and red blood cell transfusions. None of the 
blood products were available for testing for HEV serology or RNA at the time of 
submission.
The median time from alloHSCT to infection was 4.6 (range: -2-18) months. The 
median peak ALT during HEV infection was 289 (range: 138-1507) U/l. At the 
time of infection, six (75%) patients were receiving intensive immunosuppressive 
therapy (>2 agents), prescribed for GVHD prevention (n=2, 33%) or GVHD 
treatment (n=4, 66%). In the HEV infected patients, liver enzyme abnormalities 
were thought to be related to hepatic GVHD in five (63%) patients, and drug 
induced liver injury in three (38%) patients.
Four (50%) patients died with persistent HEV viremia and signs of ongoing 
hepatitis (patient A,D,E,G). Median duration of HEV infection in deceased 
patients was 4.1 (range: 2-13) months, with acute HEV infection in three patients 
and chronic HEV infection in one patient. The cause of death was respiratory 
failure due to infection (fungal, bacterial and viral) in three patients (patient 
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Figure 3 Phylogenetic tree of ORF1b HEV 
sequences in eight HEV infected alloHSCT 
recipients. Phylogenetic relation of 321 bp ORF1b 
region was calculated using Maximum likelihood, 
K2P analysis with bootstrapping (n=1000). Branch 
lengths are proportional to the evolutionary 
relationship between the sequences and internodal 
confidence of >70% is depicted in the tree. Genbank 
accession numbers, country of origin (e.g. NL), HEV 
study number (e.g. HEV001) and date of drawal 
(yyyymmdd) and AlloHSCT recipients are indicated in 
the taxa (red text). No indication for a common origin 
or for nosocomial HEV transmission was found.
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D,E,G), and one patient died of therapy refractory progressive gastro-intestinal 
GVHD (patient A). Of note, one of the deceased patients appeared to have HEV 
RNA positive cerebrospinal fluid (CSF) with retrospective testing of CSF samples 
(patient D). These samples were obtained during an episode of meningitis 
and secondary sepsis with positive CSF and blood cultures for Escherichia coli. 
Radiological evaluation (CT-scan) revealed cerebral ischemia due to infection. 
This patient eventually died of respiratory failure due to fluid aspiration with a 
low level of consciousness since the meningitis.
The four (50%) living patients cleared HEV infection within a median period 
of 6.3 (range: 2-42) months (patient B,C,F,H). One patient received ribavirin 
treatment twice daily with 400 milligram for three months after a starting dose of 
three times 600 milligram daily for ten days because of a concurrent respiratory 
syncytial virus infection (patient H). Three patients cleared HEV during cessation 
of immunosuppressive therapy (patient B,F,H). The cessation rate depended on 
the presence and/or occurrence of GVHD. Among living patients, chronic HEV 
occurred in three patients (patient B,C,F), whereas one patient was able to clear 
HEV infection within six months (patient H). After HEV diagnosis was confirmed, 
a liver biopsy was taken from two patients (patient B,F), showing hepatitis, severe 
fibrosis, and portal inflammation (Figure 4). Liver histology was available in one 
patient by autopsy, showing no abnormalities (patient G). 
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Figure 4 Liver histology of a patient with chronic HEV. The histopathology of chronic HEV 
infection in this patient is characterized by a dense lympho-plasmocellular infiltrate (dashed arrow) 
in the portal tracts, combined with severe fibrosis (F3) and porto-portal septation (*). Multiple foci of 
apoptotic bodies are seen in the lobuli surrounded by a few inflammatory cells, indicating individual 
hepatocyte necrosis (Councilman-bodies: arrow) and probably caused by viral replication.
Remarkably, one patient initially cleared the virus and showed reactivation 
after a period of 53 days of undetectable HEV RNA (patient H). At the time of 
alloHSCT, HEV RNA was detectable, though viral load was low (<143 IU/ml). 
The second viremic period was characterized as viral reactivation after alloHSCT, 
based on identical HEV-ORF1b sequences (Figure 3). This patient finally cleared 
the reactivated HEV infection within two months after diagnosis, supported by 
ribavirin treatment (as described above) and reduction of immunosuppressive 
therapy.
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DISCUSSION
Recipients of allogeneic stem cell grafts, and especially those receiving alternative 
donor grafts are at increased risk of opportunistic bacterial, fungal and viral 
infections. Here we describe the first retrospective cross-sectional study of 
hepatitis E virus infection in a large cohort of alloHSCT patients. We report a 
relatively low incidence of 2.4%, as compared to other opportunistic infections 
in alloHSCT recipients. Nevertheless, we found a high probability of 63% of 
developing chronic HEV infection. 
Previously, two cohorts of 72 and 52 alloHSCT patients were screened for HEV by 
Abravanel et al.135 and Koenecke et al.137 respectively, without positive cases for 
HEV infection or reactivation, concluding that alloHSCT patients are at low risk for 
HEV infection and reactivation. However, these two cohorts of alloHSCT recipients 
comprised a more limited number of patients. In our study we identified eight 
HEV cases in a larger cohort (n=328), confirming the HEV prevalence of 2.4% in 
immunocompromised patients.69, 89, 90, 112 Secondly, the study of Abravanel et al.135 
included a restricted follow-up period of six months after alloHSCT, while our 
study had a median follow-up time of 41 months. Additionally, misdiagnosing 
HEV as drug induced liver injury has been reported previously by Dalton et al.121, 
whereas this patient group was excluded in the study of Koenecke et al.137 To 
reduce the risk of missing HEV infections, we screened all patients for HEV RNA 
at episodes of liver enzyme abnormalities in addition to last available samples. 
Of the confirmed HEV cases, five were misdiagnosed as GVHD, and three cases 
were mistakenly diagnosed as drug induced liver injury. Diagnosis of HEV in these 
patients is hampered by relatively low peak aminotransferase levels compared 
to non-immunocompromised patients,68 which may be explained by intensive 
immunosuppressive therapy suppressing inflammation. 
In our cohort, chronic hepatitis occurred in five out of eight acute HEV cases. 
However, only six patients had sufficient follow-up for a potential diagnosis of 
chronic hepatitis, because two patients died within two months after acquiring 
HEV infection. Progression to chronic HEV in alloHSCT patients may be explained 
by an impaired immune reconstitution, including insufficient lymphocyte recovery, 
which are well known risk factors for post-transplantation infections.140-142 
In particular impaired reconstitution of CD4+ and CD8+ T-cells predispose for 
infectious morbidity,143 which is confirmed in studies with CMV and EBV viremia, 
with patients having low specific CMV and EBV CD4+ and CD8+ T-cell counts 
predisposing for CMV and EBV reactivation, respectively.144, 145 
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Phylogenetic analysis of patient derived HEV sequences before and after 
alloHSCT established HEV reactivation in one patient. This is the second case of 
HEV reactivation after alloHSCT described so far in literature.136 We could not 
unequivocally demonstrate a reinfection or reactivation in three viremic patients 
having detectable IgG prior to alloHSCT, since no HEV RNA was detected in 
available samples prior to alloHSCT. Four other patients were seronegative prior 
to transplantation, suggesting that transmission had occurred after alloHSCT. 
In industrialized countries, HEV genotype 3 predominantly infects pigs, wild 
boars and deer but also humans, and is recognized as a zoönotic agent. However 
the main modes of transmission of genotype 3 and 4 viruses remain to be 
determined.105, 134 The source of HEV infection is unclear, but HEV transmission 
may be enterically (food borne: porcine livers, shellfish), via blood or blood 
products, mother-to-child, and although rare human-to-human.16, 52 Donors and 
donated blood are not routinely tested for HEV RNA worldwide, although reports 
of several cohorts in different countries of healthy blood donors reported HEV 
RNA and HEV IgM reactivity, suggesting active infection. 65, 146, 147 
In our cohort, transmission of HEV by blood products cannot be excluded 
because six out of eight viremic patients received multiple blood transfusions. 
Unfortunately none of these blood products were available for testing at the 
time of submission. The high probability of developing chronic HEV found in this 
study was consistent with other studies in recipients of solid organ transplants.69, 
89, 90, 112 HEV infected patients are at risk (67%) of progression to fibrosis in one 
year from infection,89 and also cirrhosis (10%).71 Therefore immunocompromised 
patients should be screened prior to transplantation, and during episodes of 
liver enzyme abnormalities post-transplantation. In our study patients showed 
aberrant serology, which may be explained due to their impaired immune 
reconstitution. Thus, HEV RT-PCR testing is the preferred diagnostic method 
in these immunocompromised patients. Treatment of HEV infection after 
transplantation includes reduction of immunosuppressive therapy, while there is 
no registered drug therapy. Anecdotal evidence supports the use of oral ribavirin 
in immunocompromised patients. In our study, three patients cleared HEV with 
a dose reduction of immunosuppressive agents (i.e. cyclosporine A and/or 
prednisone) alone. Treatment with ribavirin should be considered in patients, for 
whom immunosuppression cannot be reduced, such as, for example, patients 
with active GVHD. The optimal daily dose of ribavirin is unknown, in case reports 
sustained viral response  has been described with daily dosages between 200 
mg and 1200 mg.80, 89 If HEV infection is confirmed prior to alloHSCT, it can be 
considered as a contraindication to transplantation. Clearance of HEV viremia 
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is therefore of high importance. AlloHSCT candidates are usually pre-treated 
with chemotherapy, resulting in impaired and/or delayed immune reconstitution. 
Therefore, early ribavirin treatment can be initiated to support rapid HEV 
clearance in these future alloHSCT recipients.
In conclusion, this study shows that recipients of alloHSCT are at risk for HEV 
infection, albeit with a relatively low risk. However, the probability of developing 
severe chronic hepatitis in immunocompromised patients is high. Therefore, 
patients should be screened for HEV antibodies and HEV RNA prior to alloHSCT, 
and patients with acute liver enzyme abnormalities after alloHSCT should be 
analyzed for HEV reactivation and/or infection. Moreover, HEV should be included 
in the differential diagnosis of liver GVHD and drug induced liver injury, because 
of the largely overlapping picture with respect to liver enzyme abnormalities.
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ABSTRACT
Background 
Autochthonous Hepatitis E virus (HEV) infections can have important clinical 
consequences in patients with pre-existent (liver) disease and immunocompromised 
patients. To evaluate patients at risk and optimize treatment strategies, we 
studied the clinical course and treatment outcome in patients diagnosed with 
HEV viremia in our hospital. 
Methodology 
Between January 2008 and March 2015 we included all patients with HEV 
genotype 3 (HEV gt 3) infections diagnosed by means of quantitative real-time 
reverse transcription-polymerase chain reaction test (RT-PCR). Clinical data were 
evaluated retrospectively. 
Results 
In total 79 patients were included. Forty-nine patients (62%) were male, median 
age of all patients was 52 years (range 13 - 79). Sixty-one (77%) patients were 
immunocompromised. Three patients (3.8%) had only transient viremia, forty-
three (54.5%)) cleared the infection within six months and twenty-six (32.9%) 
developed chronic hepatitis. Five patients (6,3%) were lost to follow-up. All 
patients developing chronic hepatitis were immunocompromised. Overall, 
thirteen (16%) patients within this cohort died. Three patients had pre-existent 
liver diseases and died of liver-related causes. Time between diagnosis and death 
was shorter for patients with pre-existent liver diseases (p = 0.03). Twenty-eight 
percent of patients on immunosuppressive medication achieved viral clearance 
after reducing the dose of immunosuppressive therapy. Thirty patients (38.0%) 
were treated with off-label ribavirin in which 25 (83.3%) a sustained viral 
response has been documented. Median time from the start of ribavirin to HEV 
clearance was two months. 
Conclusion
Autochthonous HEV viremia mainly presents in patients with underlying chronic 
liver diseases or an impaired immune system. Patients with pre-existent liver 
diseases who acquire an HEV infection are at high risk for complications and 
even death. The off-label use of ribavirin can cure HEV infection.
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INTRODUCTION
Hepatitis E virus (HEV) is a positive sense, single stranded, non-enveloped RNA 
virus, discovered in the early 1980s. 3 The virus consists of 4 genotypes that can 
infect humans, all with a distinct geographical distribution. HEV genotype (gt) 1 
and 2 are found in developing countries in Asia and Africa, where they can cause 
large outbreaks of acute hepatitis via the fecal-oral route. Especially pregnant 
women are at risk of a fulminant course. 148 In developed countries, HEV gt 3 
and 4 are mainly transmitted from animal reservoirs. HEV gt 3 is responsible for 
the autochthonous HEV infections in Europe, gt 4 is mainly found in Asia. Pigs 
and wild boar are thought to have the greatest contribution to the transmission 
of gt 3. 149 However recently, cases regarding transfusion-transmitted HEV gt 3 
infections have also been reported. 150, 151 About one in two patients infected 
with gt 1 and gt 2 develop clinical symptoms whereas 67 – 98% of patients 
infected with gt 3 and gt 4 remain asymptomatic. 152 The clinical features of 
acute HEV infection caused by the different genotypes cannot be distinguished 
from each other and range from transient and asymptomatic viremia to acute 
hepatitis with malaise, jaundice and even liver failure. 68, 153, 154 The fulminant 
course of the infection during pregnancy is only seen in women infected with 
HEV gt 1. 
Chronic HEV gt 3 infections are rarely seen in otherwise healthy individuals but are 
increasingly being reported in immunocompromised patients. Patients receiving 
solid-organ transplantations (SOT) that require life-long immunosuppressive 
therapy to prevent graft rejection and patients with haematological malignancies, 
are prone to develop chronic HEV gt 3.155, 156 In these patients chronic HEV 
infections can progress to fibrosis 89 and even cirrhosis 71 which occasionally 
requires liver transplantation. Chronic HEV gt 4 infections are sporadically 
reported 157 whereas chronic infections of HEV gt 1 and HEV gt 2 do not occur. 
In immunocompetent patients, an acute HEV infection normally does not require 
treatment. Given the strong association between the use of immunosuppressive 
drugs and chronic HEV, dose reduction or even withdrawal of immunosuppression 
if possible, is considered to be the first step in the treatment of HEV infections. 71 
In patients who fail to eliminate the virus after reduction of immunosuppressive 
drugs or whose dose of immunosuppressive drugs cannot be reduced, antiviral 
therapy should be considered. Antiviral therapy consists of the off-label use of 
pegylated interferon alpha or ribavirin therapy, or a combination of both. 127, 130, 
158
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Studies evaluating the clinical course of HEV gt 3 infection mainly focus on 
patients with SOT, haematological malignancies and HIV. We studied the clinical 
course in all patients diagnosed with HEV gt 3 viremia in our hospital to define 
clinical outcome, therapeutic interventions and treatment effect. 
METHODS
Sample collection
This retrospective cohort-study analysis was conducted at the Erasmus MC, 
University Medical Center Rotterdam, a tertiary referral and transplant center 
in The Netherlands. We included all patients who tested positive for HEV RNA 
genotype 3 in serum or EDTA-plasma at the Department of Viroscience between 
January 2008 and March 2015. 
Patients were tested prospectively for HEV RNA during yearly routine checkup after 
transplantation or in case of unexplained elevated liver enzymes. In rare cases, 
patients were referred from other hospitals because of unexplained elevated 
liver enzymes or for treatment of the HEV infection. In our hospital, liver, lung 
and heart transplant recipients are routinely screened for HEV infections once 
prior to transplantation and annually thereafter. Patients with haematological 
malignancies who receive an allogeneic stem cell transplantation (alloHSCT) are 
also screened prior to the transplantation and in case of unexplained elevated 
liver enzymes. At present, kidney transplant recipients are not routinely screened 
for HEV.
Patients were included if they tested positive for HEV gt 3 RNA in serum or blood, 
regardless of the HEV RNA level and anti HEV IgM or IgG status. If available, 
stored blood samples were tested to trace the first positive sample. Patients were 
excluded if the infection was caused by a genotype other than HEV gt 3. Patient’s 
baseline demographics were obtained, including sex, age, comorbidities, type 
of medication and biochemistry and virological laboratory results at the time of 
diagnosis. Based on these data, we classified the patients as immunocompetent or 
immunocompromised. Patients were immunocompromised if they met one of the 
following criteria: 1) use of immunosuppressive medication after transplantation; 
2) use of biologicals in case of rheumatoid arthritis or inflammatory bowel disease; 
3) treatment by a course of or continuous chemotherapy during the last three 
months; 4) presence of haematological malignancy or primary immunodeficiency. 
Thereafter we evaluated the medical records from recruited patients to explore 
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the clinical course, duration and outcome of the infection, laboratory results at 
peak of infection and at the end of follow-up, and therapeutic interventions. If 
available, data were collected concerning causes of death. Causes of death were 
evaluated by two authors independently without conflicting results.
Ethical approval was given by the Medical Ethical Review Board of Erasmus MC. 
Virological parameters
Serum was tested for HEV RNA by means of an internally controlled quantitative 
real-time reverse transcription-polymerase chain reaction (RT-PCR), as described 
previously 90. The RT-PCR has a lower limit of detection (95% hit rate) of 143 IU/
ml as determined by the first World Health Organization standard for HEV RNA 
nucleic acid amplification testing-based assays. 
Clinical outcome
In all patients we evaluated the clinical outcome of the infection: transient 
viremia, acute hepatitis and chronic hepatitis. Mortality due to liver disease or 
other causes was a secondary outcome parameter. Transient viremia was defined 
as the presence of HEV RNA in blood without ALT elevation. Acute hepatitis was 
defined as the presence of HEV viremia for less than six months in combination 
with an elevation of alanine aminotransferase (ALT) above the normal limit of 44 
U/l. If HEV RNA in serum was detectable for at least six months patients were 
said to have chronic hepatitis. End of infection was stated on the first day RT-
PCR was negative. Liver-related mortality was defined as death related to liver 
failure or liver-related complications. In patients treated with antiviral therapy, 
an undetectable HEV RNA load at the end of treatment was defined as end of 
treatment response (ETR) whereas undetectable HEV RNA for at least 3 months 
post treatment was defined as sustained viral response (SVR).
Data analysis
Statistical analysis was performed using SPSS version 21 (IBM The Netherlands). 
Within each clinical outcome baseline characteristics of patients were compared. 
To analyze continuous parameters with a normal distribution, Student’s t test was 
used. For categorical or dichotomized parameters, proportions between groups 
were compared using Chi squared test or Fisher’s exact test. A p-value lower than 
0.05, was considered statistically significant. 
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RESULTS
A total of 80 patients tested positive for HEV RNA in serum. In all but one patient 
HEV gt 3 was detected so a total of 79 patients were included. Thirty-two patients 
(40.5%) were tested in the context of screening before or after transplantation, 
5 (6.3%) were suspected of graft versus host disease (GvHD) and 42 (53.2%) 
were tested in case of unexplained hepatitis. Forty-nine patients were male 
(62.0%) and median age was 52 years (13 – 79). In total 61 patients (77.2%) 
were immunocompromised and 3 patients (3.8%) used low dose prednisone 
(n=2) or low dose methotrexate (n=1) (Table 1). 
Thirty-eight patients (48.1%) were SOT-recipients of which all but one used 
immunosuppressive medication, with the following type of SOT: liver (n= 16), 
heart (n=13), kidney (n=5), lung (n=1), liver and kidney (n=1), kidney and pancreas 
(n=1), heart and lung (n=1). Fifty percent of SOT-recipients were diagnosed with 
HEV viremia within 800 days after transplantation (range 7 – 7304 days). Twelve 
patients (15.2%) had a history of alloHSCT. The details on immunosuppressive 
treatment are displayed in Figure 1. Nineteen patients (24.1%) had a pre-existent, 
non-HEV related active liver disease at moment of diagnosis. 
 
Table 1 Patient characteristics
Characteristic  
Sex  
Male, number 49 (62.0%)
Female, number 30 (38.0%)
Age at onset of infection in years  
Median (range) 52 (13 – 79)
BMI kg/m2  
Median (range) 26.6 (18.3 - 39.9)
Immunocompromised  
Number 61 (77.2%)
HEV RNA-concentration at presentation IU/ml 
Median (range) 6.6E4 (<143 – 1.7E8)
ALAT, presentation U/l  
Median (range) 85 (15 – 4801)
ASAT, presentation U/l  
Median (range) 75 (17 – 1845)
ALAT, peak U/l  
Median (range) 209 (26 – 4801)
ASAT, peak U/l  
Median (range) 185 (26 – 1848)
Follow up time in days  
Median (range) 131 (1 – 2328)
Clinical implications of hepatitis E
99
C
h
ap
te
r 
3.
4
Figure 1 Causes of immunosuppression and use of immunosuppressive treatment
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Clinical course of infection
In total, 3 patients (3.8%) had only transient viremia with HEV RNA levels around 
the lower detection rate of 143 IU/ml. Two patients were heart transplant recipients 
and treated with immunosuppressive medication. They were infected more than 
six months after transplantation which made infection by transplantation unlikely 
given the incubation period of 2-6 weeks for HEV. The other patient was known 
with alcoholic liver cirrhosis and screened prior to liver transplantation by which 
transient viremia was detected. 
Forty-three patients (54.5%) had signs of acute hepatitis and cleared the 
infection within six months and 26 patients (32.9%) developed chronic hepatitis. 
5 patients (6.3%) were lost to follow up after having signs of acute hepatitis. In 
these patients we could not determine whether they developed chronic hepatitis 
or not. (Figure 2)
Figure 2 Flowchart of the clinical course in HEV-infected patients of the cohort
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Table 2 Patient characteristics of acute versus chronic hepatitis E
Characteristic
Acute  
(n = 43)
Chronic 
 (n = 26)
P-value
Sex      
Male, number 28 (65.1%) 17 (65.4%) 1.0
Female, number 15 (34.9%) 9 (34.6%)  
Age at onset of infection in years      
Median (range) 53 (16 - 67) 54 (40 - 60) 0.58
Immunocompromised, number 28 (65.1%) 26 (100%) 0.001
Solid organ transplantation, number 16 (37.2%) 18 (69.2%) 0.01
         Liver (including 1 Liver + Kidney) 11 (25.6%) 5 (19.2%) 0.55
         Heart (including 1 Heart + Lung) 2 (4.7%) 9 (34.6%) 0.002
         Kidney (including 1 Liver + Kidney) 4 (9.3%) 3 (11.5%) 1.0
         Lung (including 1 Heart + Lung) 0 2 (7.7%) 0.14
AlloHSCT 5 (11.6%) 7 (26.9%) 0.19
Immunosuppressive treatment after 
transplantation
17 (39.5%) 24 (92.3%) <0.001
All patients who developed chronic hepatitis were immunocompromised whereas 
65.1% of the patients with an acute hepatitis were immunocompromised (p = 
0.001). (Table 2) We found a significant difference in the prevalence of SOT in 
patients developing chronic hepatitis compared to acute hepatitis: 69.2% vs. 
37.2% respectively (p = 0.01). This was linked to the use of immunosuppressive 
therapy after transplantation (92.3% vs. 39.5%, p < 0.001). Especially heart 
transplant recipients significantly more often developed chronic hepatitis (p= 
0.002). The 9 heart transplant recipients who developed chronic hepatitis were 
treated with tacrolimus-based therapy whereas the only two patients with 
transient viremia had cyclosporine-based therapy. We found no significant 
difference in outcome in patients who had pre-existent, active liver diseases or 
who were immunocompromised due to haematological malignancies.
In 2 patients the clinical outcome could not be determined. One patient was 
screened for HEV after liver transplantation annually. At the moment of diagnosis 
no laboratory findings indicating hepatitis were present. One year later, qRT-PCR 
was repeated and negative. One heart transplant recipient was screened only 
once and did not have any follow up. 
102
Chapter 3.4
Deceased patients
Eventually 13 patients died, of which 4 were HEV RNA positive and 8 had cleared 
the virus at time of death. In 1 patient, the HEV status at the time of death could 
not be determined.
The four patients who were viremic at the time of death all had haematological 
malignancies and died of sepsis due to respiratory infections (n=3) and meningitis 
(n=1) (51, 53, 198 and 393 days after HEV infection). None of these patients was 
treated for the HEV infection. 
Eight patients died after clearing the infection. Three of these patients had pre-
existent liver diseases with cirrhosis. They died shortly after clearing the infection, 
i.e. after 4, 17 and 54 days. One died of liver decompensation with multi-organ 
failure, one of complications due to spontaneous bacterial peritonitis and the 
third patient died of renal failure. The other five patients who died after clearing 
the virus were immunocompromised due to haematological malignancies or 
immunosuppressive therapy. 
When comparing time from diagnosis to death between patients with and 
without pre-existent liver disease, we found a significantly shorter time for 
patients with cirrhosis (median 35 vs. 596 days; p = 0.028). This suggests that 
a HEV infection triggers acute on chronic liver disease with mortality in patients 
with pre-existent (decompensated) liver disease. 
One heart transplant recipient died of renal failure, 827 days after the HEV 
infection was diagnosed. Because the patient died in a nursery home, no 
sufficient follow up was present to determine whether he was HEV-positive at 
moment of death or not. 
Immunocompetent patients
Eighteen patients were immunocompetent. One patient had only transient 
viremia, 15 patients had acute hepatitis and 2 were lost to follow up. Eleven out 
of the 15 patients had spontaneous resolving hepatitis and 4 were successfully 
treated with ribavirin of whom three patients had underlying diseases. One 
patient had liver cirrhosis and hepatocellular carcinoma, one patient had auto-
immune hepatitis and the third patient had short bowel disease due to Crohn’s 
Disease. The fourth patient treated with ribavirin had no underlying disease but 
did have signs of non-resolving, imminent liver failure. After two days of ribavirin 
treatment (600 mg b.i.d.), HEV RNA became undetectable. 
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Immunocompromised patients
Sixty-one patients were immunocompromised. Of these patients, 27 were not 
treated. They were immunocompromised due to chemotherapy (n=8), use of 
immunosuppressive drugs (n=16), haematological malignancies (n=2) and 
common variable immune deficiency treated with immunoglobulin substitution 
(n=1). Two patients had transient viremia, 14 acute hepatitis, 4 chronic hepatitis, 
2 were lost to follow up and 5 died while HEV RNA positive. SOT-patients who 
were not treated did not clear the infection in month 3 to 6 after diagnosis 
suggesting that the diagnosis of chronic HEV infection can be made after 3 
months of HEV viremia.
Reduction of immunosuppressive drugs
Eight patients were treated solely by reducing their immunosuppressive drug 
burden. Five patients used immunosuppressive drugs after transplantation. In 
4 out of these 5 patients the calcineurin-inhibitor was adjusted with 50% dose 
reduction and in the fifth patient sirolimus was stopped. Prednisone was stopped 
in 3 out of these 5 patients. The other three patients used immunosuppressive 
drugs for other indications. In one patient mycophenolic acid for nephrotic 
syndrome was stopped and dose of cyclosporine was halved. In the second 
patient adalimumab and methotrexate for rheumatoid arthritis were temporarily 
stopped. The third patient, with a history of polycythemia vera, was treated with 
a temporary stop of hydroxycarbamide. All patients successfully cleared the virus, 
within a median of 207 days (27 - 1306). 
Ribavirin treatment
In total 30 patients were treated with ribavirin, starting a median of 97 days 
(0 - 1825) after the diagnosis of HEV infection (Table 3). Ribavirin was started at 
the discretion of the treating physician. Thirteen patients started within less than 
3 months after diagnosis, 6 within 3-4 months and 11 patients more than six 
months after moment of diagnosis. Median dose administered was 800 mg/day, 
i.e. 10.4 mg/kg (1.96 - 25.04) and median duration of treatment was 94 days 
(10 - 560). Eighty-seven percent of treated patients were immunocompromised 
whereas 76% in the non-treatment group were immunocompromised (p = 0.036) 
due to a significantly higher prevalence of SOT and use of immunosuppressive 
drugs after transplantation. When comparing these groups, other causes for a 
suppressed immune system were equally distributed between treatment and non-
treatment groups. In 10 patients the dose of immunosuppressive therapy was 
reduced a median of 45 days (10 – 365) prior to the start of ribavirin treatment. 
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In 11 patients, ribavirin treatment was started concomitantly with reduction of 
the immunosuppressive therapy.
Table 3 Patient characteristics of patients treated with ribavirin
Characteristic number (%)
Sex  
Male 19 (63.3%)
Female 11 (36.7%)
Immunocompromised 26 (86.7%)
Solid organ transplantation 19 (63.3%)
        Liver 8 (26.7%)
        Heart (including Heart + Lung) 9 (30.0%)
        Kidney 2  (6.7%)
AlloHSCT 4 (13.3%)
Immunosuppressive treatment after transplantation 22 (73.3%)
Eighty-three percent of patients (25/30) achieved SVR. Seven patients had a rapid 
viral response (< 5 weeks from start ribavirin), 10 patients had an early viral 
response (< 13 weeks) and 8 patients had a late viral response (> 13 weeks). (Figure 
3) Median time until HEV clearance was 61 days (1 – 272). Four patients were still 
being treated at end of follow up (33, 91, 102 and 161 days of treatment). Three 
of these patients reached negative RT-PCR but had no sufficient follow up yet 
to ascertain SVR. In one patient treatment was interrupted because of incurable 
oropharyngeal carcinoma. One patient was treated for only 10 days because of 
respiratory syncytial virus and had a late viral response after 272 days. 
Main adverse events were anemia, anorexia and affective disorders. In only one 
patient this caused a shortening of treatment by three weeks. 
Among the 30 patients who were treated with ribavirin, only one patient had 
recurrence. She initially responded to ribavirin after treatment with 800 mg/day 
for 90 days. No HEV RNA was detected in serum. After three months, RT-PCR 
was positive again with rising viral loads. Phylogenetic analysis was performed 
with concatenated ORF1 and ORF2 sequences, which revealed 9 nucleotide 
changes in 810bp hypervariable regions of the HEV genome. After one year, she 
was retreated successfully with ribavirin 800 mg/day for 120 days. 
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Figure 3 Time to HEV clearance (negative qualitative RT-PCR) in patients treated with 
ribavirin. Treatment was started at day 0.
DISCUSSION
We describe the clinical characteristics and outcome of HEV gt 3 infections in 
a tertiary referral hospital based population in the Netherlands and show that 
HEV can cause significant morbidity and contribute to mortality in patients. The 
off label use of ribavirin therapy provides viral clearance within a median of two 
months. To the best of our knowledge this retrospective single center study is the 
largest series so far to evaluate the clinical course and treatment outcome of HEV 
infection in Western Europe.
Our study showed a predilection for middle-aged men which is in line with 
several studies concerning autochthonous HEV infections. 68, 159 Patients in these 
studies presented at a median age of around 60 years with male to female ratios 
of 1:3. 68, 153, 159, 160 Previously it was thought that middle-aged men were more 
often exposed to HEV than women. However, recent screening of blood donors 
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in The Netherlands showed no difference in seroprevalence of HEV between 
men and women, which makes an equal exposure to the virus more likely. 161 An 
explanation for the higher incidence of symptomatic hepatitis among middle-
aged, non-transplant patients may be that these patients more often have 
significant co-morbidities than young individuals and that these comorbidities 
predispose for symptomatic HEV. Previous studies also found that excessive 
alcohol consumption (> 22 units of alcohol/week), especially present in men, 
contributes to the risk of having clinical symptoms. 162, 163 However, we were not 
able to reliably evaluate the alcohol consumption in our patients.
Our study confirms the results of previous studies, in which chronic HEV infections 
are solely found in immunocompromised patients, mostly SOT-recipients. 69, 
71 Due to the impaired immune system the virus can persist in the body for 
more than six months. 164 Moreover, some cases of chronic HEV have been 
reported in patients with HIV 165 and haematological malignancies166, 167. In our 
study seventy-five percent were SOT-recipients and 25% had a haematological 
malignancy. Especially heart transplant recipients were prone to develop chronic 
hepatitis. When comparing their medication, we found that all heart transplant 
recipients who developed chronic HEV were treated with tacrolimus-based 
immunosuppressive therapy. This was also seen in lung transplant recipients. 
Kamar et al. described earlier that the use of tacrolimus rather than cyclosporine 
A attributes to the risk of chronic HEV infections. This may be due to a greater 
down-regulation of the T-cell response against the virus. 71 Likewise, in our study 
the only two heart transplant recipients who had transient viremia were treated 
with cyclosporine A.
Several studies revealed that approximately 60% of SOT-recipients develop 
chronic infection. 71, 76, 168 In our cohort, 47% of SOT-recipients developed a 
chronic infection. This slight difference can be explained by two reasons. First, six 
out of 38 patients were successfully treated with ribavirin within six months after 
diagnosis. Hence, no evolution of the disease to chronicity was awaited. Second, 
two out of 38 patients had no sufficient follow up so a chronic infection cannot 
be excluded.
In immunocompetent patients, HEV gt 3 rarely causes a symptomatic hepatitis 
but it can result in acute fulminant hepatitis with decompensation in patients 
with underlying chronic liver disease. 154, 169 Although studied among limited 
numbers, high mortality rates up to 70% in these patients have been reported. 
Clinical implications of hepatitis E
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154 In the present study, four immunocompromised patients died while still HEV 
RNA positive. Moreover, three patients with pre-existent cirrhosis died shortly 
after clearing the virus due to liver-related causes. The time from diagnosis to 
death was significantly shorter when compared to patients without underlying 
liver diseases. In patients with pre-existent cirrhosis, the superinfection with 
HEV probably provokes such an inflammatory response that, although leading 
to clearance, causes additional damage to the liver. Eventually, the liver cannot 
recover and death may follow. 
Kamar et al. evaluated the effect of dose reduction in immunosuppressive 
therapy among SOT-recipients to achieve HEV clearance. 71 During the first 
6-month period after diagnosis, the daily dose of immunosuppressive treatment 
was reduced in 56 patients. Eighteen patients (32.1%) achieved HEV clearance 
with a median of 19.5 months after diagnosis. In our study 29 patients had 
a reduction in dose of immunosuppressive treatment and 8 (27.6%) achieved 
viral clearance. Although in two patients immunosuppressive drugs were used 
for other reasons than prevention of rejection, these drugs have considerable 
immunosuppressive properties. One patient used hydroxycarbamide, an inhibitor 
of ribonucleotide reductase, that can cause bone marrow suppression and 
leucopenia. 170 The other patient used adalimumab, an anti-tumor-necrosis-
factor-alpha agent with a strong immunosuppressive action that provides a high 
risk for serious infections. 171 
In patients with persisting HEV infections who fail to eliminate the virus after 
reduction of immunosuppressive drugs or whose dose of immunosuppressive 
drugs cannot be reduced, specific antiviral therapies are required. Complete viral 
clearance has been described for the use of pegylated interferon alpha. It is 
shown to be effective in patients with liver transplantation 127 and in one kidney-
transplant recipient 126. However, interferon therapy is contraindicated in SOT-
recipients due to the increased risk of acute rejection. In these patients, the off-
label use of ribavirin has shown good results in small case series and in one larger 
case series consisting of 59 patients. 158 Kamar et al. found SVR in 85% of patients 
treated with ribavirin. They suggest that a treatment duration of 3 months is 
sufficient to achieve SVR. However, in patients with persistent replication at 1 
month and in patients with recurrence, a longer period of treatment may be 
needed. 158 In our cohort, 30 patients were treated with ribavirin of which 87% 
were immunocompromised. Eighty-three percent of patients were successfully 
treated with ribavirin for a median of 94 days (10 – 560) and 10% had a negative 
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qRT-PCR but no sufficient follow up yet to determine SVR. We found not only a 
successful response in SOT-patients but also in three patients with haematological 
malignancies. Median treatment duration to HEV clearance was two months 
which demonstrates a rapid response after the start of treatment. Only one 
patient had recurrence but achieved viral clearance after retreatment with 
ribavirin. In this study, thirteen patients were treated after having been infected 
with HEV for less than three months. We cannot exclude that (some of) these 
patients would have had spontaneous clearance without ribavirin treatment. In 
SOT-recipients it was found by Kamar et al. that if HEV RNA persists for more 
than three months, no spontaneous clearance will be observed between months 
3 and 6 after infection. 172 This is in line with our finding that SOT-patients did not 
have spontaneous HEV clearance in month 3 to 6. We therefore recommend to 
start ribavirin treatment after three months in SOT-patients to prevent a chronic 
course with potential adverse events.
Due to the retrospective design of our study, we came across some limitations. 
First and foremost, some patients did not have sufficient or frequent follow up. 
Hereby the exact date of viral clearance could not always be determined. Second, 
the doses and durations of ribavirin altered during the last years. 
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ABSTRACT
Background & Aims
Genotype (gt) 3 hepatitis E virus (HEV) infections are emerging in Western 
countries. Partly due to the lack of suitable model systems, their transmission, 
infectivity and pathogenesis are poorly understood. 
Methods
Here we characterize the in vitro and in vivo infectivity of HEV RNA positive EDTA-
plasma, feces or liver-biopsy samples from 8 immunocompromised patients with 
chronic gt 3 HEV in the A549 cell culture system and in a human-liver chimeric 
mouse model (uPA+/+Nod-SCID-IL2Rγ-/-). 
Results
HEV antibody negative EDTA-plasma samples showed no or slower propagation 
within 2 weeks after inoculation on A549 cells, compared to feces- or liver- 
derived inocula of similar HEV RNA content. To corroborate these infectivity 
differences, selected samples were i.v. inoculated in human-liver chimeric mice. 
HEV RNA levels up to 8 log IU HEV RNA/gram, were consistently present in 100% 
of chimeric mouse livers from week 2-14 after inoculation with human feces-
derived HEV. HEV RNA was detected in feces of these mice, while HEV viremia 
was low and inconsistently present. A human liver biopsy-derived HEV inoculum 
resulted in moderate to high HEV RNA levels in mouse feces, bile and liver after 
infection. In contrast, seronegative, HEV RNA-positive EDTA-plasma was not 
infectious in any of the inoculated animals. 
Conclusion
Infectivity of feces-derived human HEV is higher compared to EDTA-plasma 
derived HEV both in vitro and in vivo. Persistent HEV gt 3 infections in chimeric 
mice, show preferential viral shedding towards mouse bile and feces, mimicking 
the course of infection in humans. 
Hepatitis E virus genotype 3 infection of human liver chimeric mice and A549 cells
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INTRODUCTION 
Emerging hepatitis E virus (HEV) genotype (gt) 3 infections are reported in western 
countries, including France, the United Kingdom and the Netherlands with 
increasing frequency 173-175. While reports showed an overall decrease in anti-HEV 
seroprevalence from 1996 to 2011, young adult blood donors demonstrated 
higher seroprevalences from 2000 to 2011 176, 177. In addition HEV RNA positive 
blood donations were reported to increase in the Netherlands since 2012 178. 
Although the exact source of this HEV gt 3 endemic is unknown, it is likely that 
domestic swine and pig farming plays a critical role. HEV RNA gt 3 was detected 
in approximately half of the pig farms in the Netherlands 179.
HEV is a non-enveloped positive-sense single-stranded RNA virus of the genus 
Orthohepevirus and family Hepeviridae 180. Four major HEV genotypes infecting 
humans have been described so far. Genotype 1 and 2 strains are only isolated 
from humans, whereas gt 3 and gt 4 strains are considered zoonotic viruses, 
present in both humans and several other species like pigs and wild game. HEV 
is spread through the oral-fecal route via contaminated water in developing 
countries or amongst others, via direct contact with animals or the consumption 
of undercooked meat in industrialized countries. In immunocompetent 
individuals, HEV infection is self-limiting, often asymptomatic and thus remains 
largely underdiagnosed. HEV infections in immunosuppressed patients, such as 
solid-organ transplant recipients, often persist and can progress quickly to liver 
fibrosis and cirrhosis 89, 181, 182.
The pathogenesis of HEV infections is poorly understood in part due to a lack 
of suitable in vitro and in vivo model systems. Antiviral treatment options for 
chronic HEV infections in solid organ transplant recipients are limited to ribavirin, 
but no randomized controlled trials have prospectively examined the optimal 
dose, duration and monitoring frequency 158. In addition, no adequate animal 
model exists for the observed chronicity rates of HEV in immunocompromised 
patients, nor do the existing natural animal hosts develop overt clinical signs of 
hepatitis 183. 
In this study, we utilize the in vitro A549 cell culture system and the established 
humanized liver urokinase-type plasminogen activator (uPA)-transgenic mouse 
model on a severely immunodeficient NOD/Shi-scid/IL-2Rγnull background (uPA-
NOG) to explore the infectivity of HEV gt 3 samples of different clinical origins 
90, 156, 184, 185. We demonstrate that in vitro and in vivo infectivity is much lower 
for human EDTA-plasma, compared to feces- and liver- derived inocula. Once 
infected, persistent intrahepatic viral replication is seen in all chimeric mice, with 
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preferential viral shedding to mouse bile and feces, reminiscent of human HEV 
infections. Chimeric human liver mice are therefore a suitable model for future 
studies on HEV infectivity, pathogenesis and antiviral efficacy. 
MATERIAL AND METHODS
Inoculum preparation 
Inocula were obtained from heart- (n=4), liver- (n=1), and allogeneic hematopoietic 
stem cell (n=2) transplant recipients and one recipient who received both heart 
and kidney grafts (see Table 1), treated either at the University Hospital Antwerp 
or the Erasmus Medical Center 90, 156. All had detectable HEV RNA in their EDTA-
plasma for more than 6 months (defined as chronic HEV infection). Inocula 
used for infection had no detectable levels of anti-HEV IgM and IgG antibodies 
according to the results obtained with a commercially available ELISA (Wantai, 
Beijing, China). Open reading frame 1 and 2 sequences of the inocula are 
available at genbank (Table 1). Clinical sequelae have been described elsewhere 
89, 90, 156. Fecal suspensions were prepared as follows: 3 gram feces was vortexed 
thoroughly in 10 ml saline and centrifuged (450g, 3 min). After 2 additional 
centrifugation steps (14000g, 5 min), the supernatant was passed through a 
0.45 µm filter. A cryopreserved liver biopsy fragment from one heart transplant 
patient was homogenized in 500 µl saline using ceramic beads. The supernatant 
was used as inoculum after centrifugation (5000g, 10 min). All inocula were kept 
at -80°C until use.
 
Table 1 Inocula of chronic HEV gt 3 patients for in vitro and in vivo infection
*Inocula used for both in vivo and in vitro infection
# AlloHSCT allogeneic hematopoietic stem cell transplantation; HTx heart transplantation; LTx liver 
transplantation; KTx kidney transplantation 
Case no. 1st year HEV+
age @ 
HEV+
Sex Morbidity#
Genbank 
accession   
ORF1
Genbank 
accession   
ORF2
HEV RNA (log IU/ml)
reference
serum feces liver
HEV0008 2008 55 F AlloHSCT JQ015407 KT198654 7.00 - [156]
HEV0014* 2011 40 F AlloHSCT KC171436 KP895853 6.84* 6.77 - [156]
HEV0033 2010 51 M HTx JQ015427 KT198656 8.67 - [89, 90]
HEV0047 2010 56 M HTx JQ015425 KT198657 7.01 - [89, 90]
HEV0063 2010 19 M LTX JQ015426 KT198658 8.04 [90]
HEV0069* 2010 62 M HTx JQ015423 KP895854 7.30 8.80* - [89, 90]
HEV0081 2009 50 M HTx + KTx JQ015418 KT198659 7.95 - [89, 90]
HEV0122* 2014 63 M HTX KP895856 KP895855 6.74* 8.80* 6.26* this publication
Hepatitis E virus genotype 3 infection of human liver chimeric mice and A549 cells
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Hepatitis E virus propagation
Human adenocarcinoma alveolar basal epithelial cells (A549) were seeded on 
a coverslip in 24-well plate, in A549 growth medium containing Dulbecco’s 
modified Eagles Medium (DMEM, Lonza) supplemented with 10% fetal bovine 
serum (FBS, Greiner Bio-one, Kremsmünster, Austria), 0.08% NaHCO3, 2 mM 
L-glutamine (Lonza), 1% penicillin/streptomycin (pen/strep, Lonza) and 0.5 µg/
µl amphotericin B (Pharmacy, ErasmusMC, Rotterdam, The Netherlands). Three 
days after seeding, cells were washed once with phosphate buffered saline (PBS, 
Oxoid, Hampshire, UK) and inoculated with either HEV derived from different 
sample types or mock and incubated for 1 hour at 36.5°C in a humidified 5% 
CO2 incubator. Liver-derived samples were diluted 1:10 prior to inoculation, to 
dilute toxic substances. The virus suspension was then removed and cells were 
washed three times with PBS before adding maintenance medium, containing 
1:1 mixture of DMEM (Lonza)/Ham’s F-12 (Life technologies), supplemented with 
2% FBS, 20 mM HEPES (Lonza), 0.4% NaHCO3, 2 mM L-glutamine, 0.3% Bovine 
Albumin Fraction V (BSA, Lonza), 1% pen/strep and 2.5 µg/µl amphotericin B 
and incubated at 36.5°C in a humidified 5% CO2 incubator. Proper washing was 
documented by the absence of HEV RNA (Ct>38) in the last PBS supernatant. 
For monitoring virus propagation, every two to three days cells were inspected 
on cytophathogenic effect (CPE) and viability, culture medium was refreshed 
with maintenance medium (1:1) and supernatant was taken for HEV qPCR. 
Supernatant was passaged onto naïve A549 cells 15-20 days after infection, 
after which the same routine was used.
To test the 50% tissue culture infectious dose (TCID50), DMEM-adapted A549 cells 
(as documented above) were cultured in a flat bottom 96 wells plate. HEV virus 
stock (positive control) and samples were then 10x serial diluted in quattro-plo (in 
a separate round bottom 96-wells plate). Subsequently, 100 µl virus suspension 
or mock were inoculated for 1 hour at 36.5°C in a 5% CO2 humidified incubator. 
After washing three times with PBS and addition of maintenance medium, the 
virus was allowed to replicate for 7 days, after which replication was read by 
qualitative HEV qPCR. TCID50 is calculated according to Spearman/Karber.
Mouse origin and genotyping
uPA-NOG mice were kindly provided by the Central Institute for Experimental 
Animals (Kawasaki, Japan) 184. Mice were bred at the Erasmus Medical Center. 
Offspring zygosity was identified using a copy-number duplex qPCR performed 
on phenol/chloroform/isoamyl-alcohol (Sigma Aldrich, St. Louis, MO, USA) 
extracted genomic mouse DNA from toe snip. TaqMan Genotyping Master 
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Mix (Life technologies, Carlsbad, CA, USA) with TaqMan uPA genotyping 
assay (Mm00422051_cn, Life Technologies) and Tert gene references mix (Life 
technologies) were used according to the manufacturer’s protocol. All animal 
work was conducted according to relevant Dutch national guidelines. The study 
protocol was approved by the animal ethics committee of the Erasmus Medical 
Center (DEC nr 141-12-11).
Human hepatocyte transplantation
uPA homozygous mice, 6-12 weeks of age, were transplanted as previously 
described 186. In short, mice were anesthetized and transplanted via intra-
splenic injection with 0.5-2 x 106 viable commercially available cryopreserved 
human hepatocytes from a single donor (Lonza, Basel, Switzerland). Graft 
take was determined by human albumin in mouse serum using enzyme-linked 
immunosorbent assay (ELISA) with human albumin cross-adsorbed antibody 
(Bethyl laboratories, Montgomery, Tx, USA) as previously described 186.
Mouse infection
Mice were inoculated intravenously (i.v.) with 135-200 µl pooled patient EDTA-
plasma (6.8 log international units (IU)/ml), individual patient EDTA-plasma (6.7 
log IU/ml), homogenized liver biopsy fragment (6.3 log IU/ml), feces (8.8 log IU/
ml or diluted to 6.8 log IU/ml) or culture supernatant from a P7 of feces (7.4 log 
IU/ml) containing HEV gt 3 as denoted in Table 1. This study was approved by 
the medical ethical committees of Erasmus MC and Antwerp University Hospital.
Histology, immunohistochemistry and HEV ORF2 immunofluorescence
To confirm in vitro HEV replication after 7 to 14 days post infection, cells were 
fixed in 80% acetone (Sigma-Aldrich) for 10 minutes, washed 3 times with PBS 
and air-dried. Cells were then blocked for 30 min at 36.5°C with 10% normal 
goat serum (MP Biomedicals, Santa Ana, CA, USA), followed by three times 
washing in PBS. Subsequently cells were stained for 1 hour at 36.5°C with a 
1:200 0.5% BSA/PBS diluted goat-α-HEV open reading frame (ORF) 2 aa434-547 
antibody (MAB8002, Merck-Millipore, Billerica, Massachusetts, USA), followed 
by staining with 1:200 0.5% BSA/PBS diluted goat anti mouse IgG conjugated 
with Alexa Fluor 488 (Life Technologies) for 1 hour at 37°C. After washing with 
PBS, cells were counterstained with 4,6-diamidino-2-phenylindole (DAPI) and 
pictures were taken using a confocal microscopy (ZEISS LSM700). 
Mouse livers were fixed in 4% formaldehyde solution (Merck-Millipore). Standard 
H&E staining was performed and human hepatocytes were identified using goat 
Hepatitis E virus genotype 3 infection of human liver chimeric mice and A549 cells
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anti-human albumin cross-adsorbed antibody (Bethyl laboratories) or mouse 
anti-human mitochondria antibody (Merck). To visualize the detected antigens, 
3,3’-diaminobenzidine (DAB, DAKO, Copenhagen, Denmark) was added as a 
substrate and slides were counterstained with hematoxylin.
HEV RNA detection
All samples were screened for the presence of HEV RNA by an internally controlled 
quantitative real-time RT-PCR, described previously 90.  The qPCR had a lower 
limit of detection in EDTA-plasma (95% hit rate) of 143 IU/ml as determined 
by the 1st World Health Organization standard for HEV RNA NAT-Based assays 
(6329/10, Paul Ehrlich Institute, Germany). Ct values above 38 were considered 
background and given the arbitrary value of 0. HEV RNA detection in serum 
samples with Ct values below 38 are indicated with their calculated values. 
Feces was pre-treated with transport and recovery buffer (STAR buffer, Roche, 
Almere, The Netherlands) and chloroform. Liver tissues were homogenized using 
ceramic beads in 500 µl RPMI (Lonza). Mouse serum, bile and liver homogenate 
supernatants, were diluted 10x before extraction due to limited sample volume 
or to dilute any impurities inhibiting the qPCR. 
Statistics
Graphpad Prism 5.01 was used for statistical analysis. Michaelis-Menten non-
linear test was used to determine goodness of fit and Kruskal-Wallis one-way 
Anova test was used to calculate the p-value. Significance was set at P<0.05.
RESULTS
HEV gt 3 from different clinical sources efficiently infects A549 cells in vitro
HEV gt 3 derived from patient HEV0069 feces was able to infect cultured 
A549 cells with HEV RNA titers up to 7 log IU/ml in culture supernatant within 
13 days post infection (p.i.). HEV was passaged seven times onto new cells, 
which resulted in increasing HEV RNA titers after each passage up to 8 log IU/
ml (Figure 1A). After establishment of efficient HEV infection in the A549 cell 
culture system, isolates from 8 chronic HEV patients were used to study the 
differences between infectivity of different specimen types (feces, EDTA-plasma 
and a liver biopsy) in vitro. Viral load was assessed weekly by qRT-PCR. Figure 1 
clearly shows differences in infectivity after one passage on A549 cells. Feces- 
(striped lines) and liver-derived HEV (blue line) show more efficient propagation 
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than EDTA-plasma samples (green lines). This finding was confirmed in vitro by a 
generally accepted TCID50 assay. Culture supernatant of feces (HEV0069) after 
1 passage and 7 passages had a 4.8 and 5.5 log TCID/ml respectively, whereas 
culture supernatant derived from EDTA-plasma (HEV0014) had only an infectivity 
of 2.5 log TCID/ml. Anti-HEV ORF2 fluorescence staining confirmed HEV protein 
expression in feces-inoculated A549 cells, but not in uninfected control cells 
(Figure 1B). HEV is visualized in cytoplasm of clustered infected cells without 
obvious cytopathogenic effects. The percentage of infected cells was estimated 
at about 10% of total cells.
Figure 1 Differences in in vitro infectivity of HEV gt 3 containing clinical samples on A549 
cells. A) Stable in vitro HEV replication of feces from multiple patients and liver in A549 cells (striped 
and blue lines respectively) and less efficient propagation of HEV-antibody free serum (green lines). HEV 
RNA was quantified with qRT-PCR in supernatant. The concentration of the initial inocula is indicated 
on the Y-axis on time point 0. Arrows indicate first viral load quantification after new passage (P6 and 
P7). The circle around the last P7 viral load of patient HEV0069, indicates the inoculum used for in 
vivo challenge. B) HEV ORF2 immunofluorescence of HEV infected and uninfected control A549 cells.
Hepatitis E virus genotype 3 infection of human liver chimeric mice and A549 cells
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Successful infection of chimeric mice with feces-derived HEV gt 3
uPA-NOG mice, successfully transplanted with human hepatocytes (see Methods) 
had increasing human albumin levels in serum (Figure 2A), which correlated 
with liver repopulation by human hepatocytes as demonstrated by H&E; 
specific human albumin and human mitochondria staining (Figure 2B) 186. To 
corroborate the observed feces-derived HEV in vitro infectivity, filtered undiluted 
fecal suspensions (see Methods) from patients HEV0069 and HEV0122 were i.v. 
inoculated into chimeric mice and the infection course was documented for 2, 6 
or 14 weeks until sacrifice. During follow-up, HEV RNA was detected in feces of 
these mice with titers up to 7 log IU/gram (Figure 2C), while HEV viremia was low 
and inconsistently detectable, with maximum viral loads of 3.6 log IU/ml (Figure 
2D). All 10 inoculated animals had high intrahepatic HEV RNA titers at sacrifice 
(up to 8 log IU HEV RNA/gram, Figure 2E), confirming the in vivo infectivity of 
feces-derived HEV gt 3 with establishment of 100% persistent infections.
Figure 20 Successful infection of human liver-chimeric mice with HEV gt 3 derived from 
feces from two chronic HEV patients. A) Human albumin levels were measured in mouse serum 
via ELISA to quantify the hepatocyte graft take at 5 and 8 weeks post transplantation (n=13, mean 
± SEM). B) Liver histology at 8 weeks post transplantation; H&E (left panel), anti-human albumin 
(middle panel), and anti-human mitochondria staining (right panel). Chimeric mice (n=10) were 
challenged i.v. with 8 log IU HEV RNA derived from human feces from patient HEV0069 (black dots) 
or patient HEV0122 (red dots) for 2, 6 or 14 weeks (n=2; 4; 4 respectively) (C-E). HEV RNA levels 
were measured by qPCR in mouse feces (C), mouse serum (D), and in mouse liver (E). Lower limit of 
detection in serum is 3.2 log IU/ml (dashed line; D).
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Differences in in vitro HEV gt 3 infectivity are reflected in vivo
In order to assess the infectivity differences of HEV RNA containing clinical samples 
a total of 19 chimeric mice were challenged with EDTA-plasma samples from 
patients HEV0014 and HEV0122, with liver homogenate from patient HEV0122, 
with feces of patient HEV0069 or with a high titre P7 culture supernatant of this 
patient’s feces (Table 1, Figure 3A). Care was taken to inject animals with similar 
HEV RNA containing inocula, with some variation due to differences in injected 
volumes (135 to 200µL). The respective inocula are indicated below the X-axis 
(Figure 3A). Given the need for liver HEV RNA determination to demonstrate or 
rule out HEV infectivity, large liver fragments of sacrificed animals were collected 
at week 6 to week 17 after inoculation. Only liver- and feces-derived inocula 
proved to be infectious in chimeric mice. Serum or A549 cell culture-derived 
inocula did not result in detectable HEV RNA levels at 6, 14 or 17 weeks after 
inoculation in any of the examined biological matrices (feces, sera, bile and 
liver; Figure 3A and data not shown). In addition, untransplanted uPA+/- mice 
inoculated with undiluted fecal suspensions from patient HEV0069 (8 log IU 
HEV RNA) remained HEV RNA negative in liver, serum and feces, indicating that 
human hepatocytes are HEV target cells in vivo (n=3; data not shown). 
The absence of detectable HEV RNA could not be ascribed to loss of chimerism, 
as none of the HEV challenged human liver chimeric mice had a critical drop in 
human albumin during the course of the experiment (Figure 3B). Intrahepatic 
HEV RNA titers do vary and correlate with the degree of liver chimerism, as 
reflected by the human albumin levels in mouse serum (R2 0.6824) (Figure 3C). 
However, the latter does not explain the infectivity differences observed between 
the different HEV containing samples, as the animal with lowest human albumin 
values at end of follow-up (50 µg/ml) still had detectable intrahepatic HEV 
RNA levels. These data therefore corroborate a genuine biological difference in 
infectivity of HEV containing samples of different origins. 
Hepatitis E virus genotype 3 infection of human liver chimeric mice and A549 cells
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Figure 3 Differences in in vivo infectivity of HEV gt 3 containing clinical samples in human 
liver chimeric mice. Chimeric mice (n=19) were challenged i.v. with HEV RNA containing inocula 
derived from EDTA plasma (patient HEV0014 and HEV0122; n=4 respectively), a cryopreserved liver 
biopsy (patient HEV0122; n=2), feces (patient HEV0069; n=2), or P7 culture supernatant of patient 
HEV0069 feces (n=7) (see Methods). The respective infectious doses are indicated below the X-axis, 
as well as the duration of the infection in weeks. HEV RNA levels were measured by qPCR in mouse 
liver at sacrifice (A). B) Serum human albumin levels at HEV inoculation and at end of follow up 
of HEV RNA negative (Black lines) and HEV RNA positive (Gray lines) mice (n=29). C) Non-linear 
regression of chimerism, indicated by human albumin level in mouse serum (X-axis), versus the HEV 
titer in the liver (Y-axis) at week 6 post infection.
HEV viral shedding follows the natural human route in infected chimeric 
mice
HEV is preferentially secreted via feces in infected individuals. In fact, HEV 
seroconverted patients continue to shed HEV in feces for several weeks, even 
when HEV serum titers drop to undetectable levels 182. We found that in infected 
animals serum titers were lower compared to feces and liver titers. In 6 infected 
mice, the average HEV RNA titers in serum, feces and liver were 2.9±0.4 log IU/
ml, 4.9±0.7 log IU/gram, 6.3±0.4 log IU/gram, respectively (mean ± SEM; P-value 
0.005 for difference, Kruskall-Wallis test). In addition, in animals from which bile 
could be obtained, average bile HEV RNA titers (6.4 log IU/ml) were in the range 
of those of positive feces samples (6.2 log IU/gram), demonstrating that virions 
are secreted preferentially through the biliary canaliculi, instead of basolaterally 
in the liver sinusoids. 
Although serum levels are low during the course of the infection, HEV RNA was 
detected in liver of all HEV inoculated chimeric animals once HEV RNA became 
detectable in feces, demonstrating the 100% chronicity rate upon established 
infection. Thus, in live animals, feces, rather than serum, is a specific read-out for 
infection success.
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DISCUSSION
Human HEV gt 3 is reported to be infectious for several non-human primates, 
rabbits and pigs 183. However, none of these potential animal models for the 
study of HEV develop a chronic infection, nor are there overt hepatitis signs. In 
this study we applied a human-liver chimeric mouse model and A549 cell culture 
system to establish and examine the infectivity of HEV gt 3 containing clinical 
samples. We demonstrated that in vitro propagation of feces- and liver-derived 
virus isolates is higher than that of EDTA-plasma derived inocula and that these 
infectivity differences in vitro are corroborated in vivo in chimeric mice.
Our data show that human liver-chimeric mice can develop a 100% chronic 
HEV infection, mimicking the infection course in solid organ transplant and bone 
marrow transplant recipients. In addition, HEV in these mice is preferentially shed 
in bile and feces, which corresponds to the viral pathobiology seen in humans. 
This chimeric small animal model may therefore fill an important gap in preclinical 
antiviral efficacy studies.
Feces- and liver-derived inocula induced gradual increases of HEV RNA levels in 
the A549 cell culture system from day 6 onwards. HEV cell surface detachment 
and gradual release into the supernatant at the first day after inoculation may 
have caused the relative high viral titers early on, which decreased further for 
plasma inocula and plateaued for both liver-and feces-derived viruses. We 
observed intrinsic HEV infectivity differences that were most apparent when 
isolates from plasma, feces and liver obtained from a single patient (HEV0122) 
were examined: only the latter 2 resulted in prolonged replication, both in vitro 
and in vivo. HEV virions from plasma and feces have been found to differ in 
virion density, ascribed to a divergent lipid membrane content on their surface. 
In addition, culture derived HEV has comparable characteristics to plasma 
derived HEV 187, 188. Differences between these viruses are probably caused by 
the detergents and proteases secreted by the pancreas, which strips the HEV 
virions from their lipid membrane upon their passage in the intestinal system 189. 
This different buoyant density may influence in vivo infectivity, as has previously 
been shown for hepatitis C virus 190. Circulating inhibiting factors, including virus-
specific antibodies, on the other hand may also negatively influence the infectivity 
of the virus preparations. However, we selected only pre-seroconversion plasma 
samples for in vitro and in vivo infectivity assays, but could not obtain productive 
infections. 
In contrast, one group demonstrated efficient in vitro HEV replication from serum 
samples of acute HEV gt 3 patients irrespective of coexisting HEV antibodies with 
Hepatitis E virus genotype 3 infection of human liver chimeric mice and A549 cells
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rapid viral replication from day 2 post-inoculation onwards 191. Others showed 
that chronic HEV gt 3 sera, but not acute phase sera, yielded productive infections 
with insertions in the ORF1 region after 5 to 6 weeks of culture 192-195. 
The observation that human plasma-derived virus is less infectious in vivo may 
be relevant for the infectivity and epidemiology of HEV in humans. Indeed, 
only a limited number of cases of transfusion transmitted HEV have been 
reported despite administration of contaminated blood products 175, 182, 196, 197. 
In addition, a recent retrospective survey of United Kingdom’s plasma pool, 
surprisingly showed that only half of HEV viremic British blood donors infected 
their recipients 175. The HEV transmission rate seemed to be dependent on the 
HEV RNA load and anti-HEV antibodies status in donor plasma. Using currently 
described tools, it will be interesting to examine the critical factors associated 
with these infectivity differences, including the role of different HEV genotypes, 
membrane lipid content and infectious dose. While recent reports have shown 
HEV gt 3 viremia among blood donors 178, Dutch national blood safety guidelines 
do not require NAT testing of the donor pool 198. This is of concern for solid 
organ transplant patients who are prone to develop chronic infections, which 
may quickly progress to severe liver fibrosis. 
In conclusion, we have shown that feces- and liver-derived HEV gt 3 induces a 
sustained infection in human liver-chimeric mice with preferential viral shedding 
towards mouse bile and feces, mimicking the course of infection in humans. 
Besides antiviral efficacy studies, this novel small animal model offers new 
avenues to study HEV pathogenesis.
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The main goal of this thesis was to study the disease burden of HEV infections in 
cohorts of immune-compromised patients. To this end we optimized diagnostic 
assays and studied HEV pathogenesis in patients and in an in vivo model for HEV 
infection. 
HEV DIAGNOSTIC ASSAYS
Until recently, testing of immune-compromised patients for HEV infections was 
mostly performed - if at all - with assays detecting HEV specific antibodies but 
lacking sensitivity and specificity, like antibody ELISAs and Western blots. From 
our studies, in which we compared frequently used ELISA systems, it became clear 
that only a minority of the available assays tested was capable to sensitively and 
specifically detect HEV antibodies. We showed, that in immune-compromised 
patients (solid organ and hematological transplant recipients) anti-HEV IgM and 
anti-HEV IgG antibody responses measured by ELISAs, were detected later with a 
median of 64 and 129 days respectively, as compared to first HEV RNA detection. 
Therefore we recommended to test immune-compromised patients, rather with 
sensitive molecular techniques, like real time RT-PCR, than with serological 
techniques. However in immune-competent individuals presenting with acute 
hepatitis, ELISA techniques may be used, since they can differentiate between 
recent (IgM) infections and those of the more distant past (IgG). This can be done 
at lower cost than HEV RNA detection, which decreases the diagnostic barrier. 
However, one should bear in mind that re-infections with HEV may occur, with 
HEV IgG antibody and RNA being simultaneously present in peripheral blood. 
Other techniques like, HEV antigen detection may also be used in the absence 
of HEV RNA testing. However the so-far only commercially available antigen 
detection assay has been reported to have a sensitivity of approximately 60% 
and specificity of approximately 86% as compared to RT-PCR199. In vitro HEV 
isolation, which has recently been developed for research purposes, cannot be 
considered a diagnostic tool, because of its relatively long turnaround time and 
low sensitivity as compared to molecular and serological assays.
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CLINICAL ASPECTS OF HEV INFECTION
Acute hepatitis E in developed countries 
Zoonotic autochthonous hepatitis E infections have been identified in Japan (gts 
3 and 4) Europe, New Zealand, and to a lesser extent in the USA159. The majority 
of hepatitis E cases in Europe are caused by HEV gt 3. Patients infected with HEV 
gt 3 often remain asymptomatic. Only 2-33% of infected individuals present 
with usually non-specific symptoms and signs like abdominal pain, malaise, fever, 
although some present with jaundice.152 A recent study has documented HEV 
gt 4 in European pigs. Two human HEV gt 4 clusters have been documented 
in France and Italy200-202 and two apparently isolated cases in Denmark and The 
Netherlands (unpublished data, Pas et al). Infections with HEV gts 3 and 4 cause 
rather similar clinical manifestations. The acute hepatitis associated with gt 4 
infection tends to be more fulminant203. Excess mortality during pregnancy is 
not seen in association with infection by either of these genotypes. In developed 
countries HEV infection appears to cause symptomatic hepatitis more commonly 
in middle-aged and elderly men (M:F ratio 3:1). The reason for this skewed 
distribution is not clear, but may be explained by a higher prevalence of pre-
existing subclinical hepatic fibrosis in such individuals204, 205. It is interesting to 
note that in patients treated with immunosuppressive drugs for inflammatory 
arthritis, acute hepatitis E has been recently described. All HEV infected patients 
in that study had a favorable outcome after three months206. 
Figure 1 Acute HEV gt 3 symptoms. The majority of infected individuals is asymptomatic, a 
relatively small proportion had common symptoms, like jaundice, anorexia, lethargy, abdominal 
pain and vomiting (**). A minority of HEV infections shows signs of myalgia, pruritus, weight loss, 
headaches, arthralgia and neurological signs(*).
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With the exception of HEV-associated neurological syndromes (see below: 
Extrahepatic manifestations), the symptoms and signs of hepatitis E are rather 
non-specific and indistinguishable from other causes of viral hepatitis (Figure 1). 
Most patients recover within 4-6 weeks, although in patients with pre-existing 
liver disease the prognosis is poor due to hepatic failure16. 
Chronic hepatitis E
Chronic HEV infection caused by HEV gt 3 is defined by the presence of HEV RNA 
in plasma and/or stool detected by RT-PCR for 6 months or more69. To date no 
chronic hepatitis has been reported with genotypes 1, 2 or 4.
We and others have reported chronic HEV infection in immune-compromised 
patients, including solid organ transplant recipients, recipients of allogeneic stem 
cell transplantation (alloHSCT) and HIV-infected patients 69, 90, 107, 156, 207. It has 
not been found in patients with inflammatory arthritis treated with immune-
suppressive drugs, who do develop acute hepatitis E 206. A prevalence of 1-3% 
of hepatitis E viremia in recipients of solid organ transplants has been reported, 
with 47-83% of the patients developing chronic hepatitis69, 90, 112. Most immune-
compromised patients have no clinical symptoms at presentation, but usually 
show increased transaminase levels 71, 89, 156. In a recent study, the clinical course 
of HEV infection in 34 immune-compromised patients in The Netherlands was 
described. Median ALT levels in patients with a chronic infection were significantly 
lower (106 U/l) compared to the levels found in patients who had spontaneous 
viral clearance within 6 months (1087 U/l) (p=0.002)208. Similar findings were 
reported from a larger cohort of mainly European transplant recipients71.
Several case reports have described chronic HEV infections in HIV infected patients 
with CD4+ counts lower than 250 cells/µl 207, 209. More recent studies suggest that 
HIV-infected patients are not at increased risk of acquiring HEV infection, but are 
at a higher risk of developing chronic hepatitis E. 
Screening of two cohorts of 72 and 52 alloHSCT patients respectively, failed 
to document cases of HEV infection or reactivation, which did not suggest in 
increased risk for such patients 135, 137. In contrast, our more extensive retrospective 
cross-sectional study in a  cohort of 328 alloHSCT patients showed an incidence 
of 2.4% HEV infection156. Our study had a median follow-up time of 41 months 
and chronic hepatitis followed the acute infection in five out of eight acute 
HEV cases (63%). In the HEV infected patients, liver enzyme abnormalities had 
been considered to be related to hepatic GVHD in five (63%) patients, and drug 
induced liver injury in three (38%) patients. One patient was diagnosed with 
HEV reactivation after a preceding infection prior to alloHSCT. This is the second 
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case of HEV reactivation after alloHSCT described in literature so far 136, 156. 
Diagnosis of HEV infection in these patients is hampered by relatively low peak 
aminotransferase levels compared to non-immune-compromised patients68, 
which may be explained by intensive immune-suppressive therapy suppressing 
inflammation. 
In recipients of solid organ transplants the use of tacrolimus rather than 
cyclosporine A as a main immunosuppressant and a low platelet count at 
diagnosis of HEV infection are two independent variables that predict the 
development of chronic HEV infection71. Progression to chronic HEV in alloHSCT 
patients is less well characterized, but may be explained by impaired immune 
reconstitution, including insufficient lymphocyte count recovery, which are 
well known risk factors for post-transplantation infections140-142. In particular, 
impaired reconstitution of CD4+ and CD8+ T-cells predisposes for higher morbidity 
associated with infectious diseases in these patients143. 
Rapid progression of fibrosis and cirrhosis in chronically infected HEV transplant 
recipients has been described122. Liver histopathology in chronic HEV infected 
heart transplant recipients for instance showed advanced fibrosis within 2 years 
after infection89. Biopsies of patients with chronic HEV showed typical signs of 
active viral hepatitis with inflammatory activity, councilman bodies and acidophilic 
degeneration89, 156. However, no distinct pathognomonic features differentiating 
HEV infections from hepatitis B or C have been identified. 
HEV induced acute on chronic liver failure
The definition of acute-on-chronic liver failure (ACLF) according to the European 
society of liver diseases is ‘acute deterioration of pre-existing, chronic liver 
disease, usually related to a precipitating event and associated with increased 
mortality at 3 months due to multisystem organ failure 210. These precipitating 
events are for instance DILI, alcoholic hepatitis, viral hepatitis preceding the 
ACLF, but also events like trauma and variceal bleeding. In the event of a HEV 
superinfection, the liver quickly deteriorates, leading to a multi-organ failure and 
in some cases death. Several studies in HEV gt 1 endemic countries reported a 
median 21% (range, 4-72%) of the cases with HEV as cause of the ACLF211. 
However, in China, endemic for HEV gt 3 and 4; a large study of HEV vs HAV 
induced ACLF in chronic hepatitis B carriers showed that outcome of HEV super-
infections is generally more severe than those of HAV. Significantly more patients 
had complications (94.9 vs 61.5% respectively), hepatic failure (39.7 vs. 11.5% 
resp.) and died (33.8 vs 1.9% resp.). When looking at the laboratory results, the 
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peak levels of serum bilirubin, serum albumin and pro-thrombin activity were 
significantly higher in the HEV induced ACLF group than in HAV induced ACLF 
patients. 
The vast majority of studies on HEV induced ACLF have been performed in Asia 
or Africa, the literature is very limited on HEV induced ACLF in Europe. According 
to Jalan et al. the main causes of ACLF in Europe are bacterial infections and 
alcoholism, but since HEV awareness is just rising and diagnostic methods were 
not accurate until recently,, the incidence of HEV induced ACLF still needs to 
be studied in Europe212. One study by Peron et al, revealed a staggering 71% 
mortality rate in patients with underlying hepatic disease (either alcoholism or 
chronic liver disease) who had a fulminant hepatitis due to a HEV infection.154
In Erasmus MC we have seen 3 patients with pre-existent liver diseases as 
underlying morbidity, dying shortly after HEV induced ACLF associated with liver 
related morbidity213, confirming that this serious condition due to HEV induced 
ACLF may also occur in Europe.
Extrahepatic manifestations
There have been a number of case reports associating HEV infection with extra-
hepatic manifestations, including pancreatitis, acute thrombocytopenia, aplastic 
anaemia, and renal disease16, 214. In addition, 5% of HEV cases present with a 
neurological manifestation215. At first, scarce case reports suggested that HEV 
may be responsible for atypical neurological symptoms. HEV RNA was detected 
in the serum and cerebrospinal fluid in a kidney-transplant patient who was 
chronically infected by HEV. The patient showed symptoms of peripheral nerve 
involvement with proximal muscular weakness that affected the four limbs joints 
with central nervous-system involvement and bilateral pyramidal syndrome216. 
HEV-associated neurological injury has been documented in both acute and 
chronic HEV infection, and in some cases HEV has been found in the cerebrospinal 
fluid217. In general, HEV has been associated with a palette of neurological 
manifestations, such as Bell’s palsy, Guillan Barré syndrome (GBS) and neuralgic 
amyotrophy218-220. Case reports on GBS and HEV come from both developed 
and developing countries, suggesting that this condition is not genotype 
specific. The majority of GBS patients report respiratory or gastrointestinal tract 
infection before the onset of GBS. Infectious agents like Campylobacter jejuni, 
cytomegalovirus (CMV), Epstein-Barr virus (EBV) and Mycoplasma pneumoniae 
have been associated with GBS218. However, in our case-control cohort study, 
we showed that 10 (5%) of 201 Guillain-Barre syndrome patients from The 
Netherlands had HEV infection at the start of their illness218. The clinical features 
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and outcome in these patients were similar to those found in Guillain-Barre 
syndrome cases not associated with HEV. The pathophysiological mechanisms 
of HEV-associated neurological injury remain unclear. The role of HEV infection 
in the pathogenesis of GBS most likely falls within the existing paradigm of a 
post infectious immune-mediated complication, rather than being caused by 
the infection itself. The presence of anti-ganglioside GM2 antibodies upon HEV 
infection was associated with GBS, suggesting molecular mimicry involving 
gangliosides221. We showed that the incidence of recent HEV infections -based 
on the presence of anti-HEV IgM- was ten times higher than in a similar group 
of healthy controls. The majority of HEV-associated cases of GBS in this large 
cohort had a sensory-motor and demyelinating form of GBS, the predominant 
subtype of GBS in the Netherlands. In all 10 cases of HEV-associated GBS, the 
neurologic illness completely dominated the clinical picture: all were anicteric, 
and the alanine aminotransferase was less than 150 IU/L in 9 of these cases. 
A further study of UK and Dutch patients with brachial neuritis showed that 5 of 
47 (10%) of cases had an associated acute HEV gt 3 infection at the start of their 
neurological illness219. All the HEV-associated NA cases had bilateral involvement 
of the brachial plexus, compared to 15/35 (43%) of the Dutch cohort without 
recent evidence of HEV infection. HEV-associated NA patients were aged 
between 34-40 year. All patients were anicteric with only mildly raised ALT’s (in 
some cases the ALT was normal), and some were viremia at presentation. Anti-
HEV IgM positivity was not related to age, gender, disease severity or outcome 
in these patients
The latter observation raises the question whether early anti-viral therapy may 
improve the natural history of either condition. This may be facilitated by either 
cito-diagnostic testing or the use of a (bedside) HEV antigen detection assay, 
described above (chapter 5.1).
The pathophysiological mechanisms of HEV-associated neurological injury are 
unknown and need to be studied in more detail. Especially when neurological 
features dominate the clinical presentation, the diagnosis can easily be missed.
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HEPATITIS E VIRUS IN BLOOD AND BLOOD PRODUCTS
Antibodies directed against HEV and HEV RNA have been found in donated 
blood in a number of countries (Table 2). Asymptomatic infection is common 
and accounts for the large numbers of blood donors who are viraemic at the 
time of donation. The majority of blood products is administered to the most 
vulnerable patient group, the immune-compromised, who are at increased risk 
for developing chronic HEV, with all clinical consequences described in this thesis. 
Due to the use of relatively insensitive serological assays, sero-prevalence has 
been underestimated in the past. Table 2 shows an overview of published studies 
in Europe, China and the USA (mainly HEV gt 3 endemic countries) in which 
sero-prevalence and HEV viremia in blood donors were assessed. In some studies 
the same dataset was assessed with different assays showing up to seven times 
underestimation of the actual sero-prevalence when measured with insensitive 
ELISAs96. With the increased performance of the anti-HEV IgG ELISAs, it has 
become clear that the sero-prevalence is higher than previously assumed, ranging 
from 3.4% in Scottish blood donors to up to 52% in the south-east of France 
(Table 2). These data suggest that HEV is more endemic in south-east France, and 
these high sero-prevalence rates are in accordance with high numbers of blood 
donors who are viraemic at the time of donation (Table 2). 
Multiple well-designed studies in the Dutch, American, British and Danish 
blood donors showed a high correlation between age and HEV antibody sero-
prevalence176, 222-224. It has been demonstrated that when evaluating sero-
prevalence levels, indeed we face an age cohort-effect. This means that not only 
as people get older they have encountered more HEV infections, but also that the 
prevalence of HEV infection in the population was higher in previous decades. 
This resulted in a relatively high sero-prevalence today due to the detection of 
long persisting HEV antibodies in the elderly.176 
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Table 2 HEV viraemia and seroprevalence in blood donors
Country
Year of 
sampling
Blood 
donors HEV 
RNA +
HEV IgG 
sero-
prev.
Assay Reference
SW France 2003-2004 - 16%* Adaltis Mansuy et al, 2008 225
2003-2004 - 52.5%* Wantai Mansuy et al, 2011 60
  2011 - 39.1%* Wantai Mansuy et al, 2015 226
Germany 1996 - 50.7%* Wantai Wenzel et al, 2014 177
2010 - 29.5%* Wantai Wenzel et al, 2013 96
2010 - 18.0%* Mikrogen Wenzel et al, 2013 96
2010 - 4.5%*
MP 
diagnostics
Wenzel et al, 2013 96
2011 1:1200 - Vollmer et al, 2012 227
- 1:4525 - Baylis et al, 2012 146
2011 - 34.3% Wantai Wenzel et al, 2014 177
 Netherlands   - 1.1%* Abbott Zaaijer et al, 1993 228
1988 - 46.6% Wantai Hogema et al, 2014 176
2000 - 27.3% Wantai Hogema et al, 2014 176
2011 1:2671 27.0% Wantai Slot et al, 2013 222
2013 1:1761 - Zaaijer, 2014 229
  2014 1: 611 -   Zaaijer, 2014 229
England - - 3.9%* Abbott Bernal et al, 1996 230
1991 - 13.0% Wantai Ijaz et al, 2009 223
2004 - 13.5% Wantai Ijaz et al, 2009 223
2007 1:7000 - Ijaz et al, 2012 231
10.0%* Wantai Beale et al, 2011 65
  2012-2013 1:2848 -   Hewitt et al, 2014 175
Sweden   9.2%* Abbott Olsen et al, 2006 232
1:7986 - Baylis et al, 2012146
N-Austria   1:8416 13.5% Wantai Fischer et al, 2015 233
Scotland   1:14.520 4.7%* Wantai Cleland et al, 2013 234
Spain 2013 1:3333 10.7% Mikrogen Sauleda et al, 2015 235
  2013   20.0% Wantai Sauleda et al, 2015 235
China 2005-2006 - 23.5%*
MP 
diagnostics
Jia et al, 2015 236
  2002-2008 - 32.6% Wantai Guo et al, 2010 237
USA Nil - Baylis et al, 2012 146
Nil 18.8% Wantai Xu et al, 2012 224
The above data are from blood donors with the exception of those marked * which are from ‘healthy 
adults’. Assays in italics have a relatively low sensitivity41, 238. 
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Studying longitudinal samples from 23 donors collected over 22 year-period, 
it was shown that the Wantai assay consistently detected long persisting HEV 
specific antibodies. Furthermore, data from The Netherlands (Table 2) and 
Germany, suggest that HEV infections have come in waves during the past 
decades: by the end of the 1980’s there was a high prevalence of roughly half 
of the German and Dutch populations had been infected with HEV, whereas the 
sero-prevalence had declined towards 27-29% by the end of 2010’s. An increase 
of HEV infections was already detected in the Netherlands from 2011 onwards, 
although this coincided with increased awareness and sensitivity of diagnostic 
assays. More recent data from the Dutch blood donors show a continuing 
upward trend, with currently 1:611 donors being HEV viremic229. Since HEV is not 
a notifiable disease in the Netherlands, there are no well-defined national data 
to support this finding. However, the Dutch National Institute of Public Health 
and the Environment (RIVM) does acknowledge an increase in the incidence of 
HEV infections from 2014 onward, based on voluntary notification of Dutch 
diagnostic laboratories (Adviesbrief deskundigenberaad DB-Z bij hepatitis E, 
dd 26-06-2015), which cannot be explained by an increase in sensitivity of 
diagnostic assays alone. Other evidence for the increase in the incidence of HEV 
infections in The Netherlands is an overall increasing sero-prevalence (19.8% 
in 1988, 7.0% in 1995, 4% in 2000 and 12.7% in 2011) in the last 10 years 
among young adults (18-21 years). Prevalence studies among this age category 
over time suffer to a much lesser extent from an age-cohort bias.
Several reports have shown that HEV can be transmitted via blood transfusion150, 
151, 196, 197, 239, though specific risk factors for transmission have poorly been 
defined. Transmission via blood products may well be less efficient than feco-
oral- transmission, as blood products originating from more than one donor, may 
contain HEV neutralizing antibodies that may interfere with transmission. The first 
blood donor transmission study was conducted in the UK, and included 225.000 
donors of whom 0.04% or 1:2848 were HEV viremic. This study revealed HEV 
transmission in 18 of 43 (43%) exposed and followed up patients. Transmission 
proved to be dependent on factors like higher viral load, presence of donor HEV 
antibodies and recipients immune suppression. The viral load was on average 1.5 
log higher (max up to 6 log IU/ml) and antibody titers were lower in the donations 
that transmitted HEV than those that did not. However in two single cases high 
viral loads (>5log) did not lead to transmission, but the authors did not specify if 
this could be attributed to the fact that this was a seropositive recipient or multiple 
donations were given, which had included sero-positive individuals175. 
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Clinical consequences of transfusion-transmitted HEV are still largely unknown. 
The sole transmission study up to now was conducted in the UK and describes 
clinical consequences. However, this study is clearly biased, since the patients 
were actively followed up after confirmed HEV contamination of the donation. 
By doing this, they stopped the more severe clinical sequelae in infected patients 
who were treated for their hepatitis. Long term follow up without intervention, 
as the current situation is in non-screening countries, has not been reported, 
which could reveal worse clinical outcome. The authors describe that in the UK 
an estimate 1200 HEV containing donations are transfused per year, and taken 
the study results into account, 43% transmission and 2/3 of the infused patients 
clear the virus without medical intervention, resulting in roughly 180 patients 
each year that do need medical intervention due to the acquired HEV infection. 
As stated above, this would mean either tapering immunosuppressive drugs, 
ribavirin treatment or, in case of HEV-ACLF very costly intensive care admissions 
or even a liver transplantation. 
INTERVENTION STRATEGIES
Currently, no preventive intervention strategies other than vaccination in China 
are in place world-wide,. Intervention strategies for hepatitis E can be conducted 
at different levels. The simplest intervention technique, at least to gain insight in 
the number of actual hepatitis E cases, is to make it a notifiable disease. In some 
countries, like Germany, this is currently done, but not in the Netherlands. The 
Dutch government now relies on voluntarily reported and therefore inaccurate 
data from diagnostic laboratories. 
In terms food-safety, intervention strategies at the source and the end of this 
HEV transmission chain, may have a major impact. Since currently HEV is present 
in raw pig products52, 240, these could be banned from consumption, or at least 
carry warnings as is also practised for raw cheese products to prevent Listeria 
infections. At the source, vaccination of fattening pigs could be a management 
measure aiming at preventing zoonotic transmission.. Although this is an 
enormous effort, with >12 million pigs in the Netherlands alone (source: CBS241), 
it could be a first step towards HEV-free swine products.
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On an individual level, intervention can take place either before HEV infection 
– HEV vaccination, HEV-specific dietary advice to risk groups and screening 
of blood donations (discussed below) – or after HEV infection, by therapeutic 
management of HEV infections through lowering iatrogenic immune suppression 
and/or anti-viral therapy. 
Treatment
Acute HEV
Currently there are no WHO nor EASL / AASLD guidelines for treatment of 
hepatitis E. Most cases of acute hepatitis E infection are self-limiting, requiring 
only symptomatic or no treatment. However a minority of the patients develop 
fulminant hepatitis, some of which may eventually require liver transplantation72, 
73. Especially patients with severe hepatitis and underlying chronic liver disease 
have a poor prognosis, although currently several have been treated successfully 
with ribavirin74.
Chronic HEV
Treatment of chronic HEV infection in transplantation patients is basically based 
on two strategies, reduction of immune-suppressive therapy and treatment with 
anti-viral agents. Peg-IFN-α-2a/b and oral ribavirin have been successfully used 
for treating chronic HEV infection in immune-compromised patients89, 125, 127, 156, 
164, 242, 243. 
Reducing the dose of immune-suppressive drugs targeting T cells can lead to 
HEV clearance in up to one third of patients76. Other studies have shown more 
limited utility of reducing immune-suppressive therapy, as one study showed 
that only 2 out of 18 solid organ transplant recipients were able to achieve viral 
clearance with this approach71, 76, 208. A possible explanation is that the evolution 
of the HEV infection could be related to the type of solid organ transplant and 
the associated level of immune-suppression employed 208. 
Peg-IFN-α-2a has been successfully used for treating HEV infection in liver- 
and kidney transplant recipients as well as in a HIV infected patient 39, 125, 127, 
243. Tapering immunosuppressive drugs or treatment with Peg-IFN-α-2a/b is not 
always possible or desirable due to the high risk of rejection, which may lead 
to chronic allograft dysfunction and death. For these patients treatment with 
ribavirin should be considered. Rapid clearance (within 3 months) of HEV RNA 
from plasma with normalizing ALT levels and sustained virological response are 
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observed in patients with chronic HEV infection after start of ribavirin treatment77. 
The optimal daily dose and treatment duration of ribavirin is unknown. In case 
reports and small case series sustained virological response has been described 
with daily dosages between 200 mg and 1200 mg80. Treatment durations of less 
than 3 months and dose reduction of ribavirin have been associated with viral 
relapses or breakthrough242. No viral relapse was observed following 5 months 
of ribavirin therapy for treatment of chronic HEV in 9 transplant recipients 77, 242. 
An in vitro study, using the HEV replicon system (chapter 4) has shown that a 
single mutation in RNA dependent RNA polymerase, found in a non-responding 
patient, was able to escape from ribavirin therapy by enhancing replication 
in human liver cells. The majority of ribavirin treated patients are sustained 
responders, but as the precise mechanistic effect of ribavirin treatment is not 
fully understood, further studies are needed to elucidate the mechanisms of this 
therapeutic intervention. 
HEV screening
Blood donations in The Netherlands: ‘to screen or not to screen, that is 
the question.’
Currently, blood donors are not routinely screened for HEV in The Netherlands. 
Whether they should be screened is subject of lively debate and on-going 
research. As stated above, if in the UK roughly 180 patients per year need medical 
care due to a donation-transmitted HEV infection, whilst in The Netherlands the 
percentage of HEV viremic donors is approximately 4.5 times higher than in the UK. 
Furthermore, the HEV sero-convertion rate, upon transfusion in the Netherlands 
is currently estimated at 1.1%. compared to the 0.1-0.2% in the Hewitt study. 
Therefore estimation of the number of Dutch recipients who become actively 
HEV infected is hard to compare with the UK situation, but the relative risk of 
becoming HEV infected by blood or blood products in The Netherlands may well 
be higher than in the UK, although the prevalence and levels of specific serum 
antibodies should also be taken into account in estimating this relative risk.175, 176.
Currently, only HIV, HTLV-1, HBV, HCV and Syphilis (Lues) are infectious agents for 
which Dutch blood donors are routinely screened. In the last two decades (1995-
2014) 381 regular repeated donors tested positive for one of these agents in the 
Netherlands (HIV-1 n=53, HBV n=110, HCV n=14, HTLV n=11 and Lues n=196) 
(personal communication Prof H. Zaaijer, Sanquin Blood supply, Amsterdam). 
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Compared to the other two agents causing viral hepatitis (HBV and HCV), the 
number of HEV viremic donors is much higher (1:611229). 
It should however be realized that infectious HEV, in contrast to HBV and HCV, 
is virtually omnipresent, found at various places in the food chain, including in 
pork products, seafood, game but also in surface water. Although immune-
compromised patients, who would be most at risk, do get dietary advise, this 
patient group may be expected to be exposed regularly to HEV infection. The 
question may be why to invest lots of money to get the blood chain HEV-free, and 
thereby losing valuable blood products. Therefore the second option, providing 
‘HEV-safe’ blood products for risk groups like immune-compromised patients 
may be a better option.
Hepatitis E virus fits well into the group of other infectious agents (like B19 
virus or CMV) for which currently selected safe blood products are produced. All 
these infections are highly prevalent, but only are a major problem for specific 
risk groups. The health council of The Netherlands has advised the minister of 
Health in 2002 to start providing ‘B19-safe blood products’, meaning presence 
of B19 antibodies in cellular products or B19 viral load <104 geq/ml in plasma244. 
However B19 antibody positive blood is considered ‘safe’ for cellular products, 
but for HEV it is not known to what extent the antibodies found in 27% of the 
Dutch blood donors can indeed neutralize infectious HEV. More HEV transfusion 
related infections were found when HEV antibody levels were low and viral 
loads were high175. This provides the basis for further studies to elucidate which 
antibody levels and which HEV viral loads could still be considered ‘safe’ for 
immune-compromised patients. 
In evaluating the need for either systematic HEV donor screening, or developing 
a policy of ‘HEV-safe blood’ for risk groups, it is also important to consider the 
overall disease burden for patients receiving blood or blood products, who 
develop HEV infection. It has a broad range from no clinical symptoms at all, 
to death due to acute-on-chronic liver failure. It is also not yet clear what the 
disease burden is, expressed in disability-adjusted life years (DALY). Finally all 
measures considered should also be evaluated in the light of the overall HEV 
exposure rate due to ‘natural’ oral-fecal and zoonotic exposure. 
Unfortunately all these considerations have not yet been included in cost-benefit 
or cost-effectiveness studies for providing ‘HEV-safe’ blood. Such studies are 
required to provide ammunition for further discussion and decision making on 
this topic. 
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Yearly transplantation screening
Given the disease burden of HEV infection on transplantation patients and 
the overall prevalence of HEV infection in The Netherlands, the question arises 
whether a policy of HEV screening of transplant donors and recipients before 
transplantation should not be adopted. In addition a subsequent annual HEV 
recipient screening, as also practiced for HAV, HBV and HCV should be considered 
As a direct result of prevalence studies in the Erasmus MC transplant recipient 
populations, the currently adopted algorithms for yearly transplant recipient 
screening have changed by adding HEV RNA for HTX and LTX. This will also be 
implemented for KTX recipients in the near future. Up until March of 2015 (~1.5 
years of screening), 32 new HEV infected patients (40% of total HEV cases in 
Erasmus MC) were identified by this proactive screening program213. Regardless 
of a possible introduction of ‘HEV–safe’ blood products, this yearly Tx screening 
for HEV should be performed, as these patients also have a significant chance to 
be infected via other transmission routes than blood transfusion.
HEV vaccine
Although great efforts have been made to develop a HEV vaccine, there are still 
major knowledge gaps to be filled. First, due to the study designs and the limited 
follow-up time, it has yet to be determined what the protective mechanisms 
are or for short- and long-term protection against hepatitis E. This is the reason 
why, in 2014 a phase IV clinical trial was initiated, of which the data are not yet 
published. Also, subsequent safety and efficacy studies in specific patient groups 
like immune-compromised should be conducted, although currently available 
data seem to suggest that the vaccine is safe in accidentally vaccinated pregnant 
women and hepatitis B surface antigen positive (HBsAg+) patients, but these 
data need to be confirmed with larger numbers of participants. 
The WHO recognizes that hepatitis E is a world-wide problem, and focuses 
its efforts on large outbreaks in low sanitized countries. Therefore a strategic 
advisory group of experts (SAGE) has been established in 2013, to write a WHO 
vaccine position paper on the use of hepatitis E vaccine, which was published 
in May 2015. In this position paper the WHO states that there is still insufficient 
data on the use of the current candidate vaccine in children <16 years and the 
cross-protection for genotypes 1-4, and therefore does not recommend the use 
of this vaccine in national vaccination programs at present245, but acknowledge 
the benefits of use in outbreak situations. 
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MODELS FOR PATHOGENESIS AND TREATMENT EFFICACY 
STUDIES
Hepatitis E virus has been shown to replicate in vitro in A549 cells derived from 
human lung cancer and on PLC/PRF/5 cells – a human hepatocellular carcinoma 
cell line189. However, since the first publication a decade ago, to our best 
knowledge, there are currently only three groups (in Japan, Germany and the 
Netherlands) world-wide who have reported propagation of wild type HEV strains 
in vitro 189, 192, 246. For research purposes, a one-cycle luciferase replicon system 
provided the tool to study basic elements of HEV replication in vivo and in vitro.31, 
247 Using this replicon system, in vitro evidence has been provided on the efficacy 
of ribavirin and α-interferon, which was supportive of clinical findings with off-
label use of these antivirals.248. However, for pathogenicity studies, several animal 
models have been described, like non-human primates, swine and rabbits, each 
with their specific advantages and disadvantages249. Non-human primates are 
only used nowadays when there is more benefit to human beings and if there 
is no other animal model available. These animals do not develop major clinical 
signs, only one of four had elevated ALT levels. Swine are only used for gt 3 and 
4 infections and only show moderate pathology. Rabbits, have been shown to 
be susceptible for HEV gt 4 infection, and rabbit HEV proved to be transmissible 
to pigs and cynomolgus macaques250. Moreover, pregnant rabbits showed high 
mortality rates once infected with rabbit HEV, reminiscent of gt 1 infections in 
humans. Though rabbits may be a good alternative for non-human primates as 
a model for HEV gt 4, no chronic infection could so far be established. Chronic 
HEV gt 3 infection was established in the immunodeficient human-liver chimeric 
mouse model (uPA+/+Nod-SCID-IL2Rγ-/-) in which livers proved to be infected 2, 
6 and 14 weeks after inoculation246, making this a promising model for future 
chronic HEV gt 3 studies.
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CONCLUSION
In the past 5 years, the knowledge of HEV infection and associated pathogenesis 
has increased considerably. Only a few years ago, hepatitis E in Europe was 
described as a travel-related import disease characterized by hepatitis; we now 
know that HEV is an endemic zoonosis with much broader clinical manifestations. 
It was classified as a virus inducing acute, transient hepatitis; however, it can 
also cause chronic infection in the most severely affected patient group – the 
immune-compromised. Understanding of the hepatitis E virus hide-outs, in the 
environment, patient populations and within the individual host, is increasing, 
although additional studies are warranted. Therefore it has become increasingly 
clear that there is no such thing as the hepatitis E phenotype, since the virus 
comes with a plethora of geographical, epidemiological and clinical ‘flavors’.
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Hepatitis E virus veroorzaakt per jaar wereldwijd meer dan 3 miljoen acute 
infecties, met meer dan 70.000 doden. Bij gezonde mensen gaat een infectie van 
het hepatitis E virus meestal gepaard met milde symptomen, o.a. vermoeidheid. 
In een sporadisch geval kan de besmetting tot een leverontsteking (hepatitis) 
leiden. Het virus zorgt voor uitbraken in ontwikkelingslanden, waarbij besmetting 
optreedt door de feco-orale route, en een hoge sterfte onder zwangere vrouwen 
veroorzaakt. Enkele decennia geleden, was men van mening dat bovenstaande 
beschrijving accurate informatie over de epidemiologie van het hepatitis E 
virus was, en werd het in Nederland vooral als een reizigersziekte beschouwd. 
Echter sinds een aantal jaren weten we dat een ander genotype (3) van het 
hepatitis E virus dan hierboven beschreven (genotype 1) vooral endemisch is in 
Westerse, geïndustrialiseerde landen. De patiënt met een slecht immuunsysteem 
(immuun- gecompromitteerden), zoals ontvangers van orgaan-transplantaten en 
patiënten met hematologische maligniteiten, kunnen aan een chronische vorm 
van hepatitis E lijden. In dit promotieonderzoek is onderzocht welke immuun 
gecompromitteerde patiënten groepen aan (een chronische vorm van) hepatitis 
E leden en wat de klinische gevolgen van hepatitis E bij deze groepen patiënten 
zijn. Daarnaast hebben we op twee manieren (in vivo en in vitro) de infectiviteit 
van verschillende lichaamsmaterialen gemeten
HEPATITIS E VIRUS
Hepatitis E virus behoort tot de familie Hepeviridae, genus Orthohepevirus A. 
Het heeft geen envelop en is ongeveer 27-34 nanometer groot. Het erfelijk 
materiaal bestaat uit positief enkelstrengs RNA van ongeveer 7200 baseparen. 
Het genoom heeft 3 leesramen, ORF1, 2 en 3, waarvan virale eiwitten zoals RNA 
afhankelijk polymerase en het capside-eiwit worden afgeschreven. Het virus kan 
op basis van het genoom, epidemiologie en geografische verspreiding worden 
onderverdeeld in 4 genotypen die mensen kunnen infecteren. Genotype 1 en 
2 komen in ontwikkelingslanden voor en veroorzaken daar grote uitbraken, 
terwijl genotypen 3 en 4 in geïndustrialiseerde landen voorkomen en endemisch 
zijn. Genotypen 1 en 2 kunnen voor zover we weten alleen mensen infecteren; 
genotypen 3 en 4 zijn zoönosen, die dus zowel bij mensen als dieren voorkomen. 
Het grootste reservoir is de varkenspopulatie, maar het virus is ook aangetoond 
in wilde dieren, zoals herten en wilde zwijnen.
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REPLICATIECYCLUS
Er is nog veel onbekend over de replicatie-cyclus van het hepatitis E virus, 
maar op basis van de karakterisatie van virale eiwitten en bekende replicatie 
strategieën van positief enkelstrengs RNA virussen, is er toch de volgende 
hypothese gevormd: het virus hecht aan de buitenkant van de cel met niet-
specifieke ‘plakkerige’ moleculen. Vervolgens zal het virus interactie aangaan 
met een nog onbekende specifieke receptor, waardoor het virusdeeltje de cel 
binnen gaat en het erfelijk materiaal wordt uitgepakt. Het positief enkelstrengs 
RNA kan meteen als sjabloon dienen voor het afschrijven van virale eiwitten, 
met behulp van de machinerie van de gastheer cel. Het geproduceerde RNA-
afhankelijk-RNA-polymerase synthetiseert vervolgens het negatief strengs RNA, 
dat op zijn beurt weer als sjabloon voor het genomisch viraal RNA kan dienen. 
De virale eiwitten vormen samen met het virale RNA een nieuw virion, dat de cel 
verlaat om nieuwe cellen te infecteren.
HEPATITIS E DIAGNOSTIEK 
Om de onderzoeksvragen in dit promotie onderzoek goed te kunnen 
beantwoorden, zijn de juiste diagnostische technieken essentieel. Bij mensen 
met een goed functionerend immuunsysteem worden direct na een infectie 
verschillende soorten antistoffen tegen het virus gemaakt. Bij een recente infectie 
worden IgM antistoffen aangemaakt, terwijl in de herstellende fase juist IgG 
antistoffen worden gevonden; de techniek waarmee we deze antistoffen kunnen 
aantonen die tegen het hepatitis E virus gericht zijn, heet ELISA. In hoofdstuk 2 
is een aantal commerciële ELISAs, die anti-HEV IgM en IgG , vergeleken. In de 
literatuur was namelijk bekend dat er grote verschillen waren in gevoeligheid en 
specificiteit van deze testen. Vervolgens zijn met deze testen ook de verschillen 
in antistof-reactie in immuun-competente en immuun-gecompromitteerde 
patiënten gemeten. Uit dit onderzoek bleek, dat de afweerreactie tegen hepatitis 
E virus van patiënten met een slecht werkend immuunsysteem enorm vertraagd 
was ten opzichte van patiënten met een normaal immuunsysteem. De conclusie 
was dat het meten van antistoffen gericht tegen het hepatitis E virus bij immuun-
gecompromitteerde patiënten niet aan te bevelen is, maar met moleculaire 
technieken het virale genoom aangetoond dient te worden.
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HEPATITIS E VIRUS IN IMMUUN-GECOMPROMITTEERDE 
PATIENTEN
Mensen met een verzwakt immuunsysteem, de immuun-gecompromitteerden 
hebben een verhoogd risico op het krijgen van een chronische hepatitis E. In 
hoofdstuk 3 is de onderzoeksvraag welke patiënten groepen in Erasmus MC 
aan hepatitis E leden en wat de klinische gevolgen daarvan waren beantwoord. 
Hiertoe zijn alle solide orgaan (hart-, long-, nier- en lever-)-transplantatie-
ontvangers getest op de aanwezigheid van HEV RNA en antistoffen tegen 
HEV, waar bij 1% een HEV-infectie werd aangetoond. Dit lijkt een laag 
percentage, maar de klinische gevolgen van chronische HEV kunnen zeer 
ernstig zijn (hoofdstuk 3.2). Het blijkt dat een chronische HEV-infectie in een 
relatief korte periode, vergeleken met andere hepatotrope virussen (HBV/
HCV), tot fibrose (littekenvorming) van de lever kan leiden. Fibrose kan leiden 
tot cirrose en hepatocellulair carcinoma, aandoeningen die levensbedreigend 
zijn. Van patiënten met hematologische afwijkingen (hoofdstuk 3.3) bleken 
2,3% patiënten HEV RNA positief. Alle patiënten waren geïnfecteerd met het 
genotype 3 en er kon geen gerelateerde (ziekenhuis) besmettingen aangetoond 
worden. Zoals ook bij andere infectieziekten werd een vertraagde afweerreactie 
tegen HEV gevonden bij de immuun-gecompromitteerde patiënten, waarbij HEV 
specifieke IgM antistoffen gemiddeld 4 maanden later meetbaar waren dan HEV 
RNA. Dit bevestigde onze bevindingen uit hoofdstuk 2. Opmerkelijk is dat HEV-
infectie zich vaak niet duidelijk klinisch presenteert. De infectie was ook bij geen 
van de door ons opgespoorde HEV geïnfecteerde patiënten gediagnosticeerd. 
Dit is wellicht te wijten aan de tot voor kort bestaande onbekendheid met 
het feit dat HEV chronische infecties kan veroorzaken en de afwezigheid van 
diagnostische mogelijkheden om een HEV-infectie aan te tonen. Echter ook 
met het feit dat patiënten veelal slechts milde leverontstekingen ontwikkelden, 
met lage transaminase-waarden heeft hier ongetwijfeld toe bijgedragen. Van 
de hematologische patiënten bleken er twee van de acht een gemiddeld ALT 
niveau te hebben binnen de normaalwaarden (ULN), bij vier was sprake van een 
verdubbeld ULN en slechts bij twee patiënten werd een meer dan viervoudig 
verhoogd ULN gevonden. Aan de andere kant konden de piek-ALT waarden 
tot meer dan 34 maal het ULN stijgen. Deze factoren leidden tot foutieve 
diagnoses, zoals toxische lever ziekte (DILI) en afstotingsziekte (GVHD). De 
juiste diagnose is van groot belang, aangezien de initiële HEV behandeling 
bestaat uit het verlagen van immuunsuppressie (zodat het immuunsysteem het 
virus kan klaren), terwijl in andere gevallen bij verhoogde leverenzymwaarden, 
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zoals bij GVHD, de immuunsuppressie juist verhoogd dient te worden om de 
afweerreactie tegen te gaan. Het verlagen van deze immuunsuppressie is een 
delicate balans tussen het voorkomen van afstoting van het transplantaat en het 
activeren van het immuunsysteem voor virusklaring. Beide (afstoting en klaring) 
geven een verhoging in ALT waarde, waardoor het bij beperkte diagnostische 
mogelijkheden voor een behandelend arts erg moeilijk is om in te schatten welk 
proces gaande is. Deze laatste overweging en omdat niet bij iedere patiënt de 
immuunsuppressie verlaagd kan worden ivm dreigende afstoting, zijn redenen 
waarom ook antivirale medicatie, voornamelijk ribavirine, wordt gebruikt voor 
de behandeling van HEV-infecties in immuun- gecompromitteerde patiënten. 
Hoofdstuk 3.4 beschrijft de onderliggende ziekten van HEV RNA positieve 
patiënten in het Erasmus MC, de klinische gevolgen en behandeling van HEV-
infecties. Uit deze studie bleek dat de meerderheid van HEV geïnfecteerde 
patiënten immuun-gecompromitteerd was door solide orgaan transplantatie 
(SOT). Vooral ontvangers van harttransplantaten hadden een groter risico op 
een HEV-infectie. Op drie patiënten na, ontwikkelden al deze HEV geïnfecteerde 
patiënten een hepatitis (verhoogde leverenzym waarden), die bij ongeveer een 
derde een chronisch beloop had. Zoals ook in de literatuur beschreven, klaarden 
geen van de SOT ontvangers de HEV-infectie tussen 3-6 maanden spontaan. Met 
deze informatie, is het wetenschappelijk onderbouwd om niet na 6 maanden 
(dus alleen chronisch geïnfecteerde patiënten), maar al na 3 maanden te starten 
met antivirale therapie. Alle 25 patiënten die behandeld werden met ribavirine, 
hebben de HEV-infectie geklaard. In totaal zijn er vier patiënten overleden met 
een actieve HEV-infectie en acht patiënten kort nadat ze de HEV-infectie hadden 
geklaard. Aangezien deze patiënten onderliggende ziekte hadden is het niet 
mogelijk om de doodsoorzaak aan de HEV-infectie alleen toe te schrijven. Echter, 
patiënten met bestaande leverziekte hadden significant snellere progressie naar 
cirrose, wat aan acuut-op-chronische lever falen (ACLF) toegeschreven kan 
worden.
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IN VITRO EN IN VIVO MODELLEN VOOR CHRONISCHE HEV-
INFECTIES
Om de gevolgen van acute en chronische HEV-infecties te kunnen bestuderen, 
zijn er geschikte technieken en modellen nodig. Een belangrijke techniek 
om eigenschappen van HEV te bestuderen is in vitro HEV kweek. Hoofdstuk 
4 beschrijft de HEV kweek op A549 long adenocarcinoma cellen, waarbij we 
een verschil van infectiviteit tussen serum en faeces is aan te tonen. Dit wordt 
bevestigd in het in vivo model van immuun deficiënte muizen met een lever die 
bestaat uit humane en muizen lever cellen. In vitro HEV kweek en het chimere 
muizenmodel zijn een basis om in de toekomst o.a. antivirale therapieën te 
bestuderen. 
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Tja, en dan ben je aankomen bij het belangrijkste (en meest gelezen) onderdeel 
van je proefschrift… nu maar hopen dat ik niemand vergeet….mocht dat toch 
gebeurd zijn, bij deze alvast excuses!
Promoveren, dat ging ik zeker NIET doen, zo dacht ik er een aantal jaren geleden 
over, tot dat je dan je master achter de rug hebt, en teamleider geworden bent, 
en natuurlijk achter komt dat zo’n doctor-titel toch wel ‘handig’ is. Ik moest er 
dus ook aan geloven. Tijdens mijn loopbaan als analist hebben Ab, Bert, Martin 
meerdere keren aan me gevraagd waarom ik nou niet ging promoveren; de tijd 
was er klaarblijkelijk nog niet rijp voor. Pas toen ik Bianca op de gang deelgenoot 
maakte van m’n gedachtenkronkels om misschien toch maar die master te gaan 
doen, kwamen de verlossende woorden in Alblasserdam’s  accent “als jij het niet 
kan, wie dan wel”. Dat gaf me net dat zetje dat ik nodig had.…en was het niet 
vanwege mijn eerste liefde in de virologie, virale hepatitis, dat ik op die ‘hepatitis 
E’-trein ben gesprongen, dan was dit wellicht nooit gebeurd. Het combineren 
van een fantastisch gezin met een (meer dan) full-time baan is al een uitdaging. 
De master studie kon mooi gecombineerd worden toen de kids nog klein genoeg 
waren om vroeg naar bed te gaan, maar eenmaal aan de PhD begonnen werden 
die kids groter en de uurtjes om ‘even’ aan je proefschrift te werken schaarser 
en vooral later. Maar als jullie dit stukje lezen is het dan schijnbaar toch gelukt, ik 
kan het haast niet geloven, ik heb Damocles verslagen!
Zonder motivators en achtervang is zo’n traject haast niet te doen, daarom dit 
dankwoord voor iedereen die zijn steen(tje) heeft bijgedragen.
Allereerst natuurlijk Ab, mijn promotor. De reden waarom ik in de virologie 
geïnteresseerd raakte tijdens mijn HLO opleiding, was een artikel uit jouw stal. 
Ik moest een review schijven, o.a. over ISCOMS, waar jij voorvechter van was. 
Daarom ook maar eens gaan kijken om bij die afdeling stage te gaan lopen, 
want die virussen waren iets ongrijpbaars wat het enorm interessant maakte. 
Omdat de uitdagingen bleven komen, heb ik nooit meer een goede reden 
gehad om weg te gaan. Na een aantal cursussen was jij degene die me aan het 
denken zetten, “ga nou eens een echte opleiding doen in plaats van al die losse 
cursusjes”. Van het een kwam het ander, je weet mensen te motiveren om door 
te gaan, de top te bereiken, daar heb ik veel respect voor. Ik ben stiekem toch 
wel een beetje trots dat het HEV ELISA paper jouw 1000e publicatie is! Dank voor 
je steun in dit traject.
Miek, ik weet het, ik had een hele pagina beloofd, en die krijg je ook, zij het 
op een andere manier dan jij wenst! We gaan al lang terug, ik zie je nog als 
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’doktertje’ net van de opleiding in het lab komen, maar als een speer je PhD 
halen, met mijn persoontje als paranimf aan je zijde. Je schoot met dezelfde 
vaart door, omdat je precies weet wat je wilt, zeker nu in de functie van medisch 
coördinator. Eindelijk is het zover, ik ben aan de beurt om achter het bankje 
staan, ik ben trots dat je mijn co-promotor bent, iets dat bevestigt wat we beiden 
weten: we kunnen goed werken samen, weten wat we aan elkaar hebben. 
Ik hoop dat we nog lang zo samen kunnen werken, je weet dat je altijd mag 
aankloppen in geval van computer-nood!
Beste Marion, dank voor de kans om mijn proefschrift af te schrijven. Hoewel de 
ebola labs toch wel enige vertraging hebben opgeleverd, was dit de meest snelle 
manier in historie om het nieuwe afdelingshoofd goed te leren kennen onder 
hoge druk. We hebben het toch ff geflikt!
Beste Bert, Hans, Charles, Jaap, Rob en Hubert, ik wil jullie allen hartelijk danken 
voor het zitting nemen in mijn promotiecommissie. Ik heb veel respect voor ieder 
van jullie en voor jullie bijdrage aan het virale hepatitis en Guillain-Barré veld.
Mijn lieve paranimfen, Nicole en Jolanda, mensen met wie ik kan lezen en 
schrijven. Nicole, mijn vriendinnetje, je weet hoe belangrijk je voor me bent, 
ieder woord wat ik daarover op zou schrijven, zou te kort schieten, ik ben zo blij 
dat je vandaag aan mijn zijde staat! Jolanda, sinds dat ik werk, werk ik met jou. 
We zijn samen ‘opgegroeid’ in de stal van Bert, en hebben bijna alle levensfases 
bij elkaar meegemaakt, weten elkaar aan te vullen en te corrigeren waar nodig. 
Dank dat jullie er zijn!
En natuurlijk kan ik het beste moleculair diagnostische team van de wereld niet 
overslaan. Op volgorde van binnenkomst : Jolanda, Judith, Cedric, Chantal, 
Manon, Mark, Claudia, Sev, Jolanda M, Freek en Anne(ik schoffel je er gewoon 
even bij)…zonder een fantastisch team is een teamleider nergens, ieder van jullie 
heeft zijn eigen kwaliteiten, en ik ben erg blij om die te mogen ondersteunen. 
Ik hoop dat jullie nog lang en gelukkig bij de klinische virologie mogen werken!
Ook de andere mensen van de unit klinische virologie zijn natuurlijk erg belangrijk 
voor me, Hans, Lilian, Machteld, Monique, Jans, Robin, Eric, Jeroen, Pieter, 
Corine, Sandra, Janine, Thea, Ada, Georgina, Mikel, Be, Mouring, Cobi, Truus, 
Marion, Soerani, Helène, Mark P. en Ruud. Speciale dank voor Guido, die de 
enige echte HEV-kweker is in het land, en natuurlijk Darina, Simone en Loubna 
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voor jullie eindeloze ondersteuning! Martin, ondanks dat je niet meer bij ons 
werkt, wil ik je toch graag bedanken voor de jarenlange prettige samenwerking, 
als ik nog eens wil sparren, dan weet ik je te vinden!
Verder bedank ik alle co-auteurs voor de prettige samenwerking tijdens het doen 
van alle research en schrijven van de te gekke publicaties. Jurjen, Martijn, Bianca 
en Ludi, succes met jullie promoties! 
Chantal R., Jolanda M., Jeroen R. en Heidi, dat waren nog eens tijden hè, Sierra 
Leone, West-Afrika. Wat hebben we daar een brok aan levenservaring op gedaan. 
Ik had me geen beter team voor Freetown1 kunnen voorstellen, dank dat jullie 
het aandurfden met mij! Ik heb er totaal geen spijt van dat mijn promotie door 
de coördinatie en uitzending van de Dutch Mobile labs zeker een half jaar in de 
wacht heeft gestaan. Het heeft me een hele hoop gebracht; vooral de realisatie 
dat als je wat wil, je het met beide handen moet aangrijpen en volbrengen (if it 
is to be, it is up to me), aangezien er genoeg mensen zijn die graag willen, maar 
de mogelijkheid niet hebben.
Alle mensen van de research unit (“boven” of te wel “de 17e”), in het bijzonder 
Chantal R., Bart, Saskia, Stalin, Theo en Petra bedankt voor de fijne samenwerking 
van de afgelopen jaren, dat er nog maar vele mogen volgen.
Balans is wat mij betreft het hoogste doel in het leven. Balans kan je alleen maar 
vinden door de juisten mensen om je heen te verzamelen, die er voor je zijn als 
het ff niet lekker gaat, en lol met je maken in goede tijden. Regina & Jan, Pim & 
Jet, Bram & Tanja, Bab & Jeroen, Amber, Thomas & Nonna, Roy & Evelyne, Erik 
& Andrea, Wim & Inge, Maurice & Lisette, Rob & Steef, Richard & Jacqueline, 
Patricia & Michael, Nicole & Suus, Judith P., lieve vrienden en familie, dank jullie 
wel voor jullie eindeloze steun! Elsje, voor jou een speciaal plekje, zoals je weet, 
je bent ontzettend belangrijk voor mij en ons gezinnetje. Je weet ons weer in 
balans te brengen als het nodig is, bijzonder hoe jij bij ons hoort, dat koester ik.
Lieve pap en mam, dank jullie wel voor de geweldige basis die jullie mij gegeven 
hebben. Pap, jouw werklust en sociale aard is aanstekelijk, en mam, ik hoop dat 
ik net zo goed voor onze kinderen kan zorgen als jij voor ons gedaan hebt. Mary 
en Wim, en natuurlijk pa en ma, dank je wel dat jullie zonder mopperen altijd 
voor ons klaar staan, onze kindjes willen opvangen als wij aan het werk zijn en 
een geweldige opa en oma zijn, die ze verdienen.
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Als laatste, maar zeker niet least, de belangrijkste personen in mijn leven, Bas, 
Noa en Ruben. Jullie liggen inmiddels op één oor, want mama moest ’studeren’. 
Bas, ik weet, het is niet altijd eenvoudig te leven met iemand die werken gewoon 
erg leuk vind, maar inmiddels hebben we onze draai daarin gevonden, en hebben 
we het erg goed samen. Dank je wel dat je de leukste man bent die ik me maar 
wensen kan, en dat je me de mooiste kindjes op aarde hebt gegeven. 
Noa en Ruben, wat ben ik ontzettend trots om jullie mama te zijn!
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